

# JOSE LLORED CAMACHO & CO.

ABOGADOS

Calle 72 No. 5-83 Piso 5, Bogotá, D.C. Tel: 6069700 Fax 6069701

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 13-089868- -00015-0000

Fecha: 2015-03-06 16:42:51 Dep. 2020 DIR.NUEVAS  
Tra. 11 PATENTEIYII Eve: 379 FASENACIONAL  
Act. 412 REPOSPRESRECU Folios: 65

Trámite: 11  
Evento: 379  
Actuación: 412

Señor

SUPERINTENDENTE DE INDUSTRIA Y COMERCIO

DIVISIÓN DE NUEVAS CREACIONES

E. \_\_\_\_\_ S. \_\_\_\_\_ D. \_\_\_\_\_

Re: PI.- **ALIOS BIOPHARMA, INC.** Solicitud de Patente de Invención en Fase Nacional PCT para "**ANÁLOGOS DE NUCLEÓTIDOS SUSTITUIDOS**".- Clase **C07H 19/20**.-Expediente número **13-089.868**.-

Yo, **ALICIA LLORED RICAURTE**, mayor, vecina de esta ciudad, identificada con la cédula de ciudadanía número 39.690.713 de Usaquén, Representante Legal en Bogotá para todos los asuntos relacionados con la Propiedad Industrial de la sociedad **ALIOS BIOPHARMA, INC.**, organizada y existente de conformidad con las leyes del Estado de Delaware, Estados Unidos de América, domiciliada en South San Francisco, Estado de California, Estados Unidos de América, atentamente manifiesto a usted que interpongo **RECURSO DE REPOSICIÓN** contra la Resolución Número **2763** dictada por el señor Superintendente de Industria y Comercio el 30 de Enero de 2015 y notificada por fijación en lista el 3 de Febrero de 2015, por medio de la cual se niega el privilegio de patente solicitado para la invención contenida en el expediente de la referencia.

## **I. FUNDAMENTOS DE DERECHO**

Como fundamento de mi recurso, me permito manifestar ante ese Despacho que el contenido de la Resolución Número **2763** evidencia que durante el examen técnico realizado a la solicitud denegada se realizó una evaluación incorrecta del objeto de la invención allí reclamada, sin considerarse su real alcance e importancia. En este sentido, no se consideró el verdadero y valioso aporte técnico que representa para el arte en cuestión los fosforotioatos análogos de nucleótidos con actividad antiviral, anticancerígena y antiparasitaria, revelados en la solicitud denegada.

Es así que, a pesar de los argumentos proporcionados por el solicitante en respuesta al Concepto Técnico emitido por ese Despacho el 26 de Junio de 2014, en la Resolución impugnada este Despacho mantiene las objeciones frente a la Claridad y el Nivel Inventivo de la solicitud, argumentando básicamente que:

*"(...) se aclara que la objeción de las reivindicaciones 61 y 62 decía que la aplicación que pueda darse a un compuesto (...) no son elementos característicos de un compuesto porque los elementos característicos son su estructura central y sus sustituyentes químicos (...)"*.

Además, el señor Examinador resalta que:

*"(...) no hay evidencia de que el incluir los sustituyentes aminoácido, polifosfato, arilo, piridinilo o quinolinilo, proporcione un compuesto con algún defecto técnico diferente al que ya proporcionaba el del documento D2, que tiene actividad por acción sobre la AMPK"*.

Consecuentemente,

*"...la persona normalmente versada en la materia, modificaría los compuestos descritos en el documento D2, incluyendo el sustituyente aminoácido de acuerdo a lo sugerido por el documento D1, teniendo en cuenta que la estructura semejante, obteniendo los compuestos propuestos en la solicitud de manera obvia (...) En consecuencia, la reivindicación 1 de acuerdo a lo divulgado en los documentos D1 y D2 carece de nivel inventivo"*.

Así como también que:

*"Dado que las reivindicaciones 2 a 60 no presentan alguna característica adicional que conceda nivel inventivo al objeto de la reivindicación 1, se considera que tampoco tienen nivel inventivo"*.

Por consiguiente, a continuación me permito brindar argumentos técnicos para no sólo demostrar ante ese Despacho que el nuevo capítulo reivindicatorio que se presenta junto con el presente recurso cumple a cabalidad con los requisitos de claridad y nivel inventivo exigidos por los artículos 18 y 30 de la Decisión 486 de 2000, sino además para establecer que la invención ha sido interpretada de manera errónea a la luz de los documentos del arte previo.

**1. PRESENTACIÓN DE SOLICITUD DIVISIONAL.**

a) Inicialmente y de conformidad con el Artículo 36 de la Decisión Andina 486 de 2000, el Artículo 7 del Decreto 2591 de 13 de Diciembre de 2000 y el Artículo 11 de la Resolución número 00210 de 15 de Enero de 2001, me permito manifestar que es deseo del solicitante dividir **la presente solicitud de patente en dos solicitudes**, a saber:

- i. Una solicitud original compuesta por **26** reivindicaciones, que tienen como base las reivindicaciones actualmente presentadas en respuesta al Oficio No. **7687** y que han sido modificadas en conformidad a lo expuesto en el numeral 2.1 del presente memorial; y
- ii. Una solicitud divisional que comprende **59** reivindicaciones que encuentran pleno sustento en el capítulo descriptivo y reivindicatorio originalmente presentado para dicha solicitud original.

b) En conexión con lo anterior, a continuación especifico los documentos anexos al presente memorial y que se relacionan con cada una de las solicitudes resultantes del presente fraccionamiento:

- i. ***Solicitud original: "ANÁLOGOS DE NUCLEÓTIDOS SUSTITUIDOS".***
  - Recibo número 15-007212, expedido por la Superintendencia de Industria y Comercio, que acredita el pago de las modificaciones mencionadas; y
  - Copia de las páginas **255 a 267** que corresponden al nuevo capítulo reivindicatorio modificado, compuesto por **26** reivindicaciones, tal y como se describe en el numeral 2.1 del presente memorial.
  - Copia de la portada de la patente americana US 8,871,737,
  - Copia del notice of allowance de la patente US 8,871,737 por parte de la USPTO
  - Copia del resumen Jordheim, L.P. et al. Nat. Rev. Drug Discovery. Vol. 12, pp. 447-464 (2013),

## JOSE LLOREDA CAMACHO & CO.

Calle 72 No. 5-83 Piso 5, Bogotá, D.C. Tel: 6069700 Fax 6069701

---

- Copia del documento Coats, S.J. et al. en Antiviral Res. Vol 102, pp. 119-147 (2104),
- ii. **Solicitud divisional: "ANÁLOGOS DE NUCLEÓTIDOS SUSTITUIDOS".**
  - Recibo número 15-006973, expedido por la Superintendencia de Industria y Comercio, que acredita el pago de los derechos que causa el presente fraccionamiento;
  - Recibo número 15-0026210, expedido por la Superintendencia de Industria y Comercio, que acredita el pago de las reivindicaciones **11 a 59**;
  - Nuevo resumen-Objeto y Finalidad de la Invención (formato digital);
  - Páginas **1 a 254** de la descripción, que corresponden al texto de la descripción de la solicitud de patente número **13-089.868** originalmente presentada (formato digital);
  - Páginas **255 a 279** que corresponden al nuevo capítulo reivindicatorio compuesto por **59** reivindicaciones que, como se comentó previamente, encuentran pleno sustento en la descripción de la presente invención (formato digital);
  - Figuras en (formato digital);
  - Extracto de la solicitud, en sus dos formas, que incluye el título que se encuentra de acuerdo con el objeto de la presente invención fraccionada y que incluye el resumen y el sector (formato digital);
  - Tarjeta de Propietario (formato digital);
  - Arte final (formato digital).
- Copia del traspaso de los derechos de la presente invención que los autores de dicho invento hacen a favor de mi representado, (formato digital);

- Copia del documento que acredita a la suscrita ALICIA LLOREDA y/o al doctor GUSTAVO TAMAYO, y/o a la doctor ANA MARIA CASTRO y/o a al doctor ENRIQUE ALVAREZ, en los términos del Párrafo 1º del Artículo 543 del Decreto-Ley 410 de 1971, como Representantes Legales en Bogotá para todos los asuntos relacionados con la Propiedad Industrial de la sociedad **ALIOS BIOPHARMA, INC.** organizada y existente de conformidad con las leyes del Estado de Delaware, Estados Unidos de América y domiciliada en South San Francisco, Estado de California, Estados Unidos de América (formato digital);
- Formato Único de Conversión, División y Fusión de Solicitudes;

c) En cuanto a la reivindicación de la prioridad respecto de la solicitud divisional, es la misma invocada en la solicitud original, la cual fue reivindicada oportunamente en Fase Internacional de la solicitud número US 61/385,363 de 22 de septiembre de 2010 y US 61/426,461 de 22 de diciembre de 2010.

d) Ratifico a usted que la sociedad titular de la solicitud fraccionada en cuestión es **ALIOS BIOPHARMA, INC.** organizada y existente de conformidad con las leyes del Estado de Delaware, Estados Unidos de América y domiciliada en South San Francisco, Estado de California, Estados Unidos de América.

e) De conformidad con lo establecido por el Artículo 36 de la Decisión 486 de 2000, solicito a ese Despacho se sirva aceptar y estudiar la solicitud divisional presentada y conceder el privilegio de patente solicitado.

## 2. CAPÍTULO REIVINDICATORIO DE LA SOLICITUD ORIGINAL.

### 2.1. Modificaciones al Capítulo Reivindicatorio

Ahora, en razón de defender la patentabilidad de la presente solicitud denegada, me permito también manifestar que el solicitante ha decidido realizar las siguientes modificaciones en el capítulo reivindicatorio de la invención actualmente presentada:

- **Nueva Reivindicación 1:** tiene como base la reivindicación 1 actualmente presentada, la cual ha sido modificada para restringir considerablemente el alcance de la materia reclamada y para asemejarse con el capítulo reivindicatorio

de la patente americana US 8,871,737. Específicamente, dichas modificaciones consisten en:

- Eliminar del preámbulo de la reivindicación la frase "(...) o un tio-monofosfato del mismo (...)".
  - Especificar para el sustituyente B<sup>1</sup> que las bases heterocíclicas son purina y pirimidina.
  - Eliminar del sustituyente R<sup>1</sup> las definiciones O<sup>-</sup> y OH.
  - Restringir el sustituyente R<sup>2</sup> a los grupos funcionales benceno, naftaleno y azuleno. Dicha modificación encuentra pleno sustento en el párrafo [0032] página 12.
  - Restringir el sustituyente R<sup>4</sup> a hidrógeno.
  - Restringir el sustituyente R<sup>5</sup> a hidrógeno.
  - Eliminar del sustituyente R<sup>6</sup> las definiciones *azido* y *ciano*.
  - Agregar la definición del sustituyente R<sup>8</sup>, el cual es selecciona del grupo que consiste de halógeno y un alquilo C<sub>1-6</sub> no sustituido. Dicha modificación encuentra pleno sustento en el párrafo [0103] página 40.
  - Restringir el sustituyente R<sup>9</sup> a hidrógeno.
  - Especificar para los sustituyentes R<sup>12</sup> y R<sup>14</sup> que son independientemente hidrógeno o un alquilo C<sub>1-6</sub> no sustituido.
  - Especificar para los sustituyentes R<sup>13</sup> y R<sup>15</sup> que son independientemente un alquilo C<sub>1-6</sub> no sustituido o un cicloalquilo C<sub>3-6</sub> no sustituido.
  - Eliminar las definiciones de los sustituyentes R<sup>10</sup>, R<sup>16</sup>, R<sup>18</sup>, R<sup>11</sup> y R<sup>17</sup>.
  - Eliminar la frase "(...) con la condición de que cuando R<sup>3a</sup>, R<sup>3b</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>7</sup>, R<sup>8</sup> y R<sup>9</sup> son todos hidrógeno, entonces R<sup>6</sup> no es azido (...)".
- **Nueva Reivindicación 2:** corresponde a la reivindicación 2 del capítulo actualmente presentado.
  - **Nuevas Reivindicaciones 3 a 6:** corresponden a las reivindicaciones 5 a 8 del capítulo actualmente presentado.
  - **Nuevas Reivindicaciones 7 a 9:** corresponden a las reivindicaciones 10 a 12 del capítulo actualmente presentado.
  - **Nueva Reivindicación 10:** corresponde a la reivindicación 14 del capítulo actualmente presentado.

- **Nueva Reivindicación 11:** tiene como base la reivindicación 15 actualmente presentada, la cual ha sido modificada para restringir el alcance de la materia reclamada. En este sentido, se especificado que el sustituyente " $R^{22}$  es un alquilo  $C_{1-6}$  opcionalmente sustituido o un cicloalquilo  $C_{3-6}$  opcionalmente sustituido". Dicha modificación tiene pleno sustento en el párrafo [0093] de la página 34.
- **Nuevas Reivindicaciones 12 y 13:** corresponden a las reivindicaciones 17 y 18 del capítulo actualmente presentado.
- **Nueva Reivindicación 14:** corresponde a la reivindicación 24 del capítulo actualmente presentado.
- **Nueva Reivindicación 15:** corresponde a la reivindicación 27 del capítulo actualmente presentado.
- **Nueva Reivindicación 16:** tiene como base la reivindicación 30 actualmente presentada, la cual ha sido modificada para restringir el alcance de la materia reclamada. En este sentido, se especificado que el sustituyente " $R^6$  es  $-OH$  o  $-OC(=O)$  alquilo  $C_{1-6}$ ; y donde  $R^7$  es  $-OH$ ,  $-OC(=O)$  alquilo  $C_{1-6}$  o halógeno; o  $R^6$  y  $R^7$  son ambos átomos de oxígeno y están unidos mediante un grupo carbonilo". Dicha modificación tiene pleno sustento en las características técnicas de las reivindicaciones 33 y 39 actualmente presentadas y en el párrafo [0088] de la página 30.
- **Nueva Reivindicación 17:** tiene como base la reivindicación 41 actualmente presentada, la cual ha sido modificada para restringir el alcance de la materia reclamada. En este sentido, se han eliminado los compuestos específicos que no cumplen con las especificaciones y modificaciones presentadas en este memorial. Asimismo:
  - Se restringe el sustituyente  $R^{F2}$  a hidrógeno y halógeno.
  - Se restringe el sustituyente  $R^{G2}$  un alquilo  $C_{1-6}$  no sustituido.
  - Se restringe el sustituyente  $R^{H2}$  a hidrógeno o  $NH_2$ .
  - Se eliminan las definiciones para los otros sustituyentes.
- **Nueva Reivindicación 18:** corresponde a la reivindicación 44 del capítulo actualmente presentado.

- **Nueva Reivindicación 19:** tiene como base la reivindicación 46 actualmente presentada, la cual ha sido modificada para restringir el alcance de la materia reclamada. En este sentido, se han eliminado los compuestos específicos que no cumplen con las especificaciones y modificaciones presentadas en este memorial.
- **Nuevas Reivindicaciones 20 a 25:** corresponden a las reivindicaciones 48 a 53 del capítulo actualmente presentado.
- **Nueva Reivindicación 26:** corresponde a la reivindicación 60 del capítulo actualmente presentado.

De acuerdo a lo anterior, me permito señalar que las reivindicaciones **3, 4, 9, 13, 16, 19 a 23, 25, 26, 28, 29, 31 a 40, 42, 43, 45, 47, 54 a 59, 61 y 62** del Capítulo Reivindicatorio actualmente presentado fueron **eliminadas** del documento modificado. Asimismo, me permito aclarar que el orden de enumeración y dependencia de las nuevas reivindicaciones se ha reajustado de conformidad con las modificaciones previamente descritas.

Adicionalmente, me permito señalar que dichas modificaciones cumplen con el propósito de restringir significativamente la materia reclamada y así permitir una mayor diferenciación de la invención de la solicitud denegada con el estado del arte previo.

De esta forma, el mencionado **capítulo reivindicatorio modificado queda constituido por 26 reivindicaciones**, la cuales no constituyen de ninguna manera una ampliación al alcance de la solicitud original y cuenta con pleno sustento en las enseñanzas de la descripción. Con lo anterior, me permito reiterar que dicho capítulo cumple a cabalidad con las disposiciones de patentabilidad establecidas en el Artículo 34 de la Decisión 486 de 2000.

## **2.2. Claridad del Nuevo Capítulo Reivindicatorio.**

Ahora bien, ese Despacho menciona en la Resolución aquí impugnada que la objeción de las reivindicaciones 61 y 62 decía que la aplicación que pueda darse a un compuesto, usando frases como "(...) *inhibir la actividad polimerasa NS5B (...)*" o "(...) *para inhibir la replicación del virus (...)*", no es un elemento característico de un compuesto. Ante esto, el señor Examinador manifiesta que los elementos de un compuesto son su estructura central y sus sustituyentes químicos.

Respecto al anterior señalamiento, muy amablemente me permito manifestar que, tal y como se explicó en el numeral 2.1 del presente memorial, las reivindicaciones 61 y 62 no hacen parte del nuevo capítulo reivindicatorio presentado junto con este documento. Por lo tanto, se considera que la objeción a este respecto ha sido completamente superada.

### 3. PRINCIPALES CARACTERÍSTICAS DE LA INVENCION DENEGADA.

Con el fin de contextualizar los motivos por los cuales ese Despacho realiza una incorrecta valoración y evaluación del arte previo, me permito señalar a continuación las principales características y ventajas técnicas asociadas a la materia revelada en la solicitud de patente negada.

En vista del nuevo capítulo reivindicatorio presentado junto con este memorial, la presente solicitud reclama de manera específica y exclusiva **fosforotioatos análogos de nucleótidos de fórmula I con exclusiva actividad antiviral, anticancerígena y antiparasitaria**. Específicamente, dichos compuestos son útiles para inhibir la actividad polimerasa de la enzima NS5B de un virus de hepatitis C *in vitro*, y con ello, inhibir su mecanismo de replicación.

Con respecto a los beneficios de la presente invención, me permito traer a colación que dichos compuestos análogos de nucleótidos de fórmula I, reclamados en la nueva reivindicación 1, constituye una novedosa e inventiva para tratar enfermedades de origen viral, cancerígeno y parasitario.

De acuerdo con la tabla 11 del Ejemplo 40 (página 240 de la memoria descriptiva), 46 compuestos específicos de la presente invención presentan actividad antiviral para el VHC satisfactoria, determinada a través de valores  $CE_{50}$  menores a 1  $\mu M$ . Específicamente, dicha actividad inhibitoria se presentó activamente en ensayos con replicones de VHC sin tratar. Similarmente, 4 compuestos de la presente invención presentaron valores de  $CI_{50}$  menores a 1  $\mu M$  (Tabla 12 Ejemplo 41 página 247), con lo que se demuestra la actividad inhibitoria de la enzima NS5B.

En este punto, es importante resaltar que dicha actividad es atribuida a la sustitución en la posición 2' de la ribosa del nucleótido de fórmula I, tal y como se describe en el párrafo [0121] de la página 86 de la memoria descriptiva:

*"En algunas realizaciones, un compuesto de Fórmula (I) (incluido un compuesto de*

*Fórmula (Ia)), o una sal farmacéuticamente aceptable del mismo, **puede actuar como un terminador de cadena de replicación de VHC.** Por ejemplo, la incorporación de un compuesto de Fórmula (I) que contiene un resto en la posición carbono 2' **puede terminar la elongación adicional de la cadena de ARN de VHC.** Por ejemplo, un compuesto de Fórmula (I) puede contener una modificación de carbono 2' cuando  $R^8$  es un grupo no hidrógeno seleccionado de halógeno, azido, ciano o un alquilo  $C_{1-6}$  opcionalmente sustituido,  $-OR^{16}$  y  $-OC(=O)R^{17}$ ". Siendo  $R^8$  definido como un halógeno o un alquilo  $C_{1-6}$  no sustituido en dicha posición, es esta característica la que otorga el efecto técnico principal a la invención, y por lo tanto, la que la diferencia crucialmente de los compuestos del estado del arte previo (ver numeral 5.1 del presente memorial).*

A la luz de las anteriores consideraciones, me permito concluir ante ese Despacho que los fosforotioatos análogos de nucleótidos de fórmula I reclamados en la solicitud denegada constituyen una alternativa eficaz y satisfactoria para la inhibición del virus de la Hepatitis C y su enzima N5SB. Dichas propiedades atribuidas a los anteriores compuestos se evidencian a lo largo de la descripción de la solicitud, particularmente en los ejemplos realizados.

#### **4. CONSIDERACIONES TÉCNICAS FRENTE A LAS ENSEÑANZAS DEL ARTE PREVIO**

Ahora, teniendo en cuenta el alcance del nuevo capítulo reivindicatorio de la invención en cuestión, me permito manifestar ante ese Despacho que los fosforotioatos de fórmula I análogos de nucleótidos en la solicitud de patente denegada presentan un inequívoco nivel inventivo frente a la combinación de las enseñanzas de los documentos "***Kinetic and mechanistic studies on the dephosphoryl reaction catalyzed in nucleoside 5 -amino acid phosphoramidates***", **Journal of Molecular Catalysis A. 2005, p.239-242 (D1)** y **WO 2006/038865 (D2)**.

En la Resolución aquí impugnada, el señor Examinador considera que la composición reclamada en la solicitud no tiene nivel inventivo puesto que, a la luz de las enseñanzas de los documentos D1 y D2, la persona del oficio normalmente versada en la materia podría derivar de manera evidente el objeto de la reivindicación 1 de la solicitud.

Frente a tal consideración, **me permito sostener que las enseñanzas de los documentos D1 y D2, solas o en combinación, de ninguna manera anticipan**

**o sugieren de manera obvia los compuestos de fórmula I con todas y cada una de las definiciones específicas para sus sustituyentes, tal y como se reclaman en el capítulo reivindicatorio modificado que se presenta junto con este memorial.**

Ahora bien, con el ánimo de demostrar ante ese Despacho que la anterior afirmación es completamente correcta, a continuación me permito realizar un análisis comparativo detallado entre la información revelada en la presente solicitud y las enseñanzas brindadas por dichas anterioridades.

**a) Los fosforotioatos de fórmula I reclamados en el capítulo reivindicatorio modificado adjunto al presente memorial no pueden ser derivados de manera obvia a partir de las enseñanzas del documento D1.**

De conformidad con lo señalado por el señor Examinador en la Resolución Número **2763**, el documento D1 divulga compuestos análogos de nucleósidos de tiofosforamidatos que tienen el sustituyente aminoácido y que tienen además utilidad en tratamientos de quimioterapia del cáncer y que poseen actividad antiviral.

Asimismo, el señor Examinador señala que dichos compuestos requieren del metabolismo intracelular de 5-mononucleótidos por la fosforilación mediada por la cinasa para poder tener actividad biológica. A su vez, dicho documento D1 revela que algunos nucleótidos-5-fosforamidatos son eficientes inhibidores del virus de VIH y proporcionan una interesante alternativa para desarrollar medicamentos nucleósidos antivirales (páginas 239 y 240).

Sin embargo, tras la atenta lectura y revisión de las enseñanzas de D1, me permito manifestar que el documento D1 tiene las siguientes deficiencias en comparación con la solicitud denegada:

❖ El documento D1 es en realidad un estudio mecánico de la reacción de desfosforilación catalizada con bases de análogos de nucleósidos. En este sentido, en ningún lugar del documento se presenta información o datos biológicos que soporten alguna actividad antiviral.


❖ El único enunciado sobre un tipo de actividad biológica se encuentra en la página 239 del documento, y se refiere a que "*algunos nucleótidos-5-fosforamidatos son eficientes inhibidores del virus de VIH y han atraído la atención como pro-drogas nucleósidas antivirales*", tal y como señalo el señor Examinador en la Resolución aquí impugnada. No obstante, dicha premisa se hace sin demostrar ningún soporte

estadístico o cuantitativo, lo que indica que tampoco se presentan datos biológicos para soportar la posible actividad antiviral de dichos compuestos.


❖ En realidad, el documento D1 no sugiere con datos que sus compuestos tengan alguna actividad biológica relevante.

Ahora bien, en cuanto a la comparación de la fórmula I de la presente invención con las estructuras de los compuestos de D1, es evidente que existen diferencias estructurales significativas entre los fosforotioatos análogos de nucleótidos sustituidos reclamados en la solicitud impugnada y los compuestos del documento D1. Dichas diferencias, se exponen a continuación:

i. Los compuestos de D1 incluyen fosforamidoatos ( $P=O$ ) mientras que los compuestos de fórmula I de la presente solicitud son **fosforoamidotioatos ( $P=S$ )**.




Fórmula I de la presente aplicación




Ejemplos de Compuestos del documento D1

ii. Los compuestos de D1 tienen en la posición  $R^2$  un  $-OH$  o un alquilo mientras que los compuestos de fórmula I de la presente solicitud en dicha posición  $R^2$  tienen exclusivamente un benceno, naftaleno y azuleno.




Fórmula I de la presente aplicación




Ejemplos de Compuestos del documento D1

iii. Los compuestos de D1 tienen en las posiciones  $R^6/ R^7$  un grupo alquilo unido (específicamente, un dimetilacetal) mientras que los compuestos de fórmula I de la presente solicitud en **dichas posiciones tienen un hidrógeno halógeno, -OR<sup>12</sup> u -OC(=O)R<sup>13</sup>.**




Fórmula I de la presente aplicación




Ejemplos de Compuestos del documento D1

iv. Los compuestos de D1 tienen en la posición  $R^8$  un hidrógeno mientras que los compuestos de fórmula I de la presente solicitud en dicha posición **R<sup>8</sup> tienen exclusivamente un halógeno o un alquilo C<sub>1-6</sub> no sustituido, el cual es preferiblemente un metilo.**



## Fórmula I de la presente aplicación



Ejemplos de Compuestos del documento D1

Ante esta última diferencia en la posición R<sup>8</sup>, me permito manifestar que esta sustitución en la posición 2' de la ribosa es crucial para la actividad anti-HCV, tal y como lo expresa Coats, S.J. et al. en Antiviral Res. Vol 102, pp. 119-147 (2104) (ver anexo). Ahora, ya que los compuestos del documento D1 no presentan dicha sustitución en la posición 2, donde sólo tienen un hidrógeno, no se esperaría que dichos análogos de nucleósidos tuvieran un efecto antiviral en contra de un virus, tal y como el de la Hepatitis C. En otras palabras, los compuestos de D1 carecen del sustituyente químico que proporcionaría alguna actividad antiviral.

Por lo tanto, una persona versada en la materia reconocería que dichos compuestos de D1 constituyen una mera y simple modificación a nucleósidos que ocurren naturalmente y que tendrían poca o ninguna actividad antiviral. **Es así, que una persona versada en la materia no se vería motivada a usar los compuestos del documento D1 para modificar análogos de nucleósidos y obtener una actividad antiviral adecuada.**

**b) Los fosforotioatos de fórmula I reclamados en el capítulo reivindicatorio modificado adjunto al presente memorial tampoco pueden ser derivados de manera evidente a partir de las enseñanzas del documento D2.**

Siguiendo el análisis de nivel inventivo, el documento D2 divulga análogos de nucleósidos con particular actividad beneficiosa para tratar la diabetes tipo 2, intolerancia a la glucosa, hiperinsulinemia, resistencia a la insulina, entre otros. Además, dicho documento D2 divulga la posibilidad que los compuestos pueden tener efectos beneficiosos contra el cáncer.

Sin embargo, tras la atenta lectura y revisión de las enseñanzas de D2, me permito manifestar que dicho documento también presenta ciertas deficiencias al comparar sus enseñanzas con la información de la invención de la solicitud denegada:

❖ La información relacionada con la actividad anticancerígena de los compuestos del documento D2 es puramente teórica. En este sentido, tampoco existe información o datos biológicos en ninguna parte del documento D2 que soporten actividad contra el cáncer o contra algún virus.

❖ El vínculo entre la proteína AMPK y el *"crecimiento y/o supervivencia de alguna células cancerígenas"*, como es revelado en el documento D2, es irrelevante para la sugerencia de la actividad antiviral de los compuestos de fórmula I de la presente invención. En este sentido, AMPK no tiene ninguna relación con la con la actividad antiviral, puesto que dicha enzima detecta fluctuaciones en la proporción de ATP y sus producto catabólico, el AMP.


❖ Al evaluar las enseñanzas del documento D2, el señor Examinador falla en reconocer que análogos de nucleósidos antivirales generalmente tienen una actividad baja en enzimas de mamíferos comparada a la actividad de análogos de nucleósidos anticancerígenos (Jordheim, L.P. et al. Nat. Rev. Drug Discovery. Vol. 12, pp. 447-464 (2013)). Esta baja actividad de nucleósidos antivirales en enzimas de mamíferos resulta en ninguna actividad cancerígena o efectos alternos.

❖ En relación a lo anterior, el señor Examinador también falla en reconocer que los análogos de nucleósidos antivirales son generalmente más diversos a nivel estructural que análogos de nucleósidos anticancerígenos, y por lo tanto, su actividad en contra del cáncer no confiere ninguna actividad en contra de un virus.


❖ El documento D2 presenta únicamente información y datos biológicos relacionados a niveles de azúcar en la sangre y niveles de triglicéridos en el serum. En este sentido, no revelan ningún soporte cuantitativo sobre alguna actividad en contra del cáncer o un virus de los compuestos reclamados.

De forma similar al análisis del documento D1, me permito manifestar que se encontraron también diferencias estructurales significativas entre los fosforotioatos análogos de nucleótidos sustituidos reclamados en la solicitud impugnada y los compuestos del documento D2. Dichas diferencias, se exponen a continuación:

i. Los compuestos de D2 pueden ser fosforamidoatos ( $P=O$ ) mientras que los compuestos de fórmula I de la presente solicitud son **fosforoamidotioatos ( $P=S$ )** (ver círculo rojo). Asimismo, los compuestos de D1 pueden tener un  $-OH$  en la posición  $R^1$  mientras que los compuestos de fórmula I de la solicitud tienen un aminoácido opcionalmente sustituido o un derivado éster de un aminoácido opcionalmente sustituido (ver flecha azul).




Fórmula I de la presente aplicación




Ejemplos 10 del documento D2

ii. Los compuestos de D2 incluyen  $\beta$ -S-tiofosfatos ( $P=S$  en el segundo átomo de fósforo) mientras que los compuestos de fórmula I de la presente solicitud son  **$\alpha$ -S-fosforamidotioatos**.




Fórmula I de la presente aplicación




Ejemplos 3 del documento D2

iii. Los compuestos de D2 incluyen  $\gamma$ -S-tiofosfatos ( $P=S$  en el tercer átomo de fósforo) mientras que los compuestos de fórmula I de la presente solicitud son  **$\alpha$ -S-fosforamidotioatos**.




Fórmula I de la presente aplicación




Ejemplos 1 del documento D2

iv. Los compuestos de D2 tienen en la posición  $R^8$  un hidrógeno mientras que los compuestos de fórmula I de la presente solicitud en dicha posición  $R^8$  **tienen exclusivamente un halógeno o un alquilo  $C_{1-6}$  no sustituido, el cual es preferiblemente un metilo.**



Fórmula I de la presente aplicación



Fórmula General del documento D2

Similar a los anteriores argumentos para el documento D1, **una persona versada en la materia no se vería motivada a usar los compuestos del documento D2 para modificar análogos de nucleósidos y obtener una actividad antiviral adecuada puesto que no existe referencia alguna a dicha actividad y las diferencias estructurales no sugieren la definición de los mismos sustituyentes de la fórmula I de los compuestos de la presente invención.**

c) **La combinación y separación de los agentes antirretrovirales en la formulación reclamada de ninguna manera puede ser derivada de las enseñanzas de los documentos D1 y D2.**

Antes de concluir con el análisis de las diferencias, es importante resaltar que algunos argumentos de la Resolución aquí impugnada son confusos puesto que las referencias a los documentos y sus contenidos son incorrectas.

En este sentido, cuando el señor Examinador afirma que *"El documento D2 es considerado el estado de la técnica más cercano a los compuestos definidos en la reivindicación 1 porque divulga compuestos análogos de nucléosidos sustituidos por aminoácido (...)"* se comete una confusión con las enseñanzas de ambos documentos, puestos que es el documento D1 el que incluye dichos aminoácidos en su estructura.

Similarmente, cuando el señor Examinador señala que *"(...) esta Oficina observa que la persona normalmente versada esperaría que este tipo de compuestos tuviese actividad antiviral, como enseña previamente el documento D2 (...)"* se comete una confusión aún más relevante porque, como ya se discutió en el literal b del presente numeral, el documento D2 no revela por ningún lado compuestos con actividad en contra de un virus.

Ahora bien, en cuanto a las diferencias más significativas encontradas entre los documentos del arte previo, es evidente que la persona del oficio medianamente versada en la materia tendría que realizar varios tipos de modificaciones a las moléculas de los documentos D1 y D2, para llegar a los compuestos que se reclaman en la presente solicitud. En este sentido, **ninguno de los dos documentos brinda ninguna sugerencia acerca de que estas modificaciones deben realizarse con el fin de llegar a obtener compuestos más adecuados.**

En este sentido, es claro que **aun cuando la persona versada en la materia incluyera el sustituyente aminoácido de D1 en los compuestos de D2, los compuestos resultantes todavía serían diferentes a los aquí reclamados ya que aún carecerían de los específicos sustituyentes que se reclaman con el capítulo reivindicatorio modificado.**

En ese orden de ideas, es claro que el señor Examinador tampoco proporciona razones técnicas que expliquen cómo la adición de un sustituyente aminoácido de D1 en los compuestos revelados en el documento D2, puede dar lugar a nuevos compuestos con una importante actividad antiviral. Tal y como se demostró a través del análisis en este memorial, dicha actividad se encuentra atribuida a la sustitución del sustituyente R<sup>8</sup> en la posición 2' de la ribosa. Ya que ninguno de los dos documentos presenta una sustitución en dicha posición, la persona versada en la materia no podría basarse en sus enseñanzas para aplicar la sustitución a dicho radical y obtener los compuestos con actividad antiviral.

En vista de todo lo anterior, es evidente que las enseñanzas del documento D2 de ninguna manera complementan las enseñanzas de D1 para llegar a los compuestos de la invención, mucho más si se tiene en cuenta que el documento D2 no hace mención alguna sobre compuestos análogos de nucleótidos con actividad antiviral, específica para el virus de la Hepatitis C.

Consecuentemente, me permito afirmar que **se descarta cualquier indicio de obviedad en las posibles modificaciones a los sustituyentes del compuesto de fórmula I y se evidencia el nivel inventivo de los fosforoamidotioatos análogos de nucleótidos de la nueva reivindicación 1 de la presente solicitud.**

Ahora bien, el punto no es si un experto en la materia podría haber llegado a la invención mediante la adaptación o modificación de las enseñanzas del documento D2 mediante las enseñanzas divulgadas en D1, sino que si lo hubiera hecho de esa manera, ¿por qué el documento D2 le motivó a hacerlo con la expectativa de resolver el problema técnico objetivo?

Es más, **¿qué razón tendría la persona versada en la materia para que, a la luz del problema resuelto por la presente invención, decidiera modificar los compuestos de D2 de manera que las estructuras resultantes comprendan compuesto derivados de fórmula I, y no otro tipo de modificación?**

En conexión con lo anterior, muy respetuosamente me permito señalar que la única motivación que tendría la persona versada en la materia para hacer esta particular modificación sería la revelación hecha por la presente invención, por lo que el análisis de nivel inventivo realizado por el Señor Examinador está enmarcado dentro de lo que en el ámbito de las patentes se conoce como "*hindsight*" o análisis "*Ex post facto*". Conociendo de antemano la invención, el Señor Examinador está seleccionando partes específicas de las enseñanzas contenidas dentro del documento D1, las cuales modifica de forma que permiten construir la materia reclamada por la reivindicación 1 de la presente solicitud. Dichas acciones o modificaciones de ningún modo podrían ser evidentes para la persona versada en la materia en el momento en el cual se desarrolló la invención.

En este sentido, vale la pena resaltar que, al tener conocimiento de la invención, es de esperarse que dichas modificaciones particulares de las enseñanzas de D2 parezcan obvias, toda vez que ya se sabe de antemano que efectivamente

estas sustituciones resuelven el problema planteado. Sin embargo, esta información no era conocida por el inventor en el momento de desarrollar la invención, por lo que no podría tener certeza de la utilidad de realizar estos pasos.

En vista de este señalamiento, y a la luz de lo discutido en el presente memorial, me permito resaltar que al no "*saltar a la vista de manera clara y directa*" a partir de la combinación de los documentos D1 y D2 un compuesto de fórmula I, como el considerado en la presente invención, y al no tenerse "*certeza clara y manifiesta*" de que dicho compuesto conservaría el efecto antiviral en contra del virus de la Hepatitis C, es claro que los documentos D1 y D2 no pueden de ninguna manera afectar el Nivel Inventivo de la solicitud en estudio.

#### **5. CONCESIÓN DE LA PRESENTE SOLICITUD EN OTRAS OFICINAS DE PATENTES.**

Finalmente y aparte de lo mencionado hasta el momento en el presente recurso, atentamente me permito resaltar ante ese Despacho que la materia revelada en la solicitud de patente en cuestión ha sido considerada como materia patentable por parte de los examinadores de la USPTO, y como consecuencia de ello ha sido concedida la patente US 8,871,737 . Adjuntamos al presente recurso copia del documento de dicha patente americana y de la decisión de conceder una patente americana (Notice of Allowance).

Así las cosas, considero de gran importancia resaltar el hecho particular de que la patentabilidad de la solicitud ha sido reconocida por los Examinadores de la USPTO, teniendo en cuenta, lo establecido en la Resolución Número 54093 de 2012, la cual en su numeral 1.2.2.5.21, establece el "*Reconocimiento de exámenes de patentabilidad de solitudes extranjeras*", y de donde se desprende la posibilidad de que a pesar de la independencia con la que cuenta la SIC, en vista de los recientes cambios en temas de patentes, ese Despacho ha empezado a darle credibilidad a las decisiones tomadas por las autoridades de Patentes de otros países, a través de la figura del "Patent Prosecution Highway PPH".

En este sentido, Colombia ha firmado el tratado del PPH con Estados Unidos, permitiendo así reconocer que a pesar de la independencia de las Oficinas de Patentes, si una solicitud ha sido reconocida como patentable en dicho país como en el presente caso en Estados Unidos, se entiende que la decisión emitida por dicha oficina, tiene más peso y puede ser tenida en cuenta a la hora de revisar la patentabilidad de una solicitud.

Por lo anterior, respetuosamente solicitamos a ese Despacho, que a la hora de revisar este caso, tenga en cuenta el resultado emitido por otra Autoridad de Patente como lo es la USPTO, y que el mismo sea considerado como un indicio fuerte de que la presente solicitud sí cuenta con los requisitos de patentabilidad exigidos por la normativa andina.

## **II. CONCLUSIÓN**

Con base en los argumentos técnicos mostrados previamente me permito manifestar ante ese Despacho que el capítulo reivindicatorio actualmente presentado goza de un inequívoco carácter novedoso frente a las enseñanzas de los documentos D1 y D2, razón por la cuales dicha materia es clara merecedora del privilegio de patente solicitado.

Así mismo me permito manifestar que el nuevo capítulo reivindicatorio cumple a cabalidad con las disposiciones de claridad exigidas por el artículo 30 de la Decisión 486 de 2000, respectivamente.

## **III. PETICIÓN**

En vista de todo lo anterior, ruego a usted proceder a estudiar nuevamente la solicitud a la luz de las modificaciones y argumentaciones presentadas, y proceder a revocar la Resolución Número **2763**, con el fin de que se conceda el privilegio de patente solicitado..

## **IV. PODER**

En este punto me permito mencionar ante ese Despacho, que el documento que acredita mi calidad de Representante Legal en Bogotá para asuntos relativos a la Propiedad Industrial de la sociedad peticionaria, fue presentado mediante mi memorial de 23 de Mayo de 2013.

## **V. ANEXOS**

Anexo al presente recurso me permito presentar:

- i) Para la solicitud original los anexos tal como fueron especificados en el **punto 1. , literal b) , i**
- ii) Para la solicitud divisional los anexos tal como fueron especificados en la **punto 1. , literal b), ii.**

**LLOREDACAMACHO & CO.**


Calle 72 No. 5-83 Piso 5, Bogotá, D.C. Tel: 6069700 Fax 6069701

---

**VI. DOMICILIO**

Mi dirección es Calle 72 No. 5-83, Piso 6º, Bogotá D.C.

Del Señor Superintendente,




ALICIA LLOREDARICAURTE

T.P. 53.215

# REIVINDICACIONES

1. Un compuesto de Fórmula (I), o una sal farmacéuticamente aceptable del mismo:



en donde:

B<sup>1</sup> es una base de purina opcionalmente sustituida o una base de pirimidina opcionalmente sustituida;

R<sup>1</sup> se selecciona del grupo que consiste en un aminoácido opcionalmente sustituido enlazado en el átomo de N y un derivado éster de un aminoácido opcionalmente sustituido enlazado en el átomo de N;

R<sup>2</sup> se selecciona del grupo que consiste en benceno, naftaleno y azuleno.

R<sup>3a</sup> y R<sup>3b</sup> se seleccionan independientemente de hidrógeno, deuterio o metilo;

R<sup>4</sup> es hidrógeno;

R<sup>5</sup> es hidrógeno;

R<sup>6</sup> se selecciona del grupo que consiste en hidrógeno, halógeno, -OR<sup>12</sup> y -OC(=O)R<sup>13</sup>;

R<sup>7</sup> se selecciona del grupo que consiste en hidrógeno, halógeno, -OR<sup>14</sup> y -OC(=O)R<sup>15</sup>;

o R<sup>6</sup> y R<sup>7</sup> son ambos átomos de oxígeno y están enlazados entre sí mediante un grupo carbonilo;

R<sup>8</sup> se selecciona del grupo que consiste en halógeno y un alquilo C<sub>1-6</sub> no sustituido;


R<sup>9</sup> es hidrógeno;

R<sup>12</sup> y R<sup>14</sup> son independientemente hidrógeno y un alquilo C<sub>1-6</sub> no sustituido; y

R<sup>13</sup> y R<sup>15</sup> son independientemente un alquilo C<sub>1-6</sub> no sustituido o un cicloalquilo C<sub>3-6</sub> no sustituido; y

en donde, cuando un sustituyente está sustituido, esta sustituido por un grupo individualmente e independientemente seleccionado de alquiloC<sub>1-6</sub>, alqueniloC<sub>2-6</sub>, alquiniloC<sub>1-6</sub>, cicloalquiloC<sub>3-8</sub>, cicloalquenilo, ariloC<sub>6-10</sub>, heteroarilo, heteroalíclicilo, (aril)alquiloC<sub>1-4</sub>, (heteroaril)alquiloC<sub>1-4</sub>, (heteroalíclicil)alquiloC<sub>1-4</sub>, hidroxí, alcoxi, ariloxi, acilo, ciano, halógeno, nitro, sulfonilo, un amino, un grupo amino mono-sustituido y un grupo amino di-sustituido.

2. El compuesto de la reivindicación 1, en donde R<sup>2</sup> es un fenilo opcionalmente sustituido.
3. El compuesto de cualquiera de las reivindicaciones 1 o 2, en donde R<sup>1</sup> es un  $\alpha$ -aminoácido unido a N opcionalmente sustituido
4. El compuesto de cualquiera de las reivindicaciones 1 o 2, en donde R<sup>1</sup> es un derivado de éster de  $\alpha$ -aminoácido unido a N opcionalmente sustituido.
5. El compuesto de cualquiera de las reivindicaciones 1 o 2, en donde R<sup>1</sup> se selecciona del grupo que consiste en alanina, asparagina, aspartato, cisteína, glutamato, glutamina, glicina, prolina, serina, tirosina, arginina, histidina, isoleucina, leucina, lisina, metionina, fenilalanina, treonina, triptófano, valina y derivados de éster de los mismos.
6. El compuesto de la reivindicación 5, en donde R<sup>1</sup> se selecciona del grupo que consiste en éster isopropílico de alanina, éster ciclohexílico de alanina, éster neopentílico de alanina, éster isopropílico de valina y éster isopropílico de leucina.
7. El compuesto de cualquiera de las reivindicaciones 1 o 2, en donde R<sup>1</sup> tiene la estructura



en donde  $R^{22}$  se selecciona del grupo que consiste en hidrógeno, un alquilo  $C_{1-6}$  opcionalmente sustituido, un cicloalquilo  $C_{3-6}$  opcionalmente sustituido, un arilo opcionalmente sustituido, un aril(alquilo  $C_{1-6}$ ) opcionalmente sustituido y un haloalquilo opcionalmente sustituido;  $R^{23}$  se selecciona del grupo que consiste en hidrógeno, un alquilo  $C_{1-6}$  opcionalmente sustituido, un haloalquilo  $C_{1-6}$  opcionalmente sustituido, un cicloalquilo  $C_{3-6}$  opcionalmente sustituido, un arilo  $C_6$  opcionalmente sustituido, un arilo  $C_{10}$  opcionalmente sustituido y un aril(alquilo  $C_{1-6}$ ) opcionalmente sustituido; y  $R^{24}$  es hidrógeno o un alquilo  $C_{1-4}$  opcionalmente sustituido; o  $R^{23}$  y  $R^{24}$  se toman juntos para formar un cicloalquilo  $C_{3-6}$  opcionalmente sustituido.


8. El compuesto de la reivindicación 7, en donde  $R^{23}$  es un alquilo  $C_{1-6}$  opcionalmente sustituido.


9. El compuesto de la reivindicación 8, en donde el alquilo  $C_{1-6}$  opcionalmente sustituido es metilo

10. El compuesto de cualquiera de las reivindicaciones 7 a 9, en donde  $R^{24}$  es hidrógeno.


11. El compuesto de cualquiera de las reivindicaciones 7 a 10, en donde  $R^{22}$  es un alquilo  $C_{1-6}$  opcionalmente sustituido o un cicloalquilo  $C_{3-6}$  opcionalmente sustituido.

12. El compuesto de la reivindicación 7, en donde





13. El compuesto de la reivindicación 12, en donde




14. El compuesto de cualquiera de las reivindicaciones 1 a 13, en donde  $R^8$  es metilo.

15. El compuesto de cualquiera de las reivindicaciones 1 a 14, en donde ambos  $R^{3a}$  y  $R^{3b}$  son hidrógeno.

16. El compuesto de cualquiera de las reivindicaciones 1 a 15, en donde  $R^6$  es  $-OH$  o  $-OC(=O)$ alquilo  $C_{1-6}$ ; y donde  $R^7$  es  $-OH$ ,  $-OC(=O)$ alquilo  $C_{1-6}$  o halógeno; o  $R^6$  y  $R^7$  son ambos átomos de oxígeno y están unidos mediante un grupo carbonilo.

17. El compuesto de cualquiera de las reivindicaciones 1 a 16, en donde  $B^1$  se selecciona del grupo que consiste en:




R<sup>F2</sup> es hidrógeno, halógeno o metilo;


R<sup>G2</sup> es un alquilo C<sub>1-6</sub> no sustituido; y


R<sup>H2</sup> es hidrógeno o NH<sub>2</sub>.


18. El compuesto de la reivindicación 17, en donde B<sup>1</sup> es





19. El compuesto de la reivindicación 1, en donde el compuesto de Fórmula (I) se selecciona del grupo que consiste en:



















o una sal farmacéuticamente aceptable de los anteriores.

20. El compuesto de la reivindicación 1, en donde el compuesto de Fórmula (I) es




o una sal farmacéuticamente aceptable del mismo.

21. El compuesto de la reivindicación 20, en donde el compuesto de Fórmula (I) es




o una sal farmacéuticamente aceptable del mismo.

22. El compuesto de la reivindicación 20, en donde el compuesto de Fórmula (I) es




o una sal farmacéuticamente aceptable del mismo.

23. El compuesto de la reivindicación 1, en donde el compuesto de Fórmula (I) es




o una sal farmacéuticamente aceptable del mismo.

24. El compuesto de la reivindicación 23 en donde el compuesto de Fórmula (I) es



o una sal farmacéuticamente aceptable del mismo.

25. El compuesto de la reivindicación 23 en donde el compuesto de Fórmula (I) es



o una sal farmacéuticamente aceptable del mismo.

26. Una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto de cualquiera de las reivindicaciones 1 a 25, o una sal farmacéuticamente aceptable del mismo, y un portador, diluyente, excipiente farmacéuticamente aceptable o combinación de los mismos.



US008871737B2

Exp. 13-084.068

26

(12) **United States Patent**  
**Smith et al.**

(10) **Patent No.:** **US 8,871,737 B2**  
(45) **Date of Patent:** **Oct. 28, 2014**

(54) **SUBSTITUTED NUCLEOTIDE ANALOGS**

(75) **Inventors:** **David Bernard Smith**, San Mateo, CA (US); **Jerome Deval**, Pacifica, CA (US); **Natalia Dyatkina**, Mountain View, CA (US); **Leonid Beigelman**, San Mateo, CA (US); **Guangyi Wang**, Carlsbad, CA (US)

(73) **Assignee:** **Alios BioPharma, Inc.**, South San Francisco, CA (US)

(\*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 307 days.

(21) **Appl. No.:** **13/236,435**

(22) **Filed:** **Sep. 19, 2011**

(65) **Prior Publication Data**

US 2012/0071434 A1 Mar. 22, 2012

**Related U.S. Application Data**

(60) Provisional application No. 61/385,363, filed on Sep. 22, 2010, provisional application No. 61/426,461, filed on Dec. 22, 2010.

(51) **Int. Cl.**

**A61K 31/70** (2006.01)  
**C07H 19/04** (2006.01)  
**C07H 19/10** (2006.01)  
**C07H 19/20** (2006.01)  
**C07H 19/06** (2006.01)  
**A61K 31/7072** (2006.01)  
**C07H 19/16** (2006.01)  
**A61K 45/06** (2006.01)  
**A61K 31/7076** (2006.01)

(52) **U.S. Cl.**

CPC ..... **C07H 19/10** (2013.01); **C07H 19/06** (2013.01); **A61K 31/7072** (2013.01); **C07H 19/16** (2013.01); **A61K 45/06** (2013.01); **A61K 31/7076** (2013.01); **C07H 19/20** (2013.01)  
USPC ..... **514/47**; **514/58**; **514/51**; **536/26.26**; **536/26.7**; **536/26.8**

(58) **Field of Classification Search**

CPC ..... **C07H 19/10**; **C07H 19/20**  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2,844,579 A 7/1958 Turner et al.  
3,180,859 A 4/1965 Hoeksema  
3,431,252 A 3/1969 Walton  
3,816,399 A 6/1974 Shaw et al.  
3,872,084 A 3/1975 Jones et al.  
3,872,098 A 3/1975 Jones et al.  
4,093,714 A 6/1978 Tolman et al.  
4,808,614 A 2/1989 Hertel  
5,378,825 A 1/1995 Cook et al.  
5,432,272 A 7/1995 Benner  
5,552,311 A 9/1996 Sorscher et al.  
5,578,718 A 11/1996 Cook et al.

5,580,967 A 12/1996 Joyce  
5,602,240 A 2/1997 De Mesmaeker et al.  
5,610,289 A 3/1997 Cook et al.  
5,616,488 A 4/1997 Sullivan et al.  
5,620,676 A 4/1997 Jacobson et al.  
5,625,056 A 4/1997 Genieser et al.  
5,631,359 A 5/1997 Chowrira et al.  
5,631,360 A 5/1997 Usman et al.  
5,639,647 A 6/1997 Usman et al.  
5,646,128 A 7/1997 Firestein et al.  
5,658,780 A 8/1997 Stinchcomb et al.  
5,677,437 A 10/1997 Teng et al.  
5,681,940 A 10/1997 Wang et al.  
5,686,599 A 11/1997 Tracz  
5,693,532 A 12/1997 McSwiggen et al.  
5,714,383 A 2/1998 Thompson  
5,721,350 A 2/1998 Chattopadhyaya  
5,728,684 A 3/1998 Cheng et al.  
5,744,595 A 4/1998 Srivastava et al.  
5,767,097 A 6/1998 Tam  
5,783,425 A 7/1998 Dudycz et al.  
5,804,683 A 9/1998 Usman et al.  
5,807,718 A 9/1998 Joyce et al.  
5,811,300 A 9/1998 Sullivan et al.  
5,831,071 A 11/1998 Usman et al.  
5,837,542 A 11/1998 Grimm et al.  
5,837,855 A 11/1998 Chowrira et al.  
5,871,918 A 2/1999 Thorp et al.  
5,892,024 A 4/1999 Chaturvedula et al.  
5,902,880 A 5/1999 Thompson  
5,952,478 A 9/1999 Baxter et al.  
5,965,721 A 10/1999 Cook et al.  
5,968,745 A 10/1999 Thorp et al.  
5,977,343 A 11/1999 Tracz  
5,985,621 A 11/1999 Usman et al.  
6,004,939 A 12/1999 Chen et al.  
6,017,896 A 1/2000 Sorscher et al.  
6,022,962 A 2/2000 Chowrira et al.  
6,030,957 A 2/2000 Uckun et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**

CA 2252144 4/2000  
CN 1290707 A 12/2001

(Continued)

**OTHER PUBLICATIONS**

Gwack et al., "DNA Helicase Activity of the Hepatitis C Virus Nonstructural Protein 3," *European Journal of Biochemistry*, 250 (1), 47-54 (1997).\*

(Continued)

*Primary Examiner* — Lawrence E Crane

(74) *Attorney, Agent, or Firm* — Knobbe Martens Olson & Bear LLP

(57) **ABSTRACT**

Disclosed herein are phosphorothioate nucleotide analogs, such as thiophosphoramidate prodrugs and thiophosphates (including  $\alpha$ -thiomonophosphates,  $\alpha$ -thiodiphosphates, and  $\alpha$ -thiotriphosphates), methods of synthesizing phosphorothioate nucleotide analogs, such as thiophosphoramidate prodrugs, and thiophosphates and methods of treating viral infections, such as HCV, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs, such as thiophosphoramidate prodrugs, and thiophosphates.

**65 Claims, 25 Drawing Sheets**

|                               |                                      |                                     |                                                  |
|-------------------------------|--------------------------------------|-------------------------------------|--------------------------------------------------|
| <b>Notice of Allowability</b> | <b>Application No.</b><br>13/236,435 | <b>Applicant(s)</b><br>SMITH ET AL. |                                                  |
|                               | <b>Examiner</b><br>Lawrence E. Crane | <b>Art Unit</b><br>1673             | <b>AIA (First Inventor to File) Status</b><br>No |

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the amendment filed 05/28/2014.  
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on \_\_\_\_\_.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on \_\_\_\_\_; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are 1-5,9-12,14-20,23,30,31,33,34,37,40,42,49,50,52-58,61,62,65-70,72-85,88,89 and 92-99. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see [http://www.uspto.gov/patents/init\\_events/pph/index.jsp](http://www.uspto.gov/patents/init_events/pph/index.jsp) or send an inquiry to [PPHfeedback@uspto.gov](mailto:PPHfeedback@uspto.gov).
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

**Certified copies:**

- a) ☐ All    b) ☐ Some    \*c) ☐ None of the:
  1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.  
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.  
**Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).**
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

1. ☒ Notice of References Cited (PTO-892)
2. ☒ Information Disclosure Statements (PTO/SB/08),  
 Paper No./Mail Date 3 documents
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
4. ☒ Interview Summary (PTO-413),  
 Paper No./Mail Date 20140528.
5. ☐ Examiner's Amendment/Comment
6. ☒ Examiner's Statement of Reasons for Allowance
7. ☐ Other \_\_\_\_\_.

/Lawrence E. Crane/  
 Primary Examiner, Art Unit 1673

PubMed

Exp. 13-089.868

Abstract

Full text links

Nat Rev Drug Discov. 2013 Jun;12(6):447-64. doi: 10.1038/nrd4010.

PUBLISHED  
REVIEWS

## Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Jordheim LP<sup>1</sup>, Durantel D, Zoulim F, Dumontet C.

### Author information

### Abstract

Nucleoside analogues have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with cancer or viral infections. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Here, we review new nucleoside analogues and associated compounds that are currently in preclinical or clinical development for the treatment of cancer and viral infections, and that aim to provide increased response rates and reduced side effects. We also highlight the different approaches used in the development of these drugs and the potential of personalized therapy.

PMID: 23722347 [PubMed - indexed for MEDLINE]

### Publication Types, MeSH Terms, Substances

### LinkOut - more resources

### PubMed Commons

[PubMed Commons home](#)

0 comments

[How to join PubMed Commons](#)



Published in final edited form as:

*Antiviral Res.* 2014 February ; 102: 119–147. doi:10.1016/j.antiviral.2013.11.008.

## Chutes and Ladders in Hepatitis C Nucleoside Drug Developments<sup>§</sup>

Steven J. Coats<sup>a</sup>, Ethel C. Garnier-Amblard<sup>a</sup>, Franck Amblard<sup>b</sup>, Maryam Ehteshami<sup>b</sup>, Sheida Amiralaie<sup>b</sup>, Hongwang Zhang<sup>b</sup>, Longhu Zhou<sup>b</sup>, Sebastien R. L. Boucle<sup>b</sup>, Xiao Lu<sup>b</sup>, Lavanya Bondada<sup>b</sup>, Jadd R. Shelton<sup>b</sup>, Hao Li<sup>b</sup>, Peng Liu<sup>b</sup>, Chengwei Li<sup>b</sup>, Jong Hyun Cho<sup>b</sup>, Satish N. Chavre<sup>b</sup>, Shaoman Zhou<sup>b</sup>, Judy Mathew<sup>a</sup>, and Raymond F. Schinazi<sup>b,\*</sup>

<sup>a</sup>RFS Pharma, LLC, 1860 Montreal Road, Tucker, GA 30084, USA

<sup>b</sup>Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University, School of Medicine, and Veterans Affairs Medical Center, Decatur, GA 30033, USA

### Abstract

Chutes and Ladders is an exciting up-and-down-again game in which players race to be the first to the top of the board. Along the way, they will find ladders to help them advance, and chutes that will cause them to move backwards. The development of nucleoside analogs for clinical treatment of hepatitis C presents a similar scenario in which taking shortcuts may help quickly advance a program, but there is always a tremendous risk of being sent backwards as one competes for the finish line. In recent years the treatment options for chronic hepatitis C virus (HCV) infection have expanded due to the development of a replicon based *in vitro* evaluation system, allowing for the identification of multiple drugable viral targets along with a concerted and substantial drug discovery effort. Three major drug targets have reached clinical study for chronic HCV infection: the NS3/4A serine protease, the large phosphoprotein NS5A, and the NS5B RNA-dependent RNA polymerase. Recently, two oral HCV protease inhibitors were approved by the FDA and were the first direct acting anti-HCV agents to result from the substantial research in this area. There are currently many new chemical entities from several different target classes that are being evaluated worldwide in clinical trials for their effectiveness at achieving a sustained virologic response (SVR) (Pham et al., 2004; Radkowski et al., 2005). Clearly the goal is to develop therapies leading to a cure that are safe, widely accessible and available, and effective against all HCV genotypes (GT), and all stages of the disease. Nucleoside analogs that target the HCV NS5B polymerase that have reached human clinical trials is the focus of this review as they have demonstrated significant advantages in the clinic with broader activity against the various HCV GT and a higher barrier to the development of resistant viruses when compared to all other classes of HCV inhibitors.

### Keywords

Hepatitis C virus; HCV; nucleoside analog; nucleotide analog; antiviral; clinical evaluation; prodrug; clinical trials; nucleosides

<sup>§</sup>[http://en.wikipedia.org/wiki/Snakes\\_%26\\_ladders](http://en.wikipedia.org/wiki/Snakes_%26_ladders)

\*Corresponding author. Address: Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Veterans Affairs Medical Center, 1760 Haygood Drive, Room 418, Atlanta, GA 30322, USA. Tel.: +1-404-727-1414; fax: +1-404 417-1535. [rschina@emory.edu](mailto:rschina@emory.edu) (R. F. Schinazi).

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## 1. Introduction

The hepatitis C virus (HCV) was identified in 1989 as a member of the *Flaviviridae* family of positive-stranded RNA virus (Choo et al., 1989). Infection of a human host by HCV results in a serious infection affecting about 3% of the worldwide population, according to the World Health Organization (WHO). The WHO also estimates that 4 million people contract HCV each year (WHO, 2012). Although the early stages of HCV infection are usually asymptomatic, and about 20% of infected individuals will naturally clear the virus, a majority of infections progress to chronic infection. A significant number of chronically infected individuals will eventually develop more serious liver problems such as cirrhosis, hepatocellular carcinoma (HCC), or liver failure requiring liver transplantation (Darby et al., 1997; Poynard et al., 2000; Tong et al., 1995). The global health burden of HCV-associated morbidity and mortality is expected to increase substantially during the next decades, as many chronically infected individuals progress to end stage disease with associated complications (Davis et al., 2003; Manns et al., 2007). In fact, in industrialized nations, HCV infection is already the leading cause for liver transplantations. Unfortunately, re-infection of the transplanted liver from an unknown reservoir often occurs post-transplantation (Hoofnagle, 1997). The virus is transmitted parenterally by contaminated blood most often from sharing contaminated needles, but also from improper sterilization of medical, dental, body piercing, or tattoo equipment. Heterosexual transmission and vertical transmission (infected mother to her child during the birthing process) of HCV can also occur, but are rare (Fishman et al., 2009; Ghosn et al., 2009). Sexual practices that involve higher levels of trauma to the anogenital mucosa or that occur when there is a concurrent sexually transmitted infection, such as HIV or genital ulceration, do present a higher risk of HCV transmission (Tohme and Holmberg, 2010).

Three major drug targets have reached evaluation in humans for chronic HCV infection (Farnik and Zeuzem, 2012; Schaefer and Chung, 2012): the NS3/4A serine protease, the large phosphoprotein NS5A and NS5B RNA-dependent RNA polymerase (RdRp) (Bobeck et al., 2010; De Francesco and Migliaccia, 2005; Huang et al., 2006). The majority of drugs that target the HCV NS3/4A serine protease are peptidomimetics and represent the only two FDA approved direct acting antiviral agents for treatment of HCV infection. Although the ultimate role of NS5A in the HCV replication cycle is not fully understood, the 49 kDa NS5A protein is required for HCV replication as it is part of the membrane bound replication complex (Lemon et al., 2010). The two main categories of HCV NS5B RdRp inhibitors are non-nucleoside and nucleoside analog inhibitors (Brown, 2009; Burton and Everson, 2009; Legrand-Abravanel et al., 2010), which differ in their chemical structure, barrier to resistance, pan-genotypic activity and mode of action.

The current FDA-approved treatments for chronic HCV are limited to pegylated interferon- $\alpha$  (IFN) alone or in combination with ribavirin (RBV) with or without protease inhibitors (PI) boceprevir (Victrelis®) and telaprevir (Incivek®) (Fig. 1) (Hughes and Shafran, 2006; Pan et al., 2012; Sheridan, 2011). Non-pegylated IFNs have also been approved including the recombinant IFN alfacon1 and natural IFN, purified from the leukocyte fraction of human blood, multiferon. Unfortunately, these treatments have limited efficacy for the GT1 population, which is the most prevalent GT in the US and China and emphasize the urgent unmet medical need for new improved therapeutic agents that are pangenotypic (Manns et al., 2001; McCown et al., 2008). These treatments also have major side effects including depression, low red and/or white blood cell counts, central nervous system toxicity, fatigue, headache, flu-like symptoms, mild alopecia, thyroid dysfunction, itching, swelling of the face, eyes, lips, tongue, or throat, skin rashes, hemorrhoids, diarrhea and teratogenic effects (Fried, 2002; Gaetano and Reau, 2013; Gordon and Keller, 2005; Hezode et al., 2012;

Keicher et al., 2005; Koch and Narjes, 2007; McHutchison et al., 2002; Pawlotsky, 2003; Wong and Lee, 2006).

In the clinic, the primary treatment goal for chronically infected HCV (CHC) persons is lifelong clearance of detectable HCV infection. When new anti-HCV chemical entities are evaluated in clinical trials, the prediction of lifelong clearance of HCV infection is often assessed by a surrogate endpoint termed sustained virologic response (SVR). SVR is determined at  $\geq 12$  weeks after discontinuation of antiviral therapy and defined as non-detectable HCV RNA in serum that is measured by sensitive assays such as a polymerase chain reaction (PCR) based determination. Two earlier predictors of SVR during clinical trials are rapid virologic response (RVR) and early virologic response (EVR) which are defined as reduction of serum HCV RNA to PCR-non-detectable levels by week 4 and achievement of  $\geq 2 \log_{10}$  reduction in serum HCV RNA level by week 12, respectively. Not all persons who eventually achieve an SVR will have met the EVR or RVR milestones and conversely reaching any or all of these three categories do not guarantee lifelong clearance of detectable HCV infection. However, these guidelines are predictive of ultimate therapy success and help clinicians determine, for example, if persons with significant side effects that fail to achieve EVR or RVR should discontinue treatment.

Nucleoside analogs that target the HCV NS5B polymerase that have reached human clinical trials will be the focus of this review as they have demonstrated significant advantages in the clinic with broader activity against the various HCV GT and a higher barrier to the development of resistant viruses when compared to all other classes of HCV inhibitors (McCown et al., 2008). The HCV NS5B polymerase catalytic site is highly conserved across the various genotypes resulting in little variation of potency of the nucleoside triphosphate inhibitors that target this protein (Asselah and Marcellin, 2012; Waheed et al., 2013). Selection of HCV mutants *in vitro* has been quite difficult with most nucleoside inhibitors and selected mutants have been found markedly unfit with little to no clinical significance (Najera, 2013; Tong et al., 2013). There have been several nucleoside analogs discovered that exhibit selective anti-HCV activity, most with modifications at the 2' and/or 4' positions of the ribose sugar. However, nucleoside analogs as a class have potential problems such as poor passive cellular permeability and the modified nucleoside may not be a suitable substrate for the three successive cellular kinases that are necessary to transform it to the biologically active nucleoside analog triphosphate (NTP) (Fig. 2). Since HCV lacks nucleoside kinase expression, conversion to the biologically active nucleoside analog triphosphate relies on the human cellular kinases (Meppen et al., 2009). In addition, antiviral activity of nucleoside analogs is heavily influenced by the levels of natural dNTP or rNTP (Fig. 2) since they compete for incorporation by viral polymerases. Nucleoside analog inhibitors of viral RNA polymerization have the additional challenge of 10 to 100 times higher levels of rNTPs relative to the corresponding dNTP (Kennedy et al., 2010; Medivir, 2011a, b; Traut, 1994). Additionally, another significant obstacle in the development of nucleoside analogs for HCV therapy is their potential to be substrates and/or inhibitors of host polymerases. As an example, in the recent unfortunate events related to the 2'-methyl substituted guanosine analogs **IDX184** and **INX-189**, the human mitochondrial RNA polymerase has become of significant concern (Arnold et al., 2012).

Prodrugs are defined as a pharmacological substance administered in an inactive (or significantly less active) form that is metabolized into an active metabolite. Prodrugs are most often employed to improve absorption, distribution, metabolism, and/or elimination (ADME) properties of the parent pharmacological substance. One of the most common applications of prodrugs is for a drug that is poorly absorbed through the gastrointestinal tract to improve oral bioavailability. A prodrug may also be used to improve the selectivity by which the drug interacts with the intended target cells or processes versus those that are

not the drug's intended target. In the HCV area, nucleoside prodrugs have demonstrated both improvement of oral bioavailability and the ability to selectively deliver nucleotide analogs to liver tissue by first pass metabolism. Nucleoside analogs themselves are prodrugs of the active triphosphate form, which is recognized and incorporated by viral polymerases or reverse transcriptases. Antiviral activity of a nucleoside analog can often be improved by conversion to a prodrug as this aids in absorption and/or cellular penetration. In the case of monophosphate prodrugs, the potential rate limiting initial phosphorylation step is bypassed leading to higher intracellular nucleoside analog monophosphate levels which in many cases leads to significantly higher triphosphate levels that can translate to a significant enhancement in antiviral activity (De Clercq and Field, 2006; Hecker and Erion, 2008; Li et al., 2008; Polijärvi-Virta and Lönnberg, 2006; Sofia, 2011; Sofia et al., 2010a).

Prodrugs have played a central role in the delivery of active agents to their target tissue with improved efficiency and fewer side effects for well over 100 years. One of the earliest and enduring prodrug applications was to salicylic acid which when converted to acylsalicylic acid (Gerhardt, 1853; Von Gilm, 1859), significantly reduced irritation to the mouth and gastrointestinal tract (Fig. 3). Salicylic acid has been used for thousands of years to ease pain and reduce fever, but it was not until the period from 1826 to 1838 that salicylic acid was isolated by a series of chemists from willow tree bark (Jeffreys, 2005).

In 1856 an industrial scale process to make salicylic acid was developed from phenol and carbon dioxide (Kolbe, 1860; Schmitt, 1885), but interestingly the correct chemical structure was not assigned until 1869 that the correct chemical structure was assigned (Schröder and Kraut, 1869). In 1897, approximately 44 years after the first synthesis, acylsalicylic acid was first prepared by Bayer and in less than two years aspirin was trademarked and was being sold worldwide. As of 2013 (160 years after the first synthesis) more than 41 kilotons (metric) of aspirin is consumed annually worldwide. Many modern prodrugs utilize the same simple ester masking of a free hydroxyl group as a prodrug strategy as is exemplified by 3'-L-valinyl ester prodrug **NM283** (Fig. 4) or 2',3',5'-triisobutyrate ester prodrug **R1626** (Fig. 5) and 3',5'-diisobutyryl ester prodrug **RG7128** (Scheme 4) which are among the first HCV clinical candidates.

## 2. Valopicitabine (NM283): the first clinical HCV nucleoside

### 2.1. Preclinical development

2'-C-Methylcytidine (Harry-O'kuru et al., 1997) also known as **NM107** (Sommadosi et al., 2008; Sommadossi and La Colla, 2001a, b; Sommadossi et al., 2004a; Sommadossi et al., 2004b, c; Storer et al., 2004), was discovered by Idenix Pharmaceuticals to be a potent inhibitor of RNA viruses replication such as bovine viral diarrhea virus (BVDV), West Nile virus (WNV), dengue-2 virus, yellow fever virus (YFV) and subsequently HCV (Kowdley et al., 2013; Sommadossi and La Colla, 2001b). Despite its broad spectrum *in vitro* activity, **NM107** displayed low oral bioavailability. To overcome this issue, **NM283** (Sommadosi et al., 2008; Sommadossi and La Colla, 2001a, b; Sommadossi et al., 2004a; Sommadossi et al., 2004b, c; Storer et al., 2004) also called valopicitabine, the 3'-O-L-valinyl ester prodrug of **NM107**, was developed (Pierra et al., 2005). In March 2006, Novartis announced to exercise its option from Idenix Pharmaceuticals to in-license the late stage development of valopicitabine.

### 2.2. Synthesis of valopicitabine (NM283)

Large scale synthesis of **NM107** and **NM283** were achieved from commercially available D-fructose by first reaction with calcium oxide and then treatment with oxalic acid to give the key 2'-C-Me-lactone **1**. Subsequent benzoylation, reduction of the lactone with Red-Al

and benzylation of the lactol **3** afforded compound **4**. At this stage, Vorbrüggen type coupling with cytosine using  $\text{SnCl}_4$  as Lewis acid followed by debenzoylation gives access to **NM107**. **NM283** is finally obtained from **NM107** after simple peptidic coupling with *N*-Boc-L-valine and Boc-removal under acidic condition (Scheme 1) (Pierra et al., 2005).

### 2.3. Clinical development

**2.3.1. Phase I/II**—In 2004, the first phase I/II study of valopicitabine was reported, wherein 48 subjects received valopicitabine at 50, 100, 200, 400 and 800 mg/day orally once daily for 15 days with 14 days of follow-up; a subset of subjects received 400 mg twice daily (Godofsky et al., 2004). During these escalation trials, a dose-related decrease of serum HCV RNA at Day 16 was observed ranging from 0.15  $\log_{10}$  at the lowest dose to 0.73  $\log_{10}$  at 400 mg/twice daily. At 400 mg/day, 50% of the subjects experienced transient mild nausea and 20% had vomiting, but all completed treatment without modifications.

**2.3.2. Phase IIa**—Following the discovery of a synergistic antiviral effect against BVDV, *in vivo*, between **NM107**, the parent compound of valopicitabine (**NM283**) and IFN, a combination study with treatment-naïve subjects involving valopicitabine and IFN was initiated (Afdahl et al., 2005). Valopicitabine was given for 24 weeks with escalation to 800 mg/day over the first week before IFN was administered (1.0  $\mu\text{g/kg}$  weekly) on Day 8. Along with a satisfactory tolerance, HCV RNA reductions increased to 3.2  $\log_{10}$  IU/mL for the combination treatment group (compared to 1.0  $\log_{10}$  IU/mL for monotherapy group). Eleven of twelve subjects treated for at least 10 weeks had substantial HCV RNA reductions superior to 2  $\log_{10}$  and four subjects were PCR-negative (<10 IU/mL).

**2.3.3. Phase IIb**—In a Phase IIb clinical trial, a 48 weeks combination of valopicitabine and IFN was evaluated in treatment-naïve subjects with HCV GT1 (Dieterich et al., 2006; Lawitz et al., 2007). This study was divided into five treatment groups: (A) IFN alone (180  $\mu\text{g}$  QW = once weekly) for 4 weeks, valopicitabine 800 mg/day starting at week 5; (B) valopicitabine 200 mg/day + IFN (180  $\mu\text{g}$  QW); (C–E) valopicitabine 800 mg/day with various week 1 induction regimens + IFN (180  $\mu\text{g}$  QW). However, due to high gastrointestinal (GI) side effects at 800 mg/day dose of valopicitabine, the protocol was amended to reduce the dose to 200 or 400 mg/day after 14–22 weeks of treatment. The rate of viral decline was shown to be valopicitabine dose-related through week 4. HCV RNA was below 600 IU/mL in most subjects by week 12 and below 20 IU/mL by week 24 and 36. Group B maintained suppression of HCV RNA through week 48 along with satisfactory tolerability.

**2.3.4. Phase IIb**—In another Phase IIb trial (Afdahl et al., 2005), a 72 week three arm combination study involving valopicitabine/IFN in non-responder subjects was designed. Subjects were randomized to: (A) valopicitabine monotherapy (800 mg/day) and 3 combinations arms: IFN (180  $\mu\text{g}$  SQ/week) with RBV (1,000–1,200 mg/day) + (A) valopicitabine (400 mg/day); (C) dose escalation 400–800 mg/day; (D) 800 mg/day or IFN/RBV retreatment. Again, due to GI issues with the 800 mg/day dose, the maximum dose was reduced to 400 mg/day. At week 48, HCV RNA suppression of treated persons with doses of 800 mg/day or escalated-dose 400 to 800 mg/day of valopicitabine, was 6 fold greater (0.8  $\log_{10}$ ) than IFN/RBV treatment demonstrating the potency of valopicitabine for the treatment of non-responder persons.

### 2.4. Conclusions

Twelve days after Idenix announced on July 1<sup>st</sup> 2007, that a triple therapy with valopicitabine and IFN/RBV cleared HCV RNA in 72% of subjects after 12 weeks of

treatment, the FDA requested that the clinical trials on valopicitabine be discontinued due “to the overall risk/benefit profile observed to date in clinical testing” (Idenix, 2007). From the beginning, this drug as plagued with GI issues and unfortunately was not potent enough to be used alone or even when combined with the standard of care (IFN/RBV).

### 3. R1479 and its prodrug R1626: balapiravir

#### 3.1. Preclinical development

Discovered and developed by Hoffmann-La Roche, Inc., but aided by technology and compound libraries obtained by the 1994 purchase of Syntex Research, the 4'-azidocytidine derivative **R1479** (Ahmed et al., 2007; Connolly et al., 2005; Devos et al., 2002; Harrington et al., 2008; Martin et al., 2004) was identified as a potent and selective inhibitor of HCV RNA polymerase. **R1479** displayed an EC<sub>50</sub> of 1.3  $\mu$ M in an HCV replicon system and did not exhibit cytotoxic or cytostatic behavior in the Huh-7 replicon cell line (Smith et al., 2007). The triphosphate form of **R1479** was found to be a substrate for HCV polymerase and it inhibited RNA chain extension after incorporation as a non-obligatory chain terminator with an IC<sub>50</sub> of 320 nM (Klumpp et al., 2006). *In vitro* and *in vivo* assessment of **R1479** revealed that like many other nucleoside analogs, **R1479** was a polar molecule with a low aqueous solubility of 10 mg/mL that led to limited absorption after oral administration (Alfredson et al., 2006; Toniutto et al., 2008). Further, **R1479** exhibited low Caco-2 permeability [(Artursson et al., 1996); Caco-2 cells are used as a model system to predict intestinal epithelial permeability] and oral bioavailability values ranging from 22% in monkey to 89% in rat. Oral absorption in human clinical studies showed 6–18% based on urine recovery.

Consequently, prodrug approaches were investigated (Alfredson et al., 2006) to improve the oral bioavailability of **R1479**. Prodrug approaches that increase lipophilicity of a compound increase the potential for passive transport across cellular membranes and thus potentially improve absorption and transport across cellular membranes. The first approach focused on using esters and amides at the 2', 3' or 5' positions of sugar to increase the lipophilicity, the second approach focused on increased lipophilicity with liver targeted cleavage using carbamate prodrugs at N4 position of cytosine and the third approach focused on amino acid esters to potentially target the PepT1 transporter for increased active intracellular transport. A five-fold increase in plasma exposure was observed with tri-isobutyrate ester prodrug **R1626** (Ahmed et al., 2007; Connolly et al., 2005; Devos et al., 2002; Harrington et al., 2008; Martin et al., 2004) in oral bioavailability in rats and monkeys. Further, results from Caco-2 experiments (Brandl et al., 2008) indicated that the hydrolysis of the prodrug is rapid and converted to **R1479** by esterases in gastrointestinal epithelial cells. Exceptional enhancement of dose proportionality combined with a 3-fold enhancement of plasma exposure both in human studies versus oral administration of **R1479** resulted in the selection of tri-isobutyrate ester prodrug **R1626** for further clinical evaluation.

#### 3.2. Synthesis of R1479 and its prodrug balapiravir (R1626)

The synthesis of 4'-azidocytidine (**R1479**) (Connolly et al., 2005) and its triisobutyrate ester prodrug **R1626** (Sarma, 2007) is outlined in Scheme 2. Starting from uridine, 5'-iodo uridine was prepared then base eliminated to the 4'-exocyclic methylene nucleoside analog **7**. Addition of iodoazide across the double bond and benzylation gave the 5'-iodo,4'-azido bis-benzoylated nucleoside **8**. Oxidative displacement of the 5'-iodo gave the 5'-*m*-chlorobenzyl ester **9** that was converted to the cytidine analog and debenzoylated to give **R1479**. **R1626** was then formed in good yield by reaction with isobutyric anhydride in the presence of potassium hydroxide (Scheme 2).

### 3.3. Clinical development

**3.3.1. Phase I**—Starting in 2006, balapiravir (**R1626**) was given to healthy subjects in single doses from 500 mg to 12,000 mg to evaluate the safety, tolerability and pharmacokinetics. High levels of **R1479** was found in plasma accompanied by low levels of both mono and diester analogs. **R1479** was found in plasma in a linear amount proportional to all doses studied. Forty healthy male subjects (13 to 34 years old) were randomized 3:1 for treatment with **R1626** or placebo and were followed up for 7 days. The most common reported adverse effects were headache and irritation at the site of ECG electrode application. The phase I study concluded that balapiravir was efficiently absorbed, rapidly converted to **R1479** and was tolerated up to a dose of 12,000 mg when orally administered in healthy subjects (Robson et al., 2007).

**3.3.2. Phase Ib**—This clinical trial was designed to study the effect of **R1626** administered as monotherapy in HCV-infected persons. A total of forty-seven GT1 subjects were randomized to oral treatment of **R1626** with doses of 500, 1,500, 3,000, 4,500 mg and placebo for 14 days (Roberts et al., 2008). As seen in the phase I study, after oral administration, **R1626** was efficiently converted to **R1479** with dose proportional pharmacokinetics observed over the entire dose range. The mean viral concentration at baseline was 6.3 log<sub>10</sub> IU/mL, after 2 weeks of dosing; the mean (and median) viral concentration decreased by 1.2 (0.8), 2.6 (2.7) and 3.7 (4.1) log<sub>10</sub> at 1,500, 3,000 and 4,500 mg, respectively. **R1626** was generally well tolerated up to 3,000 mg twice a day with mild side effects and no serious adverse events. However, there were increased adverse events at the highest dose of 4,500 mg BID. The main adverse effect seen was reversible, mild to moderate hematological changes. This study resulted in a maximum dose of 3,000 mg twice a day for **R1626** in all future clinical trials. The study concluded that treatment with **R1626** as monotherapy significantly reduced plasma HCV viral load.

**3.3.3. Phase IIa**—In this study drug resistance, efficacy and safety of the combination therapy of **R1626** along with IFN with and without **RBV** was studied over four weeks in 107 GT1 treatment-naïve patients. Subjects were randomized to 1,500 mg or 3,000 mg BID of **R1626** with IFN or 1,500 mg BID with **RBV**. Control group received standard of care (SOC) as IFN and **RBV** (Pockros et al., 2008). After the four-week treatment period all four arms continued on SOC out to 48 weeks. Results were promising at week 4 with undetectable HCV RNA (<15 IU/ml) in 29%, 69% and 74% of subjects receiving 1,500 mg BID dual therapy, 3,000 mg BID dual therapy, and 1,500 mg BID triple drug therapy, respectively, compared with 5% in the SOC arm. Sequence analysis of the entire NS5B coding region of the samples from these subjects revealed no known **R1479** resistance mutations (S96T or S96T/N142T) when compared with the baseline sequence. The main adverse event noted was grade 4 neutropenia that occurred in 50% of the persons in the **R1626** treatment groups and occurred with 78% of the persons in the 3,000 mg BID group compared to 10% in the SOC arm. Overall, this study had safety concerns related to the drug; however, most AEs were mild (80%) or moderate (16%), but 4% were rated as severe. Strong synergistic antiviral effect was seen with **R1626**, IFN and **RBV**, which suggested that the dose of one or more of these drugs could be lowered to improve the tolerability without significantly compromising efficacy.

**3.3.4. Phase IIb**—This double-blind phase II trial assessed the optimal treatment protocol for balapiravir plus IFN/**RBV** (Nelson et al., 2012). Seven arms of treatment-naïve GT1 infected subjects (N = 516) were randomized and received balapiravir 500, 1,000, or 1,500 mg twice daily, IFN 180 or 90 µg/week and **RBV** 1,000/1,200 mg/day or IFN/**RBV**. Safety concerns reduced the planned treatment duration with balapiravir from 24 to 12 weeks. From week 2 to week 12 undetectable HCV RNA was more common in all balapiravir

groups. Ultimately, the efficacy assessment was compromised by high rates of dose modifications and discontinuations, which resulted in similar SVR rates in the balapiravir groups (32–50%) and IFN/RBV group (43%). Balapiravir showed dose related serious adverse events (especially hematological, infection, ocular events) and discontinued for safety reasons in 28–36% of patients (most often for lymphopenia). Balapiravir was considered possibly related to two deaths in the balapiravir/IFN/RBV combination groups.

### 3.4. Conclusions

In Oct-2008, following an unacceptable benefit to risk ratio revealed in later Phase IIb study and lack of superior efficacy, **R1626** was withdrawn from further consideration of future drug development in the treatment of chronic hepatitis C (Klump and Smith, 2011; Roche, 2008). Interestingly, **R1626** was evaluated in adult patients infected with dengue virus in a double-blind placebo controlled trial at 1,500 and 3,000 mg BID for five days. In August 2012, Roche reported **R1626** to be well tolerated but it demonstrated no viremia improvement versus the placebo arm (Nguyen et al., 2013). In our hands the parent 4'-azidocytidine nucleoside was a weak inhibitor in the HCV replicon system ( $EC_{50} = 11 \mu M$  and  $EC_{90} = 32 \mu M$ ) and it is unclear why this drug was selected to be developed in humans.

## 4. RG7348 (MB11362)

A collaboration and license agreement between Metabasis Therapeutics, Inc. and Roche began in 2008 for the development of new treatments for HCV infection utilizing pre-clinical candidate **MB11362** and the proprietary HepDirect<sup>®</sup> liver-targeting technology. The lead HepDirect nucleoside, renamed **RG7348**, was declared a clinical candidate in the second quarter of 2009. In January 2010, Ligand acquired Metabasis and subsequently, Roche advanced **RG7348** into Phase I clinical studies (Ligand, 2010).

### 4.1. Preclinical development

The structure of **RG7348** has not yet been disclosed, but it is known that it is a double prodrug that acts as a potent and selective HCV NS5B polymerase inhibitor (Nieforth et al., 2012). **RG7348** was designed to provide high intra-hepatic levels of 4'-azidouridine triphosphate (Fig. 6). Very little preclinical data has been disclosed for **RG7348**. After oral dosing, the double prodrug was subsequently transformed by esterases and CYP3A4 (cytochrome P450 3A4) to 4'-azidouridine monophosphate **10**, which was converted by kinases to the active 4'-azidouridine triphosphate **11**, a potent and selective inhibitor of HCV polymerase.

### 4.2. Clinical development

**4.2.1. Phase I**—In 2012 Nieforth and co-workers reported a Phase I study on safety, pharmacokinetics (PK) and anti-HCV activity for GT1 subjects with **RG7348**. The study was a randomized, double-blind, placebo-controlled single ascending dose study in healthy subjects (part A: 60 subjects with 12/placebo and 8/cohort receiving 15 mg, 50 mg, 150 mg, 300 mg, 600 mg and 1,200 mg), and multiple dose study in chronic HCV GT1 subjects (part B: 12 male subjects: 4/placebo and 8/**RG7348** 150 mg BID). After **RG7348** dosing,  $C_{max}$  and  $AUC_{inf}$  for (**10**) and (**11**) increased dose proportionally from 15 to 150 mg and less than dose proportionally at higher doses. **RG7348** was well tolerated in chronic HCV persons in this proof-of-concept study. Although **RG7348** was a novel liver-targeted HCV nucleotide polymerase inhibitor, which demonstrated promising safety and PK, there was limited observed antiviral effect (mean reduction in HCV RNA  $<0.8 \log_{10}$  IU/mL at all time points) at the dose studied.

### 4.3. Conclusions

In November 2010, Roche terminated the HCV development with Ligand. There was no statement from either company that explained the basis of this decision. In January 2011, Ligand Pharmaceuticals Inc. announced a strategic relationship with Chiva Pharmaceuticals to develop multiple Ligand assets. Chiva was granted a non-exclusive HepDirect® technology license for the discovery, development and commercialization of new compounds for HCV treatment, including **RG7348**. No other advances for **RG7348** have been reported to date. Although the HepDirect technology seemed interesting, it never delivered on the promise to be liver specific and to add value to the nucleoside analogs studied.

## 5. PSI-6130

### 5.1. Chemical synthesis

$\beta$ -D-2'-Deoxy-2'-fluoro-2'-C-methyl-cytidine (**PSI-6130**) was conceived from a combination of 2'-methyl of the HCV active **NM107** with the non-selective 2'-deoxy-2'-fluorocytidine (Cedilote et al., 2008; Clark, 2005). Also, at about the same time, Pharmasset scientists discovered the modest anti-HCV activity of gemcitabine which was another 2'-disubstituted nucleoside (Stuyver, 2003). **PSI-6130** was first synthesized from commercial available cytidine in about 3% total yield (Clark et al., 2005), but a more efficient, diastereoselective and scalable process was developed using commercially available isopropylidene protected D-glyceraldehyde (Wang et al., 2009). Thus, Wittig type reaction was performed with aldehyde **12** to give the unsaturated derivative **13** (Scheme 3). After oxidative dihydroxylation, compound **15** was selectively fluorinated. Cyclisation of ester **16** under acidic conditions gave lactone **17**, which after benzylation, reduction of the lactone and further acetylation gave the key sugar **19**. Finally, introduction of the cytosine base under Vorbrüggen type coupling condition and complete debenzylation afforded **PSI-6130** in a 6.4% overall yield.

### 5.2. Preclinical development

**PSI-6130** is a potent and specific HCV RNA-dependent RNA polymerase (RdRp) inhibitor with EC<sub>90</sub> of  $5.4 \pm 2.6$   $\mu$ M in Huh-7 replicon cells (Clark et al., 2005; Stuyver et al., 2006). It is interesting to note that just a few years earlier the commonly used BVDV surrogate assay would not have identified the anti-HCV activity of **PSI-6130** because **PSI-6130** was found to be highly specific for HCV over other RNA or DNA viruses. The 5'-triphosphate of **PSI-6130** was found to be equally active against the wild-type GT1b replicon clone and the S282T mutant replicon (Murakami et al., 2007). **PSI-6130** showed no apparent cytotoxicity against various cell types, including human bone marrow and human peripheral blood mononuclear cells. No mitochondrial toxicity was observed with **PSI-6130** (Stuyver et al., 2006). An *in vitro* triple combination study of **PSI-6130** with IFN and RBV at 1:1:1 ratio indicated synergistic antiviral effect, with no apparent cytotoxicity effects with any of the combinations tested (Bassit et al., 2008). Cell-based metabolism studies with primary human hepatocytes indicated that **PSI-6130** is a unique compound that gives rise to two nucleoside triphosphates that are both potent inhibitors of the HCV RdRp (Fig. 7) (Ma et al., 2007; Murakami et al., 2007; Murakami et al., 2008). **PSI-6130** can be converted to an inactive uridine analog **PSI-6206** (also known as **RO2433**) by human cytidine deaminase (CDA) and to **PSI-6130-MP** by human 2'-deoxycytidine kinase (dCK), respectively. The formed **PSI-6130-MP** produced two active nucleoside triphosphates through two separate pathways. Thus, phosphorylation of **PSI-6130-MP** to the 5'-di- and 5'-triphosphates was catalyzed by uridine-cytidine monophosphate kinase (YMPK) and nucleoside diphosphate kinase (NDPK), respectively. In addition, metabolism studies with **PSI-6130** showed that the

monophosphate of **PSI-6130** was deaminated by 2'-deoxycytidylate deaminase (DCTD) to the uridine monophosphate derivative by and subsequently anabolized to the 5'-triphosphate **RO2433-TP** by YMPK and NDPK in a second pathway (Fig. 7). The inactive uridine analog **PSI-6206** is not a substrate for dCK and cannot be converted to **PSI-6206-MP** directly. The first cellular activation step to monophosphate is the rate-limited step among the three phosphorylation steps. Interestingly, the monophosphate species of **PSI-6130** and **PSI-6206** are very rapidly transformed into their corresponding nucleoside triphosphates, since those compounds are found at the highest concentration among all phosphate species present. Finally, **PSI-6130-TP** was a more potent inhibitor of the wild-type and S282T mutant polymerase compared to **PSI-6206-TP** (Ali et al., 2008; Ma et al., 2007; Murakami et al., 2007). Notably, **PSI-6206-TP** had a significantly longer half-life than **PSI-6130-TP** (see below).

### 5.3. Clinical development

Early animal studies involving single-dose pharmacokinetics studies with **PSI-6130** in rhesus monkeys showed low oral bioavailability for **PSI-6130** (Asif et al., 2007). An early phase I study in humans found a significant conversion to the inactive uridine analog combined with a bioavailability of 25%.

### 5.4. Conclusions

Because of these factors, a prodrug strategy was explored to potentially enhance bioavailability and provide a more selective conversion to **PSI-6130-TP**. **RG7128**, a prodrug of **PSI-6130** (refer to Section 6 of this manuscript), was ultimately selected for clinical evaluation based on its improvements in bioavailability and pharmacokinetics.

## 6. RG7128 (R7128, RO5024048, mericitabine)

### 6.1. Preclinical development and chemical synthesis

**RG7128** (mericitabine) is a 3',5'-diisobutryl ester prodrug and was prepared directly from **PSI-6130** with isobutryl chloride in the presence of DMAP and TEA in THF/H<sub>2</sub>O at 0 °C (Scheme 4) (Chun et al., 2007).

Mericitabine has excellent oral bioavailability but has very little plasma exposure and is quickly converted to **PSI-6130** in humans. Metabolism of **PSI-6130** proceeds by a bifurcated pathway to more potent triphosphate species **PSI-6130-TP** and less active uridine analog **PSI-6206-TP** and both serve as non-obligate chain terminators (Ali et al., 2008; Ma et al., 2007; Murakami et al., 2007; Murakami et al., 2008). The prodrug mericitabine demonstrated potent inhibition of stable and transient replicons with EC<sub>50</sub> values similar to those of **PSI-6130**. Both mericitabine and **PSI-6130** inhibited HCV GT1a (H77 strain) and GT1b (Con1 strain) subgenomic RNA replication, with similar levels of potency (mean EC<sub>50</sub> values, 0.31 μM and 0.51 μM, respectively) (Ali et al., 2008).

### 6.2. Clinical development

**6.2.1. Phase I**—In a two week phase I monotherapy clinical study with 32 HCV GT1 patients, mericitabine showed a mean 2.7 log<sub>10</sub> reduction in viral RNA with a dose of 1,500 mg BID (Reddy et al., 2007). HCV RNA levels were unchanged at Day 15 in six subjects who were given oral placebo in this study. In a four week, randomized, placebo-controlled phase I trial, 88% and 85% of treatment-naïve subjects, who were given 1,000 mg or 1,500 mg BID of mericitabine in combination with SOC (**IFN/RBV**), achieved undetectable RNA levels, respectively (Rodriguez-Torres et al., 2008). By contrast, only 19% subjects in SOC control group achieved no virus detectable level.

**6.2.2. Phase IIb**—In one of the phase IIb clinical trials (PROPEL) (Jensen et al., 2010; Wedemeyer et al., 2013), 408 GT1 and GT4 treatment-naïve subjects were randomized into one of five treatment arms: arm A: mericitabine 500 mg BID for 12 weeks; arm B: mericitabine 1,000 mg BID for 8 weeks; arm C: mericitabine 1,000 mg BID for 12 weeks; arm D: mericitabine 1,000 mg BID for 12 weeks; and arm E: placebo BID for 12 weeks. All subjects received **IFN/RBV** at standard doses for 24 or 48 weeks during and after mericitabine/placebo treatment. Subjects in arm A, B and C who achieved extended rapid virologic response (eRVR) stopped all treatment at week 24. Subjects who did not have an eRVR, and persons in arm D and E continued SOC to complete the 48 weeks treatment. Overall, the virologic response rates were higher in arms A–D than in arm E at weeks 4 and 12. However, the arms D (50.6%) and E (placebo, 51.2%) had similar overall SVR24 rates (primary outcome) with lower rates in the response-guided therapy arms A, B and C (48.8%, 42.0% and 32.9%, respectively).

These data demonstrated that treatment with mericitabine plus **IFN/RBV** for 8 or 12 weeks provided potent suppression of HCV RNA, was well tolerated, did not result in selection of resistant variants; however, it did not increase SVR rates compared with placebo.

An analysis from the now completed phase IIb JUMP-C trial was reported by Pockros and colleagues (Pockros et al., 2013). A total of 166 treatment-naïve persons infected with HCV GT1 or GT4 were randomized to one of two treatment arms. Subjects randomized to arm A were given mericitabine BID plus SOC (**IFN/RBV**) with response guided therapy (RGT). Persons on arm A who achieved eRVR (extended rapid virologic response; means no virus detected at week 4 and week 12) stopped all treatment at week 24. Those persons who did not achieve an eRVR also stopped the mericitabine at week 24, but continued an additional 24 weeks of SOC treatment. The subjects in control group arm B received SOC treatment for 48 weeks. The results of JUMP-C phase IIb trials showed that mericitabine was safe, and associated with higher SVR rates when compared to SOC (56.8% vs. 36.5%). The virologic response obtained at weeks 4 and 12 in the JUMP-C trial was comparable to results observed with the PROPEL trials. However, the authors note that extending treatment period from 12 to 24 weeks in the PROPEL study was not as effective in increasing SVR rates as found in the JUMP-C study. The difference in SVR rates may have contributed to differences observed in viral breakthrough rates since the PROPEL study showed an almost two-fold increase in relapse as compared to JUMP-C results (Pockros et al., 2013).

It is worth noting that a combination of mericitabine plus SOC was also effective in treating HCV GT2/3 relapsers or non-responder subjects (Gane et al., 2010). Twenty persons with GT2/3 infections, who had not achieved SVR with previous treatments were given mericitabine 1,500 mg BID plus SOC for 4 weeks, followed by SOC alone for 22–24 weeks. Ninety percent (18/20) of persons achieved RVR and 65% (13/20) achieved SVR at 12 weeks. This trial demonstrated that mericitabine plus SOC provided an effective regimen for the treatment of HCV GT2 and GT3 infected persons who have failed previous treatments.

INFORM-SVR, an ongoing phase IIb clinical trial, aims to evaluate the safety and efficacy of an all-oral **IFN**-free treatment with mericitabine and ritonavir-boosted danoprevir (**RG7227**, protease inhibitor, Fig. 8), with or without **RBV** in GT1a/1b treatment-naïve subjects. Among the different arms of the study, a 15% virus breakthrough rate was reported for GT1a and 1b persons (Gane et al., 2012). Viral breakthrough was associated with virus harboring protease inhibitor resistance conferring mutations. Importantly, a transient S282T mutation, an NS5B polymerase mutation associated with mericitabine resistance, was selected in one person.

Finally, ANNAPURNA, an ongoing phase IIb clinical trial is evaluating the combination of setrobuvir (ANA598, RO5466731, non-nucleoside polymerase inhibitor, Fig. 8), danoprevir (RG7227, RO5190591, protease inhibitor, Fig. 8) and ribavirin with or without mericitabine in patients with CHC who are either treatment-naïve or have previously experienced a null response to interferon-based treatment (Fig. 8). With an expected completion date of December 2013, this two-part five arm study will be looking at SVR12 and safety as end points. In part 2, based on results from part 1, further treatment-naïve subjects will receive a successful regimen from part 1, or a reduced intensity regimen, and interferon-based null-response persons will be added to the study (Roche, 2012).

### 6.3. Conclusions

The INFORM-SVR study is considered a milestone game changing combination since it demonstrated for the first time that an all-oral drug combination could suppress HCV replication to levels similar or exceeding SOC. It is also one of very few studies that show the selection of nucleoside analog associated resistance conferring mutations in humans, even though the apparently resistant virus was transient. The S282T mutation was not observed during other clinical triple combination trials with or without IFN, suggesting that the high barrier to resistance of mericitabine, and the low fitness of the mutant virus reduce the incidence of viral breakthrough caused by nucleoside analog resistance selection (Jensen et al., 2010; Le Pogam et al., 2010; Pockros et al., 2011; Pockros et al., 2013). The high rate of viral suppression with mericitabine combined with significant relapse rates without mutation selection indicates that longer treatments, higher doses, and/or other antiviral combinations may be necessary to make mericitabine a major player in HCV treatment. This may be due to the short half-life of PSI-6130-TP, PSI-6130-TP not reaching a viral reservoir(s), and/or overall lack of potency of PSI-6130-TP.

## 7. IDX184

### 7.1. Synthesis of IDX184

**IDX184** (Cretton-Scott et al., 2010; Sommadossi et al., 2008; Surleraux and Gosselin, 2011, 2012) was designed by Idenix Pharmaceuticals as a 2'-C-methyl guanosine (2'-C-MeG) ribonucleoside that contains a S-acyl-2-thioethyl (SATE) phosphoramidate prodrug to selectively deliver the 5'-MP of 2'-C-methylguanosine ribonucleoside to human liver. The metabolism of **IDX184** to 2'-MeG-MP takes place predominantly in liver cells and presumably involves cytochrome P450 (CYP450)-dependent and -independent processes (Zhou et al., 2011). By bypassing the rate-limiting monophosphorylation process, 2'-MeG-MP is then efficiently converted to its active 5'-TP within hepatocytes by cellular kinases. The complete metabolic pathway of **IDX184** is yet to be fully elucidated. Liver targeting may result in a favorable therapeutic index by increasing the levels of the active 2'-MeG-TP in liver cells while lowering systemic exposure to the nucleoside, potentially minimizing the risk of systemic side effects (Cretton-Scott et al., 2008).

**IDX184** was synthesized as shown in Scheme 5 **Error! Reference source not found.** (Sommadosi et al., 2008). Preparation of the *H*-phosphonate monoester precursor was achieved in three steps from commercially available 2,2-dimethyl-3-hydroxypropanoic acid methyl ester **20**, by protection of the alcohol followed by saponification, leading to compound **21** in 92% yield without purification. Installation of the side chain was performed by peptidic coupling between compound **21** and 2-mercaptoethanol, to generate alcohol **22**. Finally, treatment of compound **22** with phosphorus acid and pivaloyl chloride, followed by quenching the reaction with triethylammonium bicarbonate (TEAB), generated *H*-phosphonate monoester precursor **23** in 90% over two steps.

2'-C-Methylguanosine **24** and precursor **23** were then both treated with pivaloyl chloride to furnish intermediate **25**, which was further reacted with benzylamine to generate Tr-protected phosphoramidate diester **26** in quantitative yield. Classical deprotection with trifluoroacetic acid led to the isolation of **IDX184** in 39% yield (Scheme 5).

## 7.2. Preclinical development

In preclinical studies using an HCV replicon assay, **IDX184** exhibited 10 times greater potency than nucleosides that were in clinical development at the time. In a seven-day preclinical toxicology study of **IDX184**, no toxicities, including gastrointestinal or hematological, were observed in monkeys at doses greater than or equal to 600 mg/kg/day. In HCV GT1 infected chimpanzees, once daily oral administration of 10 mg/kg of **IDX184** produced a rapid and potent inhibition of HCV replication with mean viral load reductions of 2.5–4.0 log<sub>10</sub> after four days of dosing (Standing et al., 2008, 2009). Studies were also performed to characterize resistance mutations profiles of **IDX184**. The S282T mutation was identified in all tested cell lines and emerged around 25–77 days. Although the S282T mutant gave **IDX184** a 23-fold increase in EC<sub>50</sub>, low (5%) replicon capacity of S282T replicons was also observed as previously reported by Ludmerer et al. (Ludmerer et al., 2005). The signature S282T mutant and other drug-related resistance mutants were only established *in vitro* for cell-based administration as ultimately there were no mutant resistance found in clinical trials and no cross-resistance between **IDX184** and other classes of HCV antiviral agents (McCarville et al., 2011; McCarville et al., 2010). **IDX184** demonstrated additive antiviral activity in the HCV replicon in combination with HCV protease inhibitors and IFN and synergistic activity in combination with RBV. **IDX184** also remained fully active *in vitro* against HCV containing known protease and non-nucleoside inhibitor drug resistance mutations (Zhou et al., 2011; Zhou et al., 2009). As a result of its favorable preclinical profile, **IDX184** was selected as Idenix's lead candidate in January 2008 and Phase I clinical trials were started in July of the same year.

## 7.3. Clinical development

**7.3.1. Phase Ia**—In July 2008, a randomized, placebo-controlled, dose-escalating study was designed to evaluate the safety and tolerability of **IDX184** after oral administration in healthy subjects. Doses escalating from 5 mg to 100 mg were administered to forty-eight healthy subjects for three days, and PK data were collected (Idenix, 2008b). The most common adverse event was dizziness, 5.6% of occurrences for the **IDX184** treated group compared to 25% for the placebo cohort. Mild to moderate adverse events occurred and resolved by the end of the study. No severe adverse effects (SAE) or dose-limiting toxicity were observed. The level of **IDX184** and 2'-C-MeG in plasma remained low and dose-dependent, consistent with a liver-targeting approach. The short half-life of **IDX184** (around 1 h) in plasma suggested that **IDX184** was unlikely going to accumulate over time. In comparison, 2'-MeG in plasma has a long half-life with t<sub>1/2</sub> of approximate 18–42 h for doses above 25 mg, which reflected the long half-life of 2'-MeG-TP in the liver. The C<sub>24h</sub> of 2'-C-MeG is 0.58–2.88 ng/mL for dose higher than 25 mg of **IDX184**. Overall, **IDX184** was safe and well tolerated at a single dose up to 600 mg/kg/day. The favorable PK supported once-daily dose administration therapy in future studies involving HCV infected individuals.

**7.3.2. Phase Ib**—In December 2008, a double-blind, dose-escalating study (Phase Ib) began to evaluate the safety and antiviral activity of **IDX184** in forty-one treatment-naïve subjects infected with GT1 chronic hepatitis C (Idenix, 2008a). These persons received 25 mg QD, 50 mg QD, 75 mg QD and 100 mg QD or placebo QD for 3 days. **IDX184** was safe and well tolerated: the occurrences of adverse events were following similar pattern as the placebo-treated group with the most frequently adverse events reported being headache and

dizziness. The PK analysis data in the study was consistent with those of the previous healthy volunteers study. The mean HCV RNA reduction ( $\log_{10}$ ) ranged from 0.47 to 0.74 after treatment with 25 mg to 100 mg cohorts at day four. Significant HCV viral load decline occurred in persons receiving doses from 75 mg to 100 mg (Lalezari et al., 2012; Lalezari et al., 2009; Lalezari et al., 2010). This study helped to determine optimal doses that could be chosen for testing in later studies.

**7.3.3. Phase IIa**—In November 2009, a total of eighty subjects were enrolled to evaluate the short-term safety, the antiviral activity and PK profile of **IDX184** in combination with **IFN/RBV** in subjects with GT1 chronic hepatitis C infection. Over 14 days, individuals enrolled in this phase IIa, randomized, double-blind study (Idenix, 2009) were given sequential doses of 50 mg QD, 50 mg BID, 100 mg QD, 100 mg BID, 150 mg QD, 200 mg QD of **IDX184** in combination with **IFN/RBV** and **IFN/RBV** as the placebo cohort. Most adverse events were mild, and no serious adverse events were associated with **IDX184** plus **IFN/RBV** treatment. The pattern of side effects was similar between treatment of **IDX184** plus **IFN/RBV** and treatment of **IFN/RBV** alone. At day 15 of **IDX184** combination treatment, mean viral load reduction ( $\log_{10}$ ) was: 50 mg QD (−2.7), 50 mg BID (−4.0), 100 mg QD (−4.2), 100 mg BID (−4.1), 150 mg QD (−4.3), 200 mg QD (−3.7) of **IDX184** in combination with **IFN/RBV** and −1.5 for **IFN/RBV**. For cohorts given **IDX184** 50 mg QD, 100 mg BID and 200 mg QD, undetectable viral level (< 15 IU/mL) were found in 13–29% of the persons, whereas for 50 mg BID, 100 mg QD and 150 mg QD, 40–50% of the individuals achieved undetectable viral levels. Moreover, all **IDX184** treated cohorts led to a low level of mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels compared to **IFN/RBV** cohort. In addition, the mean plasma concentration of 2'-MeG, which was identified as predictor of viral load started to decline at Day 14 (Lalezari et al., 2013; Lalezari et al., 2010; Membreno and Lawitz, 2011).

**7.3.4. Phase I combination of IDX184 and IDX320**—In June 2010, a clinical drug-drug interaction study was initiated to evaluate the combination of **IDX320** (a macrocyclic HCV protease inhibitor, Fig. 9) and **IDX184** in healthy subjects (Idenix, 2010). This study was designed as a double blind, multiple-dose study of twenty subjects who were administered 100 mg/day of **IDX184** in combination with 400 mg of **IDX320**. The first cohort (8:2) was either treated with **IDX320/IDX184** matching placebo for seven days followed by seven additional days with **IDX320/IDX184**, or **IDX320** matching placebo/**IDX184** matching placebo. The second cohort (8:2) was given **IDX184/IDX320** matching placebo for seven days followed by seven additional days **IDX184/IDX320** or **IDX184** matching placebo/**IDX320** matching placebo. This study was designed to evaluate safety and tolerability and to assess the potential for a pharmacokinetic drug-drug interaction between **IDX320** and **IDX184** when the two drugs were administered in combination in healthy subjects. In September 2010, the FDA placed a clinical hold on **IDX184** and **IDX320** programs based on three serious adverse events (elevated liver function tests) that occurred during this combination study in healthy volunteers. In February 2011, the FDA removed the full clinical hold on **IDX184** and placed it on partial clinical hold allowing Idenix to advance in the clinic under the partial clinical hold (Idenix, 2011a).

**7.3.5. Phase I**—In April 2011, an open-label study was initiated to evaluate the relative bioavailability of **IDX184** and any potential food effect in healthy male subjects (Idenix, 2011b). The purpose of this study was to compare the amount of drug in the blood after taking either a capsule or a tablet form of the drug while fasting. Additionally, the amount of drug present in the blood after eating a meal was investigated and the safety of the tablet form of **IDX184** was evaluated in healthy volunteers. Twelve subjects received 50 mg BID **IDX184** capsules without food on Day 1, 50 mg BID **IDX184** tablets without food on Day

8, and 50 mg BID **IDX184** tablets with food on Day 15. Blood levels of **IDX184** were measured in each study participant to determine pharmacokinetic parameters including bioavailability of **IDX184**, AUC and  $C_{max}$  of **IDX184** and 2'-C-MeG. Results of this study have not been disclosed at the time of this publication.

**7.3.6. Phase IIb**—In July 2011, Idenix initiated a double-blind study of sixty-seven randomized subjects to evaluate the safety and the antiviral activity of **IDX184** in combination with **IFN/RBV** at doses of 50 mg or 100 mg QD for 12 weeks. The common adverse events were fatigue, nausea and headache, which were generally mild to moderate. No treatment-related cardiac or renal serious adverse events were observed during the study and the occurrences of all adverse events were similar between **IDX184**-combination therapy and **IFN/RBV**-therapy. Echocardiograms and N-terminal pro B-type natriuretic peptide (NT-proBNP), a biomarker that aids in the detection of congestive heart failure and cardiac dysfunction, were added in this study to address potential cardiac concerns. Heart rate, AV conduction and cardiac depolarization remained normal. Several subjects in each group developed new T-wave inversions that were not judged to be clinically significant. The increases seen in NT-proBNP levels were greater than 200% of baseline, but reversible. In the 50 mg and 100 mg of **IDX184** in combination with **IFN/RBV** cohorts, 94% and 87% of subjects, respectively, achieved undetectable virus level at a median of 8 weeks of treatment. At week 12, a 76% and 82% rate of complete EVR was observed in the 50 mg and 100 mg treatment arms, respectively (Lawitz et al., 2012a). In January 2012, Idenix submitted interim phase IIb data to the FDA requesting for the removal of the partial clinical hold on **IDX184**. In February 2012, the partial clinical hold on **IDX184** was removed by the FDA allowing the initiation of dosing in the phase IIb study.

#### 7.4. Conclusions

In August 2012, the FDA placed **IDX184** and **IDX19368** (another HCV nucleotide polymerase inhibitor for which Idenix had previously filed an IND, but had not initiated clinical studies) on partial clinical hold due to cardiac adverse events seen in the phase II clinical trial of **BMS-986094** (refer to section 15 of this manuscript). All three drugs are 2'-C-methyl guanosine nucleotide prodrugs. In December 2012, Idenix completed the submission of requested cardiac safety data for **IDX184** to the FDA. Idenix had found no evidence for severe cardiac effects in all of their clinical studies to date. In the meantime, in October 2012, Idenix started a three-year observational study to evaluate the durability of sustained viral response and the kinetics of antiviral-resistant HCV in subjects who participated in studies of Idenix anti-HCV direct acting antivirals, including **IDX184**. In February 2013, the FDA communicated that **IDX184** (and **IDX19368**) programs would remain on clinical hold, and, as a result, Idenix decided to terminate the development of these programs. A reason for FDA concern over **IDX184** and related compounds is the resultant NTP derived from **IDX184** is identical to the NTP derived from **BMS-986094**. Cardiac toxicity for **BMS-986094** was demonstrated to be dose-related and the postulated reason for the cardiac toxicity was mitochondrial toxicity. Of note, 2'-C-MeG-TP has been shown to be a substrate for incorporation by human mitochondrial RNA polymerase (Arnold et al., 2012). However, cell free assays can be misleading since the nucleoside may never be phosphorylated in mitochondria. Nevertheless, Idenix decided not to pursue this drug further since by then they had identified nucleoside analogs with superior virological and toxicological profiles.

## 8. PSI-6206 to PSI-7851 to GS-7977 (PSI-7977; sofosbuvir)

### 8.1. Discovery and preclinical profiling

The presence of 2'-deoxy-2'-fluoro-2'-C-methyluridine **PSI-6206** metabolite along with its triphosphate **PSI-6206-TP** was recognized during metabolism studies on **PSI-6130** in cell culture and in monkeys (see discussion Section 5.2). These compounds were evaluated for their anti-HCV activity in replicon assay (Ma et al., 2007). While the uridine nucleoside **PSI-6206** was devoid of anti-HCV activity in culture, **PSI-6206-TP** demonstrated a potent and selective inhibition of HCV NS5B polymerase with mean  $IC_{50} = 1.19 \mu M$ . Subsequent stability studies using primary human hepatocytes showed that **PSI-6206-TP** had significantly longer half life ( $t_{1/2} = 38$  h) than its analogous cytidine triphosphate **PSI-6310-TP** ( $t_{1/2} = 6$  h) (Murakami et al., 2008).

Cellular pharmacology with **PSI-6206** demonstrated that it was very poorly phosphorylated to the monophosphate nucleotide (**PSI-6206-MP**), which could explain the lack of anti-HCV activity. The phosphoramidate prodrug approach was taken to bypass the initial unproductive phosphorylation step (Murakami et al., 2010). After *in vitro* and *in vivo* profiling of multiple potential prodrugs, phosphoramidate prodrug **PSI-7851** was selected as the lead compound. **PSI-7851**, an equal mixture of two phosphorous diastereoisomers **PSI-7976** and **PSI-7977** (Berrey et al., 2013; Chun et al., 2010; Clark, 2005; Cleary et al., 2013; Ross et al., 2010; Sofia et al., 2008) was shown to be a potent and selective inhibitor of HCV replication ( $EC_{50} = 0.52 \mu M$ ) with no associated bone marrow, mitochondrial or other cellular toxicity. Its potential efficiency was further demonstrated by high levels of triphosphate (**PSI-6206-TP**) formation in primary human hepatocytes and in the livers of rats, dogs and monkeys when administered *in vivo* (Sofia et al., 2010a). *In vitro* studies, showed **PSI-7851** had a broad range of antiviral activity across different HCV GTs (Lam et al., 2012). Based on impressive preclinical data, **PSI-7851** was selected for future development and progressed into phase I human clinical trials.

### 8.2. Synthesis of PSI-7851 and PSI-7977 (GS-7977)

Subsequently, a method was developed to separate the two **PSI-7977** and **PSI-7976** diastereoisomers. The  $S_p$  diastereoisomer **PSI-7977** ( $EC_{90} = 0.42 \mu M$ ) was shown to be more potent inhibitor than the  $R_p$  diastereoisomer **PSI-7976** ( $EC_{90} = 7.5 \mu M$ ) in replicon assays (Sofia et al., 2010a). However, when both diastereoisomers were tested in primary human hepatocytes almost equal amounts of active triphosphate (**PSI-6206-TP**) was formed, suggesting both isomers may be equally active in the liver cells (Murakami et al., 2010). Enzymatic studies showed Cathepsin A (CatA) and carboxylesterase 1 (CES) could both catalyze the first step hydrolysis (of the carboxyl ester linkage between the carboxylic acid from amino acid moiety and the isopropyl alcohol) of phosphoramidate prodrugs **PSI-7977** and **PSI-7976**. **PSI-7977** was found to be a better substrate for CatA while **PSI-7976** was preferentially hydrolyzed by CES1 (Murakami et al., 2010). The apparent discrepancy between replicon data and primary human hepatocytes was related to the different expression of these enzymes in replicon cell lines and primary human hepatocytes (Murakami et al., 2010; Sofia et al., 2010a). Both isomers were devoid of cytotoxicity when tested against a broad range of cell lines. Mitochondrial toxicity was evaluated up to  $100 \mu M$  in both CEM and HepG2 cells and no toxicity was observed for **PSI-7977** while **PSI-7976** showed  $CC_{90}$  of 72 and  $68.6 \mu M$  for inhibition of mtDNA and rDNA, respectively in HepG2 cells (Sofia et al., 2010a). Pure  $S_p$  isomer **PSI-7977** was selected for future clinical studies due to its higher potency in replicon assay and better safety profile. To date, **PSI-7977** (now called sofosbuvir or **GS-7977**) is the only nucleotide analog HCV polymerase inhibitor that has completed phase III clinical trials and this drug is expected to receive FDA approval by the end of 2013.

### 8.3. Synthesis of single isomer PSI-7977 (sofosbuvir, GS-7977)

The first generation synthesis of **PSI-7977** involved direct reaction of phosphoryl chloride reagent **28a** with 2'-deoxy-2'-fluoro-2'-C-methyluridine (**PSI-6206**) and separation of the two diastereoisomers by crystallization (Sofia et al., 2010a) (Scheme 6). Ultimately, with some modifications to the chemistry and workups during process development, the yield from (**28a**) to the mix of **PSI-7976** and **PSI-7977** (48:51) was improved to 45.7% from which the single isomer **PSI-7977** was isolated in 15% yield after crystallization (Ross et al., 2010).

This approach was further optimized by using *p*-nitrophenol as the leaving group of the phosphorylating agent as shown in (**28b**) (Scheme 6). In this case a 47% of a 3:1 mix of **PSI-7977** and **PSI-7976** were obtained. Separation of (**28b**) into its single diastereomers gave the desired chiral phosphorylating reagent **28c**, which upon reaction under basic conditions gave clean inversion at the phosphorous centers to give **PSI-7977** as the single desired *S<sub>p</sub>* diastereomer. Pentafluorophenyl was used in a similar manner with the phosphorylating reagent **28d** which allowed for a multigram synthesis of single *S<sub>p</sub>* isomer **PSI-7977** without the need for a chiral catalyst, chiral auxiliary or column purification (Ross et al., 2011; Ross et al., 2010).

### 8.4. Clinical trials for PSI-7977 (GS-7977; sofosbuvir)

**8.4.1. Phase I**—In March 2009, clinical trials for **PSI-7851** (also known as **GS-9851**; mixture of diastereoisomers **PSI-7976** and sofosbuvir) were completed in 42 healthy volunteers. The administration of single dosage of 25 mg up to 800 mg QD was shown to be generally safe and well tolerated with no adverse events when compared with the placebo arm and with a pharmacokinetic profile consistent with once-daily dosing (Denning et al., 2012). Phase Ia trials with **PSI-7851** also evaluated safety and tolerability for three day monotherapy at different doses (50 mg, 100 mg, 200 mg, 400 mg) in treatment-naïve subjects. Reductions in viral load were observed without any serious adverse events when compared to the placebo arm (Lawitz et al., 2013c). In fact, the 400 mg QD dose led to a decrease of 1.76 log<sub>10</sub> IU/mL after three days of treatment compared to the related mericitabine, which after 14 days at 1,500 mg with QD dosing, gave a 1.48 log<sub>10</sub> IU/mL drop.

**8.4.2. Phase IIa**—The safety, antiviral activity and tolerability of three different doses of sofosbuvir in combination with **IFN/RBV** were assessed in treatment-naïve persons with GT1 HCV infection. Sixty-four subjects were randomized (1:1:1:1) to receive one of three once-daily doses of sofosbuvir (100, 200 and 400 mg) or placebo plus **IFN/RBV** for 28 days, which was followed by 44 weeks treatment with **IFN/RBV** alone therapy. All who received sofosbuvir experienced rapid virologic response (RVR) of 88%, 94% and 93% for 100, 200, and 400 mg dose, respectively. In comparison, only 21% of the subjects achieved RVR in the control arm. No viral breakthrough was observed during 28 days treatment; however, eight individuals had relapsed during **IFN/RBV** treatment (four on sofosbuvir 100 mg; two on sofosbuvir 400 mg and two on placebo arm). SVR24 rates were higher for subjects in all arms with sofosbuvir treatment (56% for 100 mg dose, 83% for 200 mg dose, and 84% for 400 mg dose) than those in the **IFN/RBV** arm (43% achieved SVR after 24 weeks). The most frequent adverse effects during 28 days treatment were fatigue, nausea, chills, headache and joint pain. No serious adverse events or discontinuation was reported in first 28 days. Sofosbuvir 200 and 400 mg doses were selected for future studies (Rodriguez-Torres et al., 2013).

**8.4.3. Phase IIb**—Several phase IIb clinical trials have addressed the safety and efficacy of sofosbuvir treatment in the treatment of HCV GTs. Results from four studies (PROTON, ELECTRON, QUANTUM and ATOMIC) are summarized below.

**8.4.3.1 PROTON:** In this double-blind, randomized study the efficacy of sofosbuvir in combination with **IFN** and **RBV** in treatment-naïve persons with HCV GT1, 2 and 3 was evaluated. A total of 121 treatment-naïve subjects with GT1 infection were randomly assigned to three different groups (2:2:1 ratio) to receive **IFN/RBV** with 200 mg sofosbuvir, 400 mg sofosbuvir, or placebo for 12 weeks followed by additional **IFN/RBV** treatment for 12 weeks or 36 weeks depending on the subject's response. Among GT1 persons, 98% of subjects on triple therapy achieved RVR compared to 19% in the placebo group. 88% of those on 200 mg dose of sofosbuvir and 91% of those on 400 mg sofosbuvir achieved SVR12 while less than 50% achieved SVR in placebo cohort. All IL28-BT/T GT persons included in the study (13/13) achieved SVR12 following triple therapy. Finally, combination therapy with sofosbuvir was even more effective for treatment-naïve persons with GT2/3 HCV infections. In this cohort, all 24 subjects who stayed on therapy achieved SVR12 (Gane et al., 2013b; Lawitz et al., 2013b; Pham et al., 2004; Radkowski et al., 2005).

**8.4.3.2. ELECTRON:** This study was designed to evaluate the efficacy of sofosbuvir with **RBV**, with or without **IFN** in treatment-naïve or treatment-experienced persons with GT1, 2, or 3 HCV infections. Sofosbuvir monotherapy, reductions in **RBV** dose, and changes in duration of therapy were also evaluated. One hundred and fifty five subjects with all three HCV GTs were divided into eleven treatment groups (Radkowski et al., 2005). In a randomized cohort, forty treatment-naïve subjects with HCV GT2 and GT3 infections were divided into four arms. All groups received sofosbuvir (400 mg QD) + **RBV** BID for 12 weeks. Three of the arms also received **IFN** for 4, 8 and 12 weeks, respectively. SVR24 was achieved for all subjects enrolled in the four arms (cohorts 1 to 4) (Gane et al., 2013b; Gane et al., 2012). In an additional arm (cohort 5), wherein ten treatment-naïve persons with HCV GT2 or GT3 received sofosbuvir monotherapy for 12 weeks, SVR24 rates were 60%. A shortened 8-week triple therapy arm (cohort 6) was also evaluated in ten GT2 or GT3 subjects and SVR24 was achieved for all participating subjects. In cohort 7, twenty-five treatment-naïve subjects with GT2 or GT3 were treated with sofosbuvir plus **RBV** for 8 weeks. Full (100%) SVR was achieved in this cohort. Cohort 8 evaluated treatment of ten GT2/3 subjects with sofosbuvir + reduced dose **RBV** (800 mg) and resulted in a reduced SVR rate of ~60%. Twenty-five treatment-experienced subjects with GT2 and GT3 HCV infections were treated with sofosbuvir and **RBV** (cohort 9). All subjects in this arm achieved RVR while 68% attained SVR at 12 weeks. Finally, a 12-week **IFN**-free sofosbuvir plus **RBV** treatment was evaluated in ten GT1 null-responders (cohort 10) and in twenty-five GT1 treatment-naïve subjects (cohort 11). Treatment-naïve subjects with GT1 achieved SVR12 of 84% while only one out of ten null-responder subjects achieved SVR12 (Table 1).

In summary, 12-week treatment with sofosbuvir and **RBV** resulted in 100% SVR24 in treatment-naïve, GT2/3 subjects. This regimen was less optimal for treatment-experienced subjects with GT2/3 or null-responders with GT1 infections. It was concluded that duration of less than 12 weeks or reduced **RBV** dose might adversely impact treatment efficacy. Reduced dosage of **RBV** in treatment-naïve difficult GT1 subjects in 24 weeks treatment was less efficient (SVR4 56%) than full dose **RBV** (77%). Addition of sofosbuvir to **IFN** + **RBV** regimen considerably improved the response rate among all GTs and shortened the duration of therapy. **IFN**-free combination showed high percent of cure rate in untreated individuals, but was less efficient in treatment-experienced patients or null-responders.

**8.4.3.3. ATOMIC:** This phase IIb clinical trial evaluated the combination of sofosbuvir with IFN/RBV for 12- or 24-weeks in treatment-naïve GT1, GT4, and GT6 persons (a total of 332 subjects were enrolled). Additionally, treatment-naïve persons with GT1 were treated with sofosbuvir in combination with IFN/RBV followed by 12 week treatment with sofosbuvir alone or in combination with RBV. The results from this study suggest that 12 week triple combination therapy was as effective as 24 week treatment for this group of subjects. Furthermore, it was found that sofosbuvir, with or without RBV after initial treatment, can be effective in achieving high SVR rate (Kowdley et al., 2013).

**8.4.3.4. Phase II sponsored by the National Institute of Allergy and Infectious Diseases (NIAID):** Initiated in 2011, NIH investigators recruited 60 GT1 HCV treatment-naïve subjects, into a two-part open label study (Gilead, 2011). As a proof of concept, in the first part, ten patients with mild to moderate liver fibrosis were treated with 400 mg/day of sofosbuvir and weight-based RBV for 24 weeks. All nine subjects who completed the 24-week course had an undetectable level of the virus 24-weeks post treatment and were deemed cured. Subsequently, in the second group of fifty subjects where thirteen suffered from serious liver damage, all took 400 mg/day sofosbuvir with the subjects being split between weight-based and low-dose (600 mg/day) RBV. SVR-24 rates of 68% were observed in the weight-based group and 48% in the low-dose group (Osinusi et al., 2013). Seven grade 3 adverse events were reported (anemia, neutropenia, nausea, hypophosphatemia, and cholelithiasis or pancreatitis), but none resulted in discontinuation of treatment. This NIH-sponsored study of Gilead's sofosbuvir combined with RBV demonstrated a safe and effective interferon-free approach for even some of the toughest HCV cases.

**8.4.4. Phase III—**Multiple phase III clinical trials have been initiated to evaluate the safety and efficacy of HCV treatments that contain sofosbuvir. Results from four trials (FUSION, FISSION, POSITRON and NEUTRINO) are summarized below.

**8.4.4.1. FUSION:** In June 2012, the randomized, double-blind trial was initiated in 200 treatment-experienced individuals with GT2 and GT3 who were assigned to two treatment groups to receive sofosbuvir (400 mg daily) with RBV (1,000 mg or 1,200 mg) for duration of 12 or 16 weeks. The study also included persons with compensated cirrhosis at baseline. In the 12-week treatment group the SVR12 rate was 86% for GT2 and 30% for GT3 infected subjects. In the 16-week treatment group SVR12 rate was 94% for GT2 and 62% for GT3 subjects. No adverse side effects were observed that were attributed to sofosbuvir treatment (Gilead, 2013d).

**8.4.4.2. FISSION:** This randomized, active-controlled study, initiated in December 2012, aimed to compare 12-week course with sofosbuvir 400 mg/RBV with 24-week standard of care treatment IFN/RBV treatment in genotype 2 and 3 treatment-naïve persons. The study met its primary efficacy end point with 67% of subjects achieving SVR12 in both groups. All common adverse effects ( $\geq 10\%$ ) occurred more frequently in IFN/RBV arm. Most frequently observed adverse events ( $\geq 10\%$ ) in the sofosbuvir/RBV group were fatigue, headache, nausea, insomnia and dizziness (Gilead, 2013a).

**8.4.4.3. POSITRON:** This randomized, double-blind, placebo controlled study was initiated in March 2012 and was designed to evaluate sofosbuvir plus RBV for persons who were IFN-intolerant or ineligible/unwilling to take IFN. Two hundred and seven subjects with GT2 and GT3 HCV infections were enrolled. Of those, 15% had compensated cirrhosis and 53% were GT2. Among individuals with GT2, 93% achieved SVR12, among those with

GT3 and the small percentage that had cirrhosis, 61% also achieved SVR-12 (Gilead, 2012); however the overall SVR12 rate was 78% in GT3 and GT4 combined.

**8.4.4.4. NEUTRINO:** This study was initiated in June 2012 in 327 treatment-naïve subjects with GT1, GT4, GT5 and GT6 to evaluate treatment outcomes of a 12-week course of sofosbuvir with IFN and RBV treatment. Overall, triple combination was found to be superior with 90% of subjects achieving SVR12 compared to a predefined historic control SVR rate of 60 percent. The most common adverse events (reported in >20%) were fatigue, headache, nausea, insomnia and anemia (Gilead, 2013a).

## 8.5. Conclusions

Sofosbuvir, **PSI-7977** (now **GS-7977**) is the most promising pan-genotypic antiviral drugs against HCV infection identified to date. In combination with SOC or other DAAs such as protease and NS5A inhibitors (see below), it demonstrated high percentage of cure rate among all GTs. Like earlier, anti-HCV nucleoside analogs sofosbuvir showed a clear synergistic effect when dosed in combination with **RBV**. Two small and separate early clinical studies showed that **RBV** could lower HCV viral load, but did not cure any subjects tested (Di Bisceglie et al., 1992; Reichard et al., 1991). In our hands, **RBV** has no anti-HCV activity in the Huh7 replicon system suggesting that the antiviral effect may be due to a host effect (Bassit et al., 2008).

SVR rates were consistently lower among GT3 patents in phase III studies reporting preliminary data. Early *in-vitro* genotype studies with sofosbuvir found similar EC<sub>90</sub> values for inhibition of GT1b (Con1)-, GT1a (H77)-, and GT2a (JFH-1)-derived replicons and for GT1b chimeric replicons containing the NS5B region from the J6 GT2a isolate and from GT2b and GT3a isolates (Lam et al., 2012). Thus, there was no published preclinical indication of lower efficacy versus GT3 and it remains to be seen if this pattern holds true as more data are disclosed.

On April 8, 2013, based on these clinical studies, Gilead submitted a new drug application to U.S. FDA for the use of sofosbuvir and **RBV** as an all-oral regimen in GT2 and three individuals and in combination with IFN/RBV for the treatment-naïve persons with GT1, 4, 5 and 6 HCV infection (Gilead, 2013c). On October 25, 2013, an FDA advisory committee voted unanimously (15 to 0) in favor of approval of the use of sofosbuvir in persons infected with GT2 and GT3 in combination with **RBV**. The committee also recommended (15-0) sofosbuvir in combination with IFN and **RBV** for treatment of chronic HCV in treatment-naïve adults with GT1 and GT4 infections.

## 9. Combinations of sofosbuvir with other DAAs

### 9.1. Sofosbuvir (PSI-7977; GS-7977) plus daclatasvir (BMS-790052)

The all-oral, IFN/RBV-free, combination of direct acting antivirals (DAA) involving sofosbuvir an NS5B polymerase inhibitor, and daclatasvir (**BMS-790052**) (Fig. 12), an NS5A inhibitor, has been explored as an attractive approach toward HCV treatment (Sulkowski et al., 2012a; Sulkowski et al., 2012b).

**9.1.1. Phase IIa**—The first combination study of sofosbuvir and daclatasvir with or without **RBV** was reported in a phase IIa trial (AI444-040 study) in treatment-naïve subjects with GT1a/1b, GT2, or GT3 HCV infection (Sulkowski et al., 2012a). Eighty-eight subjects were enrolled to receive sofosbuvir (400 mg QD) and daclatasvir (60 mg QD) in combinations with or without **RBV** for 24 weeks. HCV RNA levels were monitored up to 48 weeks after discontinuation of antiviral therapy. Based on the interim results, overall,

more than 95% of all treatment-naïve subjects with any GT tested achieved SVR4, but in GT1a/1b subjects the SVR4 was 100% (HCV RNA < 10 IU/mL). The combination of sofosbuvir and daclatasvir was generally well tolerated, and, of special significance, **RBV** only contributed to adverse effects and had no effect on virologic response.

An additional eighty-two GT1a/1b subjects were randomized to the AI444-040 study to receive sofosbuvir (400 mg QD) and daclatasvir (60 mg QD) in combination with or without **RBV** for 12 weeks. In a recent update of the study (Sulkowski et al., 2012b), with a total of 170 treatment-naïve individuals with GT1a/1b, GT2, or GT3 HCV infection enrolled to receive sofosbuvir (400 mg QD) and daclatasvir (60 mg QD) in combinations with or without **RBV** for 24 weeks, in GT1a/1b, GT2, or GT3 and 12 weeks in GT1a/1b more than 93% of all treatment-naïve subjects achieved SVR. Importantly, 43 out of 44 (98%) GT1 subjects achieved SVR24 and 41 out of 44 (93%) of GT2 and GT3 subjects achieved SVR24. *IL28B* GT, viral subtype, and the administration of **RBV** had no effect on virologic response. The combination of sofosbuvir and daclatasvir were generally safe and well tolerated. The development of anemia in ≤ 21% subjects was only observed with **RBV** treatment.

**9.1.2. Phase II**—The safety and efficacy of sofosbuvir (400 mg QD) and daclatasvir (60 mg QD) in combination with or without **RBV** for 24 weeks was evaluated in forty-one GT1 subjects who experienced virologic failure with previous telaprevir- or boceprevir-based triple therapy. Sofosbuvir plus daclatasvir arm and sofosbuvir plus daclatasvir plus **RBV** arm demonstrated high SVR12 rate of 100% and 95%, respectively (Sulkowski et al., 2013).

## 9.2. Sofosbuvir plus ledipasvir (GS-5885)

The multipart phase II ELECTRON study aimed to evaluate the safety and efficacy of sofosbuvir-containing regimens with or without **IFN** and/or **RBV** in GT1, GT2 and GT3 individuals (Gane et al., 2013b) (See section 8.3.3.2 for additional details). One arm of this study focused on an all-oral regimen in GT1 treatment-naïve and null-responders in which subjects were treated with sofosbuvir and **RBV** over 12 weeks (Gane et al., 2013a). Other arms of the study were similar in design, but also included ledipasvir (**GS-5885**, Fig. 12), a direct acting antiviral NS5A inhibitor. Among treatment-naïve subjects (N = 25) and null-responders (N = 10) who received sofosbuvir plus **RBV** without ledipasvir, SVR12 rates were 84% and 10%, respectively. However, all individuals [treatment-naïve (N = 25) and null-responders (N = 10)] receiving ledipasvir in combination with sofosbuvir and **RBV** showed 100% SVR12 regardless of treatment history (Gane et al., 2013a). Common adverse events included anemia, depression and headache.

There are currently several ongoing phase II and phase III clinical studies for evaluating the safety, tolerability and antiviral efficacy of a once daily fixed-dose combination tablet containing ledipasvir (90 mg), and sofosbuvir (400 mg) with or without **RBV** (1,000 or 1,200 mg/day divided BID) in GT1 HCV infected subjects. The latest updates from these trials are summarized in the sections below (Gilead, 2013b).

**9.2.1. ION-1**—In October 2012, Gilead launched a phase III trial for evaluating safety and efficacy of sofosbuvir and ledipasvir with and without **RBV** for 12 or 24 weeks among treatment-naïve GT1 subjects. Each arm enrolled fifty individuals (total 200 subjects). Based on the initial results of the 12-week arms, the trial will expand to include 800 subjects (Gilead, 2013b).

**9.2.2. ION-2**—A second phase III study for fixed-dose sofosbuvir/ledipasvir began in January 2013. The study plans to enroll 400 treatment-experienced GT1 subjects who have failed previous IFN-containing regimens (with or without protease inhibitors). This study will evaluate treatment response in a 12-week regimen with **RBV** and a 24-week regimen with or without **RBV** (Gilead, 2013b).

**9.2.3. LONESTAR**—A new Phase II clinical trial is now underway to study sofosbuvir/ledipasvir for 12 weeks and of sofosbuvir/ledipasvir with and without **RBV** for 8 weeks. This is the first trial to enroll hundred GT1 treatment-naïve persons for the shorter 8-week treatment duration. Treatment with sofosbuvir plus ledipasvir (with or without **RBV**) for 12 weeks will also be evaluated for treatment-experienced GT1 persons who have failed the protease inhibitor-containing regimen (Gilead, 2013b).

**9.2.4. ION-3**—In May 2013, Gilead started a Phase III, multicenter, randomized, open-label study to evaluate the safety, tolerability and antiviral efficacy of sofosbuvir/ledipasvir (400/90 mg) with or without **RBV** (1,000 or 1,200 mg/day divided BID) administered once daily for eight weeks versus sofosbuvir/ledipasvir (SOF/LDV) administered once daily for 12 weeks in treatment-naïve non-cirrhotic subjects with chronic GT1 HCV infection (Gilead, 2013e). The primary outcomes of this study are to determine the sustained virologic response twelve weeks after discontinuation of therapy (SVR12), as well as monitoring the number/frequency of adverse events and potential laboratory abnormalities.

### 9.3. PSI-7977 (GS-7977; sofosbuvir) plus simeprevir (TMC435)

Simeprevir (**TMC435**) (Fig. 12) is an HCV protease inhibitor currently in phase III clinical trials for HCV infection. In November 2011, a phase II clinical trial (the COSMOS study) evaluating the combination of sofosbuvir and simeprevir with or without **RBV** in individuals who are HCV GT1 null-responders to prior IFN/**RBV** with METAVIR stage either F0-F2 (cohort 1) or F3-F4 (cohort 2) was initiated. The study aims to randomize ninety subjects per cohort in a 2:1:2:1 ratio to the following arms: simeprevir 150 mg once daily + sofosbuvir 400 mg once daily for 24 weeks with or without **RBV**, or simeprevir 150 mg once daily + sofosbuvir 400 mg once daily for 12 weeks with or without **RBV**. For cohort 1, a safety and efficacy interim analysis was conducted when approximately 20% of the planned randomized patients reached the end of treatment or permanently discontinued treatment early. Interim data demonstrated RVR in 13/15, 8/11, 20/23, 5/10 in simeprevir with sofosbuvir and **RBV** (24 weeks), simeprevir and sofosbuvir (24 weeks), simeprevir with sofosbuvir and **RBV** (12 weeks), and simeprevir plus sofosbuvir (12 weeks), respectively (Lawitz et al., 2013a). Similar RVR rates were observed with simeprevir plus sofosbuvir + **RBV** treated for 12 or 24 weeks. However, lower RVR rates were observed without **RBV** for 12 (50%) and 24 week (72%) treatments. Interim SVR4 results from the 12 week arms of cohort 2 in the ongoing COSMOS study, including treatment-naïve or previous null-responder HCV patients all with METAVIR score F3-F4 were recently reported. Treatment for 12 weeks with simeprevir and sofosbuvir, with or without ribavirin, led to SVR4 rates of 96% and 100%, respectively (Medivir, 2013). All arms of this study at 12 weeks were generally considered safe and well tolerated. However, anemia and increased bilirubin was observed in 13.0% and 9.3% of the patients in the **RBV** containing arms, respectively. These events were not observed in the non-**RBV** containing arms.

### 9.4. Sofosbuvir (GS-7977; PSI-7977) a pyrimidine plus PSI-938 a purine nucleotide analog

For information on the phase II NUCLEAR and QUANTUM trials refer to sections 11.3.2 and 11.3.3 of this manuscript.

## 10. R7432

In 2010, Roche initiated a phase I clinical trial of **R7432** in a dose-escalation study with sixty persons enrolled (Roche, 2010). This study was discontinued by February of 2012 (Roche, 2011a, b). Unfortunately, the chemical structure of **R7432**, the clinical trial results and an explanation for the discontinuation has not been disclosed.

## 11. PSI-938 (PSI-352938)

Purine nucleoside derivatives of mericitabine were designed to be second-generation agents with improved potency, pharmacokinetics, and resistance profiles. The guanosine derivative **PSI-938** (also known as **PSI-352938**) was a result of these studies (Chun et al., 2010; Clark, 2005; Du et al., 2009; Reddy et al., 2010; Sofia et al., 2010b). This derivative is a cyclic phosphate prodrug of a 2'- $\alpha$ -F-2'- $\beta$ -C-methyl class of nucleosides. The choice for this particular prodrug was based on observations from previous studies which showed that nucleotide cyclic phosphate prodrugs were precursors of the nucleotide monophosphate with enhanced cellular permeability *in vitro* (Gunic et al., 2007).

### 11.1. Synthesis of PSI-938

Pharmasset reported a multi-kilogram process synthesis of **PSI-938** requiring no chromatography (Reddy et al., 2011; Wang et al., 2009). 2'- $\alpha$ -F-2'- $\beta$ -C-methyl-2'-deoxy lactone **29** was prepared as described in Scheme 8. Benzoylation was originally used to complete the synthesis of a key intermediate similar in structure to compound **29** (Scheme 8). However, a switch to 4-chlorobenzyl protection afforded more crystalline intermediates that allowed for a multi-step synthesis that did not require any column chromatography.

The conclusion of the **PSI-938** synthesis is shown in Scheme 9. The *p*-chlorobenzoyl protected lactone **29** was reduced to lactol **30**, and it is interesting to note that upon standing the  $\beta/\alpha$  anomeric mixture isomerized to the thermodynamically more stable  $\beta$ -lactol. An Appel reaction at low temperature then furnished bromo derivative **31**. Glycosylation of compound **31** with 2-amino-6-chloro purine followed by treatment with sodium ethoxide in ethanol provided the unprotected 6-ethoxy purine nucleoside **32**. After extensive investigation, conditions were found for the formation of the 3',5'-cyclic phosphate **PSI-938** (*cis*-*R<sub>p</sub>* configuration) in high diastereoselectivity (>95%): it was finally isolated in 52% yield and greater than 99.5% diastereoselectivity after direct crystallization.

### 11.2. Preclinical development

In an HCV replicon cell assay, **PSI-938** had an EC<sub>90</sub> of 1.37  $\mu$ M with no cytotoxicity up to 100  $\mu$ M (Reddy et al., 2010). It demonstrated prolonged stability in simulated gastrointestinal fluid, simulated intestinal fluid, human plasma, and human liver S9 (*in vitro* model for liver stability). Expanded cytotoxicity data showed no cytotoxicity in a variety of cell lines and no mitochondrial toxicity. Rats treated with the compound had high levels of the triphosphate in the liver. Interestingly, **PSI-938** was equally active against the NS5B S282T mutant replicon. It also showed a high barrier of resistance and a different resistance profile than that of **RG-7128** (Lam et al., 2011). **PSI-938** was found to be metabolized by a phosphorylation pathway distinct from **RG-7128**. These promising results lead Pharmasset to nominate **PSI-938** as a preclinical candidate in June 2009 (Pharmasset, 2009).

### 11.3. Clinical development

**11.3.1. Phase I**—A phase I single ascending dose trial began in early 2010 (Pharmasset, 2010). Healthy male and female volunteers received a single dose of **PSI-938** ranging from 100 mg to 1,600 mg. No dose-limiting toxicity was identified. In August 2010, a multidose

ascending dose trial was conducted in forty subjects chronically infected with HCV GT1. Subjects received 100 mg QD, 200 mg QD, 300 mg QD, and 100 mg BID for seven days. **PSI-938** demonstrated potent antiviral activity with an average drop of 4 log<sub>10</sub> IU/mL in mean HCV RNA from baseline. A consistent decline of HCV RNA levels was observed with no viral breakthrough. **PSI-938** was shown to be safe and well tolerated. No adverse events were reported as well as any subject discontinuations (Pharmasset, 2011c).

**11.3.2. Phase IIa, NUCLEAR**—The combination of sofosbuvir and **PSI-938** represented the first once daily dual-nucleotide IFN/RBV-free study for HCV treatment (Lawitz et al., 2011). Sofosbuvir, a pyrimidine, and **PSI-938**, a purine, are both NS5B polymerase inhibitors. In March 2011, Pharmasset published the results of the Phase IIa NUCLEAR trial in HCV GT1 treatment-naïve subjects. The study evaluated the safety, PK and antiviral activity of **PSI-938** and sofosbuvir administered as monotherapy or in combination for seven to fourteen days. Forty subjects were enrolled in cohorts 1–4 receiving **PSI-938** (300 mg QD) as monotherapy and/or sofosbuvir (400 mg QD) in combinations, and the treatment regimens resulted in median drops of HCV RNA that ranged from 5.0 to 5.2 log<sub>10</sub> IU/mL. **PSI-938** was generally safe and well tolerated over seven to fourteen days, with no adverse events or subject discontinuations. HCV RNA rapidly declined in the first three days followed by continued decrease until end of treatment or assay limit of detection (LOD) was reached. Of the 24 subjects who received the combination treatment, 22 (92%) achieved HCV RNA levels of <15 IU/mL after fourteen days of treatment. Of note, sofosbuvir and **PSI-938** had similar HCV RNA reductions over seven days. The NUCLEAR study suggested that the combination of sofosbuvir and **PSI-938** was generally safe and well tolerated with no viral breakthrough and no significant pharmacokinetic interaction during the seven to fourteen day therapy. These promising results were followed by FDA Fast Track designation in August 2011 (Pharmasset, 2011d).

**11.3.3. Phase IIb, QUANTUM**—In September 2011, Pharmasset initiated the Phase IIb QUANTUM trial in approximately 450 adults of all viral genotypes to assess safety and SVR rates at 12 or 24 weeks for **PSI-938**, **PSI-7977** (sofosbuvir), and various combinations of the drugs with and without RBV (Pharmasset, 2011c). The trial evaluated interferon-free regimens of sofosbuvir 400 mg QD and **PSI-938** 300 mg QD with and without RBV over 12 or 24 weeks in treatment-naïve patients. The trial also evaluated **PSI-938** monotherapy. SVR24 was the primary endpoint of the trial with patients equally randomized across the following arms: 1) **PSI-938** only; 2) **PSI-938** and sofosbuvir; 3) sofosbuvir and RBV; 4) **PSI-938**, sofosbuvir, and RBV and 5) a placebo control of 24 weeks.

Unfortunately, routine safety monitoring detected “laboratory abnormalities associated with liver function” among the 235 individuals in the study who were receiving treatment with **PSI-938** alone or in combination with sofosbuvir or sofosbuvir and RBV (Pharmasset, 2011a). The remaining 12 and 24-week sofosbuvir and RBV combination arm continued unchanged to generate data in support of the NEUTRINO trial (see section 8.4.4.4).

#### 11.4. Conclusions

In December 2011, **PSI-938** was dropped from the follow-up phase IIb QUANTUM trial and further clinical evaluation due to abnormalities in liver function (Pharmasset, 2011b). No future plans for **PSI-938** have been reported. It is unfortunate that a relatively high dose of this drug was used for the main studies, since it is likely that a lower dose would have also been effective with no apparent untoward effects especially when used with sofosbuvir.

## 12. TMC649128

### 12.1. Preclinical development

**TMC649128** (Johansson et al., 2008; Jonckers et al., 2011) is a nucleoside NS5B polymerase inhibitor and has demonstrated an attractive pre-clinical profile: it displayed *in vitro* activity across multiple HCV GTs with a high genetic barrier to resistance. It was disclosed in May 2008, when Medivir entered into an R&D agreement with Ortho Biotech Products LP, an affiliate of Tibotec, to develop medications to treat HCV infection targeting NS5B virus polymerase. Under the agreement, Medivir and Tibotec jointly performed preclinical studies to identify potential compounds. As an effort to explore 4'-azido-2'-modified cytidines as potential HCV polymerase inhibitors known for their antiviral HCV activities, Medivir's scientists designed and synthesized 4'-azido-2'-deoxy-2'-methylcytidine **33** (Nilsson et al., 2012) (Fig. 13), which exhibited a moderate anti-HCV activity (Johansson et al., 2008). Although all the ester prodrug derivatives only exhibited similar or slightly lower activity compared with (**33**), the isobutyl ester (**TMC649128**) demonstrated greatly improved mean maximum plasma concentration ( $C_{\max} = 4.65 \mu\text{M}$ ) and hence a larger area under the curve ( $\text{AUC}_{0-t} = 12.7 \text{ } 3 \mu\text{M} \times \text{h}$ ) and oral bioavailability ( $F = 65\%$ ).

### 12.2. TMC649128 synthesis

**TMC649128** was synthesized as shown in Scheme 10: Glycosylation of **4** with silylated uracil in the presence of tin chloride allowed for the formation of compound **33**. Treatment of compound **33** with ammonia in methanol led to the clean deprotection of the benzoyl group, leading to compound **34** in quantitative yield. Protection of the 3'- and 5'-hydroxyl groups with a TIPDS protective group, followed by deoxygenation via free-radical chemistry gave compound **36** in 97% yield with selectivity of 93:7 (Li and Piccirilli, 2003). Deprotection of the TIPDS group with TBAF generated compound **37** in high yield. Nucleoside **37** was then converted to the olefin compound **38** (Verheyden and Moffatt, 1975). Treating exocyclic olefin with iodine and benzyltriethylammonium azide, followed by benzylation, provided 4'-azido nucleoside **40** in 81% yield over two steps. Oxidative nucleophilic substitution of compound **40** with *m*-chloroperbenzoic acid/*m*-chlorobenzoic acid in DCM afforded protected azido derivative **41**, which was readily converted to 4'-azido-2'-deoxy-2'-methyl cytidine (**42**) by treatment with *l*-H-tetrazole and 4-chlorophenyldichlorophosphate followed by ammonia deprotection. Final acylation of both 3'- and 5'-hydroxy groups led to the formation of **TMC649128**.

### 12.3. Clinical development

**12.3.1. Phase Ia**—In January 2011, Medivir announced the start of phase Ia trial of the hepatitis C polymerase inhibitor **TMC649128**. This first in human, double-blind, randomized, placebo-controlled trial, was successfully completed in June 2011 to assess the safety, tolerability, and pharmacokinetics of increasing single oral doses of **TMC649128** in nine healthy volunteers. After each administration of the drug and up to four weeks after the last administration, safety assessments (blood and urine tests, blood pressure, pulse, electrocardiogram, and physical examination) were performed (Medivir, 2011b; Tibotec, 2011b).

**12.3.2. Phase Ib**—In June 2011, Tibotec initiated a phase Ib, double-blind, randomized and placebo-controlled study in GT1 HCV-infected individuals to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of multiple ascending doses of **TMC649128** given as monotherapy and in combination with IFN and RBV. The pharmacokinetic/pharmacodynamic relationship for antiviral activity, active metabolite and safety of **TMC649128** and its metabolite were assessed. The short-term safety and

tolerability of the co-administration of **TMC649128** and **IFN** plus **RBV** during multiple dosing for 14 days in treatment-naïve GT1 HCV-infected participants was explored. The short-term antiviral effect of the combination of **TMC649128** with **IFN** and **RBV** was also preliminary assessed (Medivir, 2011c; Tibotec, 2011a).

### 12.3. Conclusions

In November 2011, this study was terminated, since the antiviral activity was considered insufficient to warrant further clinical development of **TMC649128** (Medivir, 2011a).

## 13. GS-6620

### 13.1. Preclinical development

**GS-6620** (Butler et al., 2011; Butler et al., 2009; Cho et al., 2011a; Cho et al., 2011b; Cho and Wolckenhauer, 2011) is a pangenotypic, liver-targeted nucleotide prodrug developed by Gilead Sciences for the treatment of HCV. **GS-6620** was shown to have a favorable inhibitory profile *in vitro* whereby the incorporation of corresponding triphosphate resulted in chain-termination. Cell culture resistance selection assays reported the selection of the S282T mutation in the NS5B viral polymerase. This mutation conferred >200-fold resistance in *in vitro* experiments with purified recombination S282T mutant enzyme (Fenau et al., 2011). Oral administration of **GS-6620** to animals resulted in efficient delivery of the nucleoside triphosphate metabolite into the liver (Lawitz et al., 2012b).

### 13.2. GS-6620 synthesis

The synthesis of **GS-6620** is outlined in Scheme 11 (Cho et al., 2013). The tribenzylated 2'-C-Me sugar **43** was efficiently connected to the heterocyclic base **44** under lithium-halogen exchange conditions. The 1'-cyano group was introduced under Lewis acid conditions to give **46** which was followed by a boron trichloride promoted debenzylation to give C-nucleoside analog **47**. Formation of the 5'-phosphoramidate and 3'-isobutyl ester are preformed utilizing standard nucleoside protocols to give **GS-6620**.

### 13.3. Clinical development

The favorable preclinical characteristics of this compound made it a candidate for phase I clinical trials wherein safety, tolerability, pharmacokinetics and antiviral activity were evaluated in a multi-center, randomized, placebo controlled, multiple-dose escalation first-in-man study in 2010. Out of the ninety treatment-naïve subjects enrolled in the study, twelve showed signs of mild adverse events related to treatment. Two subjects who received the highest dose of treatment (900 mg BID) had virus levels below the limit of detection at the end of the five-day dosing period.

### 13.4. Conclusions

Although **GS-6620** was safe and well tolerated over five day of administration period, it was found that exposure to the drug was markedly lower in humans as compared to pre-clinical animal studies with substantial intra- and inter-subject variability seen in all cohorts. Gilead Sciences indicated that without further optimization of drug delivery to improve PK and antiviral activity, future clinical development would not occur for **GS-6620** (Lawitz et al., 2012b).

## 14. ALS-2200 (VX-135) and ALS-2158

In June 2011, Vertex licensed both a purine and pyrimidine nucleoside prodrug inhibitors of HCV NS5B polymerase from Alios Biopharma (Vertex, 2011). Both uridine nucleoside

analog **ALS-2200 (VX-135)** and adenosine nucleotide analog **ALS-2158** (Beigelman et al., 2010; Beigelman et al., 2012a; Beigelman et al., 2012b; Smith et al., 2012) entered phase I clinical trials in December 2011. The exact structure of these nucleoside analogs has not yet been disclosed.

#### 14.1. ALS-2258 clinical development

In an early clinical study, the purine **ALS-2158** did not show sufficient antiviral activity and the study was discontinued in September 2012 (Vertex, 2012b).

#### 14.2. ALS-2200 clinical development

On the other hand, preliminary seven-day viral kinetic data with the pyrimidine prodrug **ALS-2200(VX-135)** administered at 200 mg QD (Marcellin et al., 2012) demonstrated a median drop of 4.18 log<sub>10</sub> (range -3.6, -5.2) in HCV RNA in combination with **RBV** in treatment-naïve chronic HCV subjects with GT1. Five of eight subjects achieved HCV RNA levels below the limit of quantification, and two of these five achieved HCV RNA levels below the limit of detection after seven days of dosing. Similar results were obtained with monotherapy of **ALS-2200** (200 mg, once-daily, seven days). Adverse events during the study were mild to moderate with no subject discontinuations.

**14.2.1. Phase II**—As of November 2012 (Vertex, 2012a, d) future multiple phase II developments of **ALS-2200 (VX-135)** were envisaged: the first one was initiated with GlaxoSmithKline's NS5A inhibitor **GSK2336805** (Vertex, 2012d) (Fig. 14) but was terminated in June 2013 when Vertex and GSK mutually decided to cease the collaboration for a phase II study and prioritized other projects. A second study is planned for the second half of 2013 with **VX-135** in combination with Janssen's protease inhibitor simeprevir (**TMC435**, Fig. 12) in patients with GT1 HCV (Vertex, 2012a). Vertex also planned to begin a study of **VX-135** in combination with protease inhibitor Incivek® (telaprevir), the company's existing drug for persons with chronic GT1 HCV. Two additional studies include evaluating the safety and efficacy of **VX-135** plus **RBV** in treatment-naïve subjects with chronic Hepatitis C and planned study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of **VX-135** and daclatasvir in GT1 chronic hepatitis C subjects. All of these Phase II studies will evaluate safety, tolerability and SVR12 using 12 week all oral regimens in subjects with GT1 HCV. So far, Vertex completed dosing of 100 mg and 200 mg of **VX-135** in combination with **RBV** in Europe and both doses were well tolerated with no discontinuations. No serious adverse events have been reported and no liver or cardiac safety issues have been identified. Most recently, in April 2013, Vertex started a study of 100 and 200 mg doses of **VX-135** in combination with daclatasvir (**BMS-790052**), an NS5A inhibitor being developed by BMS (Vertex, 2012c), with results expected in early 2014. However, in July 2013, the FDA notified Vertex that a partial clinical hold had been placed on Vertex's ongoing phase II US study of **VX-135** (Vertex, 2013). This partial hold prevented further evaluation of the 200 mg dose of **VX-135** due to reversible elevated liver enzymes in patients receiving 400 mg of **VX-135** in combination with **RBV** in a European phase II study. Evaluation of the 100 mg dose of **VX-135** in combination with **RBV** in the U.S. continued. In addition, the recently initiated dosing of 100 and 200 mg of **VX-135** in combination with daclatasvir as part of a phase II study in New Zealand also continued.

### 15. BMS-986094 (INX-189/INX-08189)

#### 15.1. Synthesis of BMS-986094

**BMS-986094** (Chamberlain et al., 2010; McGuigan and Perrone, 2008) is a double prodrug of 2'-C-methylguanosine triphosphate developed by Inhibitex and later acquired by Bristol-

Myers Squibb (Fig. 15). The synthetic route started with trimethylsilyl (TMS) triflate mediated glycosylation of tetrabenzoyl 2'-C-methyl sugar **4** and 6-chloroguanine. The resulting benzoylated 6-chloro nucleoside **49** was then converted to unprotected 6-O-methyl analog **50** by substitution of the chlorine with sodium methoxide in methanol at room temperature. For the prodrug portion, the phosphorochloridate **53** was prepared in two steps by treatment of 1-naphthol with phosphorus oxychloride in presence of triethylamine followed by reaction with *t*-BuCH<sub>2</sub>-L-valine ester. Finally, reaction of (**53**) with (**50**) was conducted in THF in presence of *N*-methylimidazole (NMI) to generate the target compound, **BMS-986094**, in 18% yield as a mixture of diastereoisomers (Scheme 12) (McGuigan et al., 2010a; McGuigan et al., 2010b). As the anti-HCV activity and estimated half-life values were very similar between the two phosphorous diastereomers, **BMS-986094** was tested as a mixture in the latter studies.

This 1-naphthyl neopentyl alanine phosphoramidate derivative of 6-O-methoxy-2'-C-methylguanosine showed potent inhibition in an HCV replicon 1b assay (EC<sub>50</sub> = 0.01 μM, EC<sub>90</sub> = 0.04 μM) and demonstrated a 500 fold greater potency than the parent 6-O-methoxy nucleoside (Kolykhalov et al., 2009; McGuigan et al., 2010a; McGuigan et al., 2010b). However, in comparison with other clinical anti-HCV agents, **BMS-986094** was relatively toxic in multiple cell lines, with CC<sub>50</sub> values of 0.32, 2.23, 2.81, and 15.0 μM in Huh7 (human hepatoma), HepG2 (human hepatoma), BxPC3 (human pancreatic), and CEM (human T lymphocyte) cells, respectively (Furman et al., 2011). Other studies showed that **BMS-986094** caused bone marrow toxicity in the low micromolar range along with toxicity in kidney, blood, skeletal muscle, CNS and intestinal cells. Additional studies suggested that **BMS-986094** could cause unique tissue specific toxicity based on *in vitro* assay results, with the lowest CC<sub>50</sub> values in bone marrow cells (Hutchins et al., 2009; Standing, 2012). Furthermore, in a 14-day study, no appreciable nucleoside analog-associated mitochondrial toxicity was observed in CEM and HepG2 cells treated with **BMS-986094** up to 1 μM (Vernachio et al., 2011). It is not clear why higher concentrations were not reported.

## 15.2. Clinical development

**15.2.1. Phase Ia**—In a first-in-human, single-ascending oral dose (3 mg to 100 mg or a matching placebo) phase Ia study, **BMS-986094** was well tolerated with pharmacokinetics that supported once daily dosing (Patti et al., 2011). In a separate double-blind, placebo-controlled, dose-escalation study, 70 treatment-naïve HCV GT1 subjects dosed with **BMS-986094** at 9, 25, 50, 100, 200 mg once-daily for seven days resulted in a mean decrease in viral load of -0.62, -1.02, -1.53, -2.54 and -4.25 log<sub>10</sub> IU/mL, respectively. Doses of 9, 25 and 100 mg once-daily were also investigated in combination with **RBV** over seven days, producing -0.75, -1.56 and -3.79 log<sub>10</sub> IU/mL reduction in viral load, respectively. The drug was well tolerated at all doses (Rodriguez-Torres et al., 2011).

**15.2.2. Phase II**—After **BMS-986094** was granted Fast-Track Status by the FDA in March 2011, various Phase II trials were scheduled to commence in 2011 to continue investigating drug combinations for longer treatment periods. After Bristol-Myers Squibb bought Inhibitex in January 2012, **INX-189** was renamed **BMS-986094**. A 12 week Phase II clinical study in GT2/3 treatment-naïve individuals, in which **BMS-986094** was dosed at either 0, 25, 50 or 100 mg in combination with **RBV** and **IFN** resulted in RVR rates of 58%, 82%, 78% and 75%, cEVR rates of 92%, 93%, 100% and 88%, and eRVR rates of 58%, 75%, 78% and 71%, respectively. No virologic breakthroughs were observed over the course of therapy (Lawitz et al., 2012c).

### 15.3. Conclusions

The development of **BMS-986094** was discontinued as a result of a series of significant adverse events: in August 2012, a subject receiving 200 mg once daily dosing died of heart failure and another eight subjects were diagnosed with severe kidney and heart damage (Sheridan, 2012). The study was suspended and further development of **BMS-986094** was discontinued; however, a follow-up safety evaluation in subjects who participated in prior clinical studies is ongoing (BMS, 2012). The cause(s) of these serious side effects are still under investigation at this time. It is not clear if the observed toxicity was due to the nucleoside triphosphate itself or due to potential toxic metabolites, such as neopentyl alcohol, 1-naphthanol and methanol, released during the enzymatic cleavage of the prodrug moiety or because of the extremely high levels of nucleoside triphosphates produced. Cardiac toxicity for **BMS-986094** was demonstrated to be dose-related and the postulated reason for the cardiac toxicity was mitochondrial toxicity. As mentioned above, 2'-C-MeG-TP has been shown to be a substrate for incorporation by human mitochondrial RNA polymerase (Arnold et al., 2012). Toxicities observed during preclinical *in vitro* studies should have resulted in closer monitoring of clinical toxicities that would have led to an earlier discontinuation of the clinical study of **BMS-986094**.

### 16. Lessons Learned

To date, nucleoside inhibitors appear to be the most promising of the three classes of direct-acting antiviral agents currently in phase III clinical studies. Recent progress in the development of nucleoside prodrugs, particularly sofosbuvir, solidifies our belief that this agent could become the best-in-class and backbone of future HCV combination chemotherapy. As such, sofosbuvir is an important milestone in the fight against HCV. The unforeseen surprises noted with nucleoside inhibitors in development are drug specific and not a class effect. The de-risking events based on carefully conducted preclinical developments and clinical trials suggest that we are on the verge of a huge game changer in the field of HCV with proof-of-concept already established for an all-oral cure for HCV. It is clear that early preclinical toxicology and pharmacology can make or break a newly drug preferably before clinical trials are begun. The tragic events related to **BMS-986094** only re-emphasizes the need for researchers to fully preclinically evaluate compounds using robust predictive toxicological tests and thorough toxicity screening in various cell-based systems and particularly mitochondrial toxicity which is paramount for the success of a new chemical entity, especially for nucleoside analogs. To assess mitochondrial toxicity, the use of the newly developed mitovir (*mitochondrial* dysfunction caused by antiviral ribonucleoside) score was recently proposed (Arnold et al., 2012). The mitovir score can be readily obtained during preclinical studies and may be useful to quantify the mitochondrial toxicity potential of compounds. The possibility exists that some infected persons might be more susceptible to mitochondrial toxicity when treated with nucleoside analogs due to their inherent mitochondrial or nuclear transcription dysfunction. The bar has been raised with the FDA when it comes to toxicity associated with nucleoside analogs as is reflected by their actions with **IDX184** and **VX-135**, although exact details and guidance has not yet been forthcoming.

It is also clear that the prodrug selected may enhance oral bioavailability, but may also concurrently increase toxicity by delivering the active metabolite in high levels to undesirable compartments causing significant off-target side effects and even death. Thus, for treatment of HCV infection it is important that the drug is primarily liver targeted due to first pass effect with extensive hepatic extraction and that nucleoside triphosphate production and metabolism remain largely localized in the liver, the site of HCV replication with low systemic exposure. In the context of a viral liver infection, it is ideal for the nucleoside prodrug to be quickly metabolized and preferentially activated in the liver such

that it does not go into systemic circulation and result in off-target exposure of the nucleoside or its triphosphate. For example, the side effects that were noted with both **IDX184** and **INX-189** would indicate that the drug was escaping first pass metabolism and reaching some degree of systemic exposure. Additionally, the intracellular half-life of the nucleoside triphosphate might be more important than the amount of NTP formed. After all, the active metabolite has to persist in the liver long enough to suppress and eliminate viral load. Furthermore, an oral prodrug that is unstable in gastric fluid/GI tract or the plasma may never reach its target to deliver the nucleoside monophosphate to the liver. It is also clearer now that the most desirable nucleoside analogs are those that are pangenotypic and will be effective in all HCV infected persons, especially the difficult-to-treat persons with advanced liver disease including those with decompensated cirrhosis. It is also becoming apparent that one pill may not fit all especially for underdeveloped countries where access and cost of the best combinations may become a severe obstacle to cures (Hagan and Schinazi, 2013).

The HCV drug development tsunami will continue and be broadly felt across many areas of healthcare in the next decade. It is anticipated that the prospects of a cure for millions of infected persons will in time become possible despite the cost of treatment since we have a moral obligation to provide life saving medicines that cure globally. However, it will take courageous leadership at various levels of society and government to succeed in eradicating HCV globally (Hagan and Schinazi, 2013).

## Acknowledgments

### Acknowledgements & Disclosures

This work was supported in part by CFAR NIH grant 2P30AI-050409 (to RFS) and by the Department of Veterans Affairs (to RFS). Dr. Schinazi is the founder and a major shareholder of RFS Pharma, LLC. Emory received no funding from RFS Pharma, LLC to perform this work and *vice versa*.

## References

- Afdahl N, Rodriguez-Torres M, Lawitz E, Godofsky E, Chao G, Fielman B, Knox S, Brown N. Enhanced antiviral efficacy for valopicitabine (**NM283**) plus Peg-Interferon in hepatitis C patients with HCV genotype-1 infection: Results of a Phase IIa multicenter trial. *J Hepatol.* 2005; 42:39–40.
- Ahmed, HA.; Alfredson, TV.; Birudaraj, K.; Brandl, MT.; Phuapradit, W.; Shah, NH.; Stefanidis, D. HCV prodrug formulation. *PCT Int Appl.* WO 2007068615. 2007.
- Alfredson, T.; Sarma, K.; Brandl, M.; Larrabee, S.; Wu, X.; Tu, Y.; Liu, H.; Smith, D.; Birudaraj, R.; Li, F.; Tran, T.; Hadig, X.; Hill, G.; Daley, R.; Blue, D.; Berger, N.; Symons, J.; Cammack, N.; Ipe, D.; Berns, H.; Lakatos, I.; Swallow, S.; Klumpp, K. Design and evaluation of novel HCV polymerase inhibitor prodrugs with enhanced oral bioavailability. *AAPS Annual Meeting*; San Antonio, TX. 2006.
- Ali S, Leveque V, Le Pogam S, Ma H, Philipp F, Inocencio N, Smith M, Alker A, Kang H, Najera I, Klumpp K, Symons J, Cammack N, Jiang WL. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor **PSI-6130** lack cross-resistance with **R1479**. *Antimicrob Agents Chemother.* 2008; 52:4356–4369. [PubMed: 18838588]
- Arnold JJ, Sharma SD, Feng JY, Ray AS, Smidansky ED, Kireeva ML, Cho A, Perry J, Vela JE, Park Y, Xu Y, Tian Y, Babusis D, Barauskus O, Peterson BR, Gnat A, Kashlev M, Zhong W, Cameron CE. Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependant Nuclear Transcription to Antiviral Ribonucleosides. *PLoS Pathog.* 2012; 8:e1003030. doi: 1003010.1001371/journal.ppat.1003030. [PubMed: 23166498]
- Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. *Adv Drug Deliv Rev.* 1996; 22:67–84.
- Asif G, Hurwitz SJ, Shi J, Hernandez-Santiago BI, Schinazi RF. Pharmacokinetics of the antiviral agent  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine in rhesus monkeys. *Antimicrob Agents Chemother.* 2007; 51:2877–2882. [PubMed: 17562805]

- Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. *Liver Int.* 2012; 32 (Suppl 1):88–102. [PubMed: 22212578]
- Bassit L, Grier J, Bennett M. Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. *Antivir Chem Chemother.* 2008; 19:25–31. [PubMed: 18610555]
- Beigelman, L.; Blatt, L.; Wang, G. Substituted nucleoside and nucleotide analogs. PCT Int Appl. WO 2010108140. 2010.
- Beigelman, L.; Blatt, L.; Wang, G.; Rajwanshi, VK.; Dyatkina, NB.; Smith, BD. Substituted nucleotide analogs. PCT Int Appl. WO 2012040126. 2012a.
- Beigelman, L.; Smith, BD.; Deval, J.; Rajwanshi, VK. Cyclic nucleotide analogs. PCT Int Appl. WO 2012088155. 2012b.
- Berrey, MM.; Hinds, R.; Symonds, WT.; Ray, AS.; Mo, H.; Hebner, CM. Methods and compositions for treating hepatitis C virus. PCT Int Appl. WO 2013066748. 2013.
- BMS. A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase I Study with **BMS-986094 (INX-08189)**. Clinical trial NCT017322848. 2012. retrieved from: <http://clinicaltrials.gov/show/NCT017322848>
- Bobek DR, Coats SJ, Schinazi RF. Advances in Nucleoside Monophosphate Prodrugs as Anti-hepatitis C Virus. *Agents Antivir Ther.* 2010; 15:935–950.
- Brandl M, Wu X, Holper M, Hong L, Jia Z, Birudaraj R, Reddy M, Alfredson T, Tran T, Larrabee S, Hadig X, Sarma K, Washington C, Hill G, Smith DB. Physicochemical Properties of the Nucleoside Prodrug **R1626** Leading to High Oral Bioavailability. *Drug Dev Ind Pharm.* 2008; 34:683–691. [PubMed: 18612909]
- Brown NA. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. *Expert Opin Investig Drugs.* 2009; 18:709–725.
- Burton JRJ, Everson GT. HCV NS5B Polymerase Inhibitors. *Clin Liver Dis.* 2009; 13:453–465. [PubMed: 19628161]
- Butler, T.; Cho, A.; Graetz, BR.; Kim, CU.; Metobo, SE.; Saunders, OL.; Waltman, AW.; Xu, J.; Zhang, L. Processes and intermediates for the preparation of 1'-substituted carba-nucleosides. PCT Int Appl. WO 2011035250. 2011.
- Butler, T.; Cho, A.; Kim, CU.; Saunders, OL.; Zhang, L. 1'-Substituted carba-nucleoside analogs for antiviral treatment. PCT Int Appl. WO 2009132135. 2009.
- Cedilote, M.; Cleary, TP.; Zhang, P. Alternate process for preparing 3,5-O-micron-acyl-2-fluoro-2-C-methyl-D-ribo- $\gamma$ -lactone. PCT Int Appl. WO 2008090046. 2008.
- Chamberlain, S.; Hutchins, J.; Medela, K.; McGuigan, C.; Vernachio, J.; Aljarah, M.; Gilles, A. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections. PCT Int Appl. WO 2010081082. 2010.
- Cho, A.; Kim, CU.; Metobo, S.; Ray, AS.; Xu, J. 2'-Fluoro substituted carba-nucleoside analogs for antiviral treatment. PCT Int Appl. WO 2011035231. 2011a.
- Cho, A.; Kim, CU.; Ray, AS.; Zhang, L. 1'-Substituted-carba-nucleoside prodrugs for antiviral treatment. PCT Int Appl. WO 2011150288. 2011b.
- Cho, A.; Wolckenhauser, SA. Methods for the preparation of diastereomerically pure phosphoramidate prodrugs. PCT Int Appl. WO 2012012465. 2011.
- Cho A, Zhang L, Xu J, Lee R, Butler T, Metobo S, Aktoudianakis V, Lew W, Ye H, Clarke M, Doerffler E, Byun D, Wang T, Babusis D, Carey AC, German P, Sauer D, Zhong W, Rossi S, Fenaux M, McHutchison JG, Perry J, Feng J, Ray AS, Kim CU. Discovery of the First C-Nucleoside HCV Polymerase Inhibitor (**GS-6620**) with Demonstrated Antiviral Response in HCV Infected Patients. *J Med Chem.* 2013 ASAP. 10.1021/jm400201a
- Choo QL, Kuo G, Weiner A, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science.* 1989; 244:359–362. [PubMed: 2523562]
- Chun, B-K.; Clark, J.; Sarma, K.; Wang, P. Antiviral nucleosides. PCT Int Appl. WO 2007065829. 2007.

- Chun, B-K.; Du, J.; Rachakonda, S.; Ross, BS.; Sofia, MJ.; Pamulapati Reddy, G.; Chang, W.; Zhang, HR.; Nagarathnam, D. Synthesis of purine nucleosides. PCT Int Appl. WO 2010075554. 2010.
- Clark, J. Modified fluorinated nucleoside analogues. PCT Int Appl. WO 2005003147. 2005.
- Clark JL, Hollecker L, Mason JC, Stuyver LJ, Tharnish PM, Lostia S, McBrayer TR, Schinazi RF, Watanabe KA, Otto MJ, Furman FA, Stec WJ, Patterson SE, Pankiewicz KW. Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J Med Chem. 2005; 48:5504–5508. [PubMed: 16107149]
- Cleary, D.; Reynolds, CJ.; Berrey, MM.; Hinds, RG.; Symonds, WT.; Ray, AS.; Mo, H.; Hebner, CM.; Oliyai, R.; Zia, V.; Stefanidis, D.; Pakdaman, R.; Casteel, MJ. Compositions and methods for treating hepatitis C virus. PCT Int Appl. WO 2013082003. 2013.
- Connolly, TJ.; Durkin, K.; Sarma, K.; Zhu, J. Processes for preparing 4'azido nucleoside derivatives. PCT Int Appl. WO 05000864. 2005.
- Cretton-Scott, E.; Gupta, K.; Hernandez-Santiago, B.; Larsson, M. Compounds and pharmaceutical compositions for the treatment of viral infections. PCT Int Appl. WO 2010014134. 2010.
- Cretton-Scott E, Perigaud C, Peyrottes S, Licklider L, Camire M, Larsson M, La Colla P, Hildebrand E, Lallois L, Bilello J, McCarville J, Seifer M, Liuzzi M, Pierra C, Badaroux E, Gosselin G, Surleraux D, Strandberg DN. In vitro antiviral activity and pharmacology of **IDX184**, a novel and potent inhibitor of HCV replication. J Hepatol. 2008; 48:S220.
- Darby SC, Ewart DW, Giangrande PLF, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, Ludlam CA, Preston FE. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet. 1997; 350:1425–1431. [PubMed: 9371165]
- Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003; 9:331–338. [PubMed: 12682882]
- De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol. 2006; 146:1–11. [PubMed: 16284630]
- De Francesco R, Migliaccia G. Challenges and successes in developing new therapies for hepatitis C. Nature. 2005; 436:953–960. [PubMed: 16107835]
- Denning J, Cornpropst MT, Flach SD, Berrey MM, Symonds WT. Pharmacokinetics, safety, and tolerability of **GS-9851**, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects. Antimicrob Agents Chemother. 2012; 57:1201–1208. [PubMed: 23262999]
- Devos, RR.; Hobbs, CJ.; Jiang, W-R.; Martin, JA.; Merrett, JH.; Najera, I.; Shimma, N.; Tsukuda, T. 4'-Substituted nucleosides. PCT Int Appl. WO 02100415. 2002.
- Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatol. 1992; 16:649–654.
- Dieterich D, Lawitz E, Nguyen CT, Santoro J, Gitlin N, McEniry D, Chasen R, Goff J, Knox S, Kleber K, Belanger B, Brown N. Early clearance of HCV RNA with valopicitabine (**NM283**) plus Peg-interferon in treatment-naïve patients with HCV-I infection: First results from a phase IIb trial. J Hepatol. 2006; 44:S271–272.
- Du, J.; Nagarathnam, D.; Pamulapati Reddy, G.; Ross, BS.; Sofia, MJ. Nucleoside cyclicphosphates. PCT Int Appl. WO 2009152095. 2009.
- Farnik H, Zeuzem S. New antiviral therapies in the management of HCV infection. Antivir Ther. 2012; 17:771–783. [PubMed: 22626842]
- Fenaux, M.; Cheng, G.; Mabery, E.; Ku, K.; Eng, S.; Vela, J.; Feng, J.; Delaney, W.; Mo, H.; Ray, A.; Zhong, W. **GS-6620**, A Novel Anti-hepatitis C Virus Nucleotide Prodrug, Has a High in vitro Barrier to Resistance. 46th Annual Meeting of the European Association for the Study of the Liver (EASL); Berlin, Germany. 2011.
- Fishman, S.; Childs, K.; Dieterich, D.; Carriero, D.; Uriel, A.; Mullen, M.; Factor, S.; Fierer, D.; Branch, A. Age and risky behaviors of HIV-infected men with acute HCV infection in New York City are similar, but not identical, to those in a European outbreak. 16th Conference on Retroviruses and Opportunistic Infections (CROI); Montreal, Canada. 2009.

- Fried MW. Side effects of therapy of hepatitis C and their management. *Hepatology*. 2002; 36:S237–S244. [PubMed: 12407599]
- Furman PA, Murakami E, Niu C, Lam AM, Espiritu C, Bansal S, Bao H, Tolstykh T, Micolochick SH, Keilman M, Zennou V, Bourne N, Veselenak RL, Chang W, Ross BS, Du J, Otto MJ, Sofia MJ. Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor **PSI-353661**. *Antivir Res*. 2011; 91:120–132. [PubMed: 21600932]
- Gaetano JN, Reau N. Hepatitis C: management of side effects in the era of direct-acting antivirals. *Curr Gastroenterol Rep*. 2013; 15:305. [PubMed: 23269576]
- Gane EJ, Rodriguez-Torres M, Nelson DE, Jacobson IM, McHutchison JG, Duca A, Hyland R, Hill G, Albanis EM, Symonds WT, Berrey MM. Sustained virologic response (SVR) following **RG7128** 1500 mg BID/Peg-IFN/RBV for 28 days in HCV genotype 2/3 prior nonresponders. *J Hepatol*. 2010; 52:S16.
- Gane, EJ.; Stedman, CA.; Hyland, RH.; Ding, X.; Pang, PS.; Symonds, WT. 20th Conference on Retroviruses and Opportunistic Infections (CROI); March 3–6 2013; Atlanta, GA. 2013a.
- Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. *N Engl J Med*. 2013b; 368:34–44. [PubMed: 23281974]
- Gane, EJ.; Stedman, CA.; Hyland, RH.; Pang, PS.; Sorensen, RD.; Symonds, WT.; Hindes, RD.; Berrey, MM. Once daily sofosbuvir (GS-7977) regimens in HCV genotype 1–3: The ELECTRON trial. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); Boston, MA. 2012.
- Gerhardt C. Untersuchungen über die wasserfreien organischen Säuren. *Ann Chem Pharma*. 1853; 87:149–179.
- Ghosh, J.; Larsen, C.; Piroth, L.; Duval, X.; Auperin, I.; Delarocque-Astagneau, E.; Gervais, A.; Alric, L.; Pol, S.; Chaix, M-L. Evidence for ongoing epidemic sexual transmission of HCV (2006 to 2007) among HIV-1-infected men who have sex with men: France. 16th Conference on Retroviruses and Opportunistic Infections (CROI); Montreal, Canada. 2009.
- Gilead. **GS-7977** Alone or with Ribavirin for Hepatitis C. Clinical trial NCT01441180. 2011. retrieved from: <http://clinicaltrials.gov/ct2/show/NCT01441180?term=01441180&rank=01441181>
- Gilead. Gilead announces sustained virologic response rate of 78% from phase 3 study of sofosbuvir for genotype 2/3 hepatitis C infected patients. Press release. 2012. retrieved from: <http://www.gilead.com/news/press-releases/2012/11/gilead-announces-sustained-virologic-response-rate-of-78-from-phase-3-study-of-sofosbuvir-for-genotype-23-hepatitis-c-infected-patients>
- Gilead. Gilead announces sustained virologic response rates from two phase 3 studies of sofosbuvir for hepatitis C. Press release. 2013a. retrieved from <http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&id=1780873>
- Gilead. Gilead Provides Update on Hepatitis C Development Programs. Press release. 2013b. retrieved from: <http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&id=1771657>
- Gilead. Gilead submits new drug application to U.S. FDA for Sofosbuvir for the treatment of Hepatitis C. Press release. 2013c. retrieved from: <http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&id=1804362>
- Gilead. Gilead's Sofosbuvir for hepatitis C meets primary endpoint in fourth pivotal phase 3 study. Press release. 2013d. retrieved from: <http://www.gilead.com/news/press-releases/2013/2/gileads-sofosbuvir-for-hepatitis-c-meets-primary-endpoint-in-fourth-pivotal-phase-3-study>
- Gilead. Safety and Efficacy of Sobosbuvir/Ledipasvir Fixed-Dose Combination +/- Ribavirin for the Treatment of HCV (ION-3). Clinical trial NCT01851330. 2013e. retrieved from: <http://clinicaltrials.gov/ct2/show/NCT01851330?term=ion-01851333&rank=01851331>
- Godofsky E, Afdahl N, Rustgi V, Shick L, Duncan L, Zhou XJ, Chao G, Fang C, Fielman B, Myers M, Brown NA. First clinical results for a novel antiviral treatment for Hepatitis C: a phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of **NM283**. *J Hepatol*. 2004; S1:35.
- Gordon CP, Keller PA. Control of hepatitis C: a medicinal chemistry perspective. *J Med Chem*. 2005; 48:1–20. [PubMed: 15633995]

- Gunic E, Girardet JL, Ramasamy K, Stoisavljevic-Petkov V, Chow S, Yeh LT, Hamatake RK, Raney A, Hong Z. Cyclic monophosphate prodrugs of base-modified 2'-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. *Bioorg Med Chem Lett*. 2007; 17:2452–2455. [PubMed: 17331721]
- Hagan LM, Schinazi RF. Best strategies for global HCV eradication. *Liver Int*. 2013; 33(Suppl 1):68–79. [PubMed: 23286849]
- Harrington, PJ.; Hilbrand, S.; Sarma, K. Process for preparation of 4'-azido cytidine derivatives. PCT Int Appl. WO 2008071571. 2008.
- Harry-O'kuru RE, Smith JM, Wolfe MS. A Short, Flexible Route toward 2'-C-Branched Ribonucleosides. *J Org Chem*. 1997; 62:1754–1759.
- Hecker SJ, Erion MD. Prodrugs of phosphates and phosphonates. *J Med Chem*. 2008; 51:2328–2345. [PubMed: 18237108]
- Hezode, C.; Dorival, C.; Zoulim, F.; Poynard, T.; Mathurin, P.; Pol, S.; Larrey, D.; Cacoub, P.; De Ledinghen, V.; Bourlière, M.; Bernard, PH.; Riachi, G.; Alric, L.; Samuel, D.; Barthe, Y.; Fontaine, H.; Carrat, F.; Bronowicki, J-P. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the french early access program (ANRS CO20-CUPIC); International Liver Congress; 2012; 2012. retrieved from: [http://mobile.ilcapp.eu/EASL\\_161/poster\\_23756/program.aspx](http://mobile.ilcapp.eu/EASL_161/poster_23756/program.aspx)
- Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. *Hepatology*. 1997; 26:15S–20S. [PubMed: 9305658]
- Huang Z, Murray MG, Secrist IJA. Recent development of therapeutics for chronic HCV infection. *Antivir Res*. 2006; 71:351–362. [PubMed: 16828888]
- Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000–2005 Update. *Ann Pharmacother*. 2006; 40:74–82. [PubMed: 16368925]
- Hutchins J, Chamberlain S, Chang C, Ganguly B, Gorovits E, Hall A, Henson G, Kolykhalov A, Liu Y, Muhammad J, Perrone P, Gilles A, Holl S, Madela K, McGuigan C, Patti J. In vitro activity and in vivo pharmacokinetics of highly potent phosphoramidate nucleoside analogue inhibitors of hepatitis C NS5B. *Antivir Res*. 2009; 82:A28.
- Idenix. Valopicitabine development program placed on clinical hold in the United States. Press release. 2007. retrieved from: <http://www.thefreelibrary.com/Valopicitabine+Development+Program+Placed+on+Clinical+Hold+in+the+...-a0166344307>
- Idenix. Double-blind, Dose-Escalating Study of **IDX184** in Chronic Hepatitis C Treatment-Naïve Subjects. Clinical trial NCT00807001. 2008a. retrieved from: <http://clinicaltrials.gov/ct2/show/NCT00807001?term=idx00807184&rank=00807005>
- Idenix. Single-dose escalation study of **IDX184** in healthy volunteers. Clinical trial NCT00730431. 2008b. retrieved from: <http://clinicaltrials.gov/ct2/show/NCT00730431?term=idx00730184&rank=00730436>
- Idenix. Safety and antiviral activity of **IDX184** in combination with pegylated interferon and ribavirin. Clinical trial NCT01011166. 2009. retrieved from: <http://clinicaltrials.gov/ct2/show/NCT01011166?term=idx01011184&rank=01011161>
- Idenix. A drug-drug interaction study evaluating the combination of **IDX320** and **IDX184** in healthy subjects. Clinical trial NCT01157104. 2010. retrieved from: <http://clinicaltrials.gov/ct2/show/NCT01157104?term=idx01157184&rank=01157102>
- Idenix. Idenix Pharmaceuticals Provides Updates on Three Clinical Development Programs. Press release. 2011a. retrieved from: <http://ir.idenix.com/releasedetail.cfm?ReleaseID=611432>
- Idenix. A open-label study to evaluate the relative bioavailability of **IDX184** and food effect in healthy male subjects. Clinical trial NCT01335607. 2011b. retrieved from: <http://clinicaltrials.gov/ct2/show/NCT01335607?term=idx01335184&rank=01335603>
- Jeffreys, D. Aspirin: the remarkable story of a wonder drug. New York: Bloomsbury; 2005. p. 38–40.
- Jensen DM, Wedemeyer H, Herring RW, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej NH, Pockros P, Vierling JM, Ipe D, Hill GZ. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with **RG7128** plus Peg-IFN alfa-2a (40KD)/**RBV**: Planned week 12 interim analysis from the PROPEL study. *Hepatology*. 2010; 52:360A. [PubMed: 20578152]

- Johansson, N-G.; Kalayanov, G.; Martin, JA.; Smith, BD.; Winqvist, A. HCV Nucleoside inhibitor. PCT Int Appl. WO 2008043704. 2008.
- Jonckers, TH.; Raboisson, P.; Vandyck, K.; Pelcman, M.; Sund, BC.; Wahling, HJ.; Passos Pinho, PM.; Winqvist, A.; Nilsson, KM. Phosphoramidate derivatives of nucleosides. PCT Int Appl. WO 2011039221. 2011.
- Keicher, JD.; Roberts, CD.; Dyatkina, NB. Nucleoside compounds for treating viral infections. PCT Int Appl. US 0107312. 2005.
- Kennedy EM, Gavegnano C, Nguyen L, Slater R, Lucas A, Fromentin E, Schinazi RF, Kim B. Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. *J Biol Chem*. 2010; 285:39980–39991.
- Klump K, Leveque V, Le Pogam S, Ma H, Jiang WR, Kang H, Granycome C, Singer M, Laxton C, Hang JQ, Sarma K, Smith DB, Heindl D, Hobbs CJ, Merrett JH, Symons J, Cammack N. The novel nucleoside analog **R1479** (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. *J Biol Chem*. 2006; 281:3793–3799. [PubMed: 16316989]
- Klump, K.; Smith, DB. Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (**R1626**) for the Treatment of HCV Infection. In: Kazmierski, WM., editor. *Antiviral Drugs: From Basic Discovery through Clinical Trials*. John Wiley & Sons, Inc; Hoboken, NJ, USA: 2011.
- Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. *Curr Top Med Chem*. 2007; 7:1302–1329. [PubMed: 17627559]
- Kolbe H. Über Synthese der Salicylsäure. *Ann Chem Pharma*. 1860; 113:125–127.
- Kolykhalov, A.; Chamberlain, S.; Gorovits, E.; Hutchins, J.; Liu, Y.; Muhammad, J.; Raja, N.; Vernachio, J.; Henson, G.; Madela, K.; Gilles, A.; McGuigan, C.; Patti, J. HEP DART: Frontiers in Drug Development for Viral Hepatitis. Hawaii, USA: 2009. In vitro characterization of **INX-189**, a highly potent phosphoramidate nucleoside analogue inhibitor of HCV.
- Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdahl N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hinds RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicenter phase 2 trial. *Lancet*. 2013; 381:2100–2107. [PubMed: 23499440]
- Lalezari J, Asmuth D, Casiro A, Vargas H, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bolyai J, Mayers D. Short-term monotherapy with **IDX184**, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection. *Antimicrob Agents Chemother*. 2012; 56:6372–6378. [PubMed: 23070151]
- Lalezari, J.; Asmuth, D.; Casiro, A.; Vargas, H.; Patrick, GD.; Liu, W.; Pietropaolo, K.; Zhou, XJ.; Sullivan-Bolyai, J.; Mayers, D. Antiviral activity, safety and pharmacokinetics of **IDX184**, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); Boston, MA. 2009.
- Lalezari J, Box T, O'Riordan W, Mehra P, Nguyen T, Poordad F, Dejesus E, Kwo P, Godofsky E, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou X-J, Sullivan-Bolyai J, Mayers D. **IDX184** in combination with peginterferon alfa-2a and ribavirin for two weeks in treatment-naïve patients with chronic hepatitis C. *Antivir Ther*. 2013 Epub ahead of print. 10.3851/IMP2552
- Lalezari J, Poordad F, Mehra P, Nguyen T, Dejesus E, Godofsky E, Dubuc-Patrick G, Chen J, Pietropaolo K, Zhou XJ, Sullivan-Bolyai JZ, Mayers D, Group ICI. Antiviral activity, pharmacokinetics and safety of **IDX184** in combination with pegylated interferon (pegIFN) and ribavirin (**RBV**) in treatment-naïve HCV genotype 1-infected subjects. *J Hepatol*. 2010; 52:S469.
- Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA. Genotype and Subtype Profiling of **PSI-7977** as a Nucleotide Inhibitor of Hepatitis C Virus. *Antimicrob Agents Chemother*. 2012; 56:3359–3368. [PubMed: 22430955]
- Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Zennou V, Otto MJ, Furman PA. In vitro Selection of HCV Replicons with Reduced Sensitivity to **PSI-352938**, A Cyclicphosphate Prodrug of  $\beta$ -D-2'- $\alpha$ -F-2'- $\beta$ -C-Methylguanosine. *Antivir Res*. 2011; 90:A22.

- Lawitz E, Box T, Pruitt M, Rodriguez-Torres M, Nguyen T, Lalezari J, Vargas H, Goff J, Hineostroza F, Luketic V, Mehra P, Dubuc-Patrick G, Donovan E, Chen J, Pietropaolo K, Zhou XJ, Sullivan-Bolyai JZ, Mayers D. High rates of rapid virologic response (RVR) and complete early virologic response (cEVR) with **IDX184**, pegylated interferon and ribavirin in genotype 1 HCV-infected subjects: interim results. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); Nov. 9–13 2012; Boston, MA. 2012a.
- Lawitz E, Ghalib R, Rodriguez-Torres M, Nguyen T, Lalezari J, Vargas H, Goff J, Hineostroza F, Luketic V, Mehra P, Dubuc-Patrick G, Donovan E, Chen J, Pietropaolo K, Zhou XJ, Sullivan-Bolyai JZ, Mayers D. Suppression of viral load through 4 weeks post-treatment results of a once-daily regimen of Simeprevir + Sofosbuvir with or without ribavirin in hepatitis C virus GT1 null responders. 20th Conference on Retroviruses and Opportunistic Infections (CROI); March 3–6 2013; Atlanta, GA. 2013a. Paper #155LB
- Lawitz E, Hill J, Marbury T, Hazan L, Gruener D, Webster L, Majauskas R, Morrison R, DeMicco M, German P, Stefanidis D, Svaroskaia E, Arterburn S, Ray A, Rossi S, McHutchison J, Rodriguez-Torres M. **GS-6620**, a liver-targeted nucleotide prodrug, exhibits antiviral activity and favorable safety profile over 5 days in treatment-naïve chronic HCV genotype 1 subjects. 47th Annual Meeting of the European Association for the study of the Liver; Barcelona, Spain. 2012b.
- Lawitz E, Lalezari J, Freilich B, Ghalib R, Gambarin-Gelwan M, Tarum HA, Shiffman ML, DeMicco MP, Gitlin N, Marbury TC, Nguyen TT, Beavers KL, Wright D, Kowdley KV, Younossi ZM, Rustgi VK, Patti J, Campaneria R, Wenzel ED, Zamparo J, Boparai N, Yin P, Barry AN, Hughes EA. **BMS-986094 (INX-08189)** plus peginterferon alfa-2a and ribavirin results in treatment-naïve HCV-genotype 2/3 patients compared to peginterferon alfa-2a and ribavirin: week 12 results. *Hepatology*. 2012c; 56:566A.
- Lawitz E, Lalezari J, Hassanein T, Kowdley KV, Poordad F, Sheikh AM, Afdahl NH, Bernstein DE, DeJesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotype 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. *Lancet Infect Dis*. 2013b; 13:401–408. [PubMed: 23499158]
- Lawitz E, Nguyen T, Younes Z, Santoro J, Gitlin N, McEniry D, Chasen R, Goff J, Knox S, Kleber K, Belanger B, Brown N. Clearance of HCV RNA with valopicitabine (**NM283**) plus peg-interferon in treatment-naïve patients with HCV-1 infection: Results at 24 and 28 weeks. *J Hepatol*. 2007; 46:S9.
- Lawitz E, Rodriguez-Torres M, Denning J, Cornpropst MT, Clemons D, McNair L, Berrey MM, Symonds WT. Once Daily Dual-Nucleotide Combination of **PSI-938** and **PSI-7977** Provides 94% HCV RNA < LOD at day 14: First Purine/Pyrimidine Clinical Combination Data (The NUCLEAR Study). *J Hepatol*. 2011; 54:S543.
- Lawitz E, Rodriguez-Torres M, Denning JM, Albanis E, Cornpropst MT, Berrey MM, Symonds WT. Pharmacokinetics, pharmacodynamics, and tolerability of **GS-9851**, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. *Antimicrob Agents Chemother*. 2013c; 57:1209–1217. [PubMed: 23263000]
- Le Pogam S, Yan JM, Kosaka A, Ji Y, Gonzaludo N, Ewing A, Klumpp K, Najera I. No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV infected patients on nucleoside polymerase inhibitor **RG7128** and Peg-IFN/RBV combination treatment for up to 12 weeks: Interim analysis from the PROPEL study. *Hepatology*. 2010; 52:701A.
- Legrand-Abravanel F, Nicot F, Izopet J. New NS5B polymerase inhibitors for hepatitis C. *Expert Opin Investig Drugs*. 2010; 19:963–975.
- Lemon SM, McKeating JA, Pietschmann T, Frick DN, Glenn JS, Tellinghuisen TL, Symons J, Furman PA. Development of novel therapies for hepatitis C. *Antivir Res*. 2010; 86:79–92. [PubMed: 20417376]
- Li F, Maag H, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. *J Pharm Sci*. 2008; 97:1109–1134. [PubMed: 17696166]

- Li N, Piccirilli JA. Synthesis of the phosphoramidite derivatives of 2'-deoxy-2'-C-methyl cytidine. *J Org Chem.* 2003; 68:6799–6802. [PubMed: 12919052]
- Ligand. Roche's progress of **RG7348** into phase I clinical trial triggers \$6.5M milestone payment to Ligand. Press release. 2010. retrieved from: <http://investor.ligand.com/Investors/News-and-Events/Press-Releases/Press-Release-Details/2010/Ligand-Completes-Acquisition-of-Metabasis/default.aspx>
- Ludmerer SW, Graham DJ, Boots E, Murray EM, Simcoe A, Markel EJ, Grobler JA, Flores OA, Olsen DB, Hazuda DJ, LaFemina RL. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. *Antimicrob Agents Chemother.* 2005; 49:2059–2069. [PubMed: 15855532]
- Ma H, Jiang WR, Robledo N, Leveque V, Ali S, Lara-Jaime T, Masjedizadeh M, Smith DB, Cammack N, Klumpp K, Symons J. Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor  $\beta$ -D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (**PSI-6130**) and Identification of a Novel Active 5'-Triphosphate Species. *J Biol Chem.* 2007; 282:29812–29820. [PubMed: 17698842]
- Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment—finding the right path. *Nat Rev Drug Discov.* 2007; 6:991–1000. [PubMed: 18049473]
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet.* 2001; 358:958–965. [PubMed: 11583749]
- Marcellin P, Popa S, Berliba A, Moscalu I, Boyer N, Kauffman RS, Koziel MJ, Garg V, Tong M, Chanda SM, Zhang Q, Westland C, Beigelman L, Blatt LM, Fry J. **ALS-2200**, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naïve genotype 1 (GT1) patients. *Hepatology.* 2012; 56:235A.
- Martin, JA.; Sarma, K.; Smith, BD.; Smith, M. Antiviral nucleoside derivatives. PCT Int Appl. WO 2004046159. 2004.
- McCarville JF, Dubuc G, Donovan E, Mayers D, Seifer M, Standring D. No resistance to **IDX184** was detected in 3-day and 14-day clinical studies of **IDX184** in genotype 1-infected HCV subjects. *J Hepatol.* 2011; 54:S488–S489.
- McCarville, JF.; Li, B.; Panzo, R.J.; Gillum, J.M.; Soubasakos, MA.; Bilello, J.P.; Lallo, L.B.; Seifer, M.; Standring, DN. In vitro and in vivo resistance profile of **IDX184**, a novel nucleotide analog for the treatment of HCV infection. 5th International Workshop on Hepatitis C - Resistance and New Compounds; Boston, MA. 2010.
- McCown MF, Rajyaguru S, Le Pogam SI, Ali S, Jiang WR, Kang H, Symons J, Cammack N, Najera I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. *Antimicrob Agents Chemother.* 2008; 52:1604–1612. [PubMed: 18285474]
- McGuigan C, Gilles A, Madela K, Aljarah M, Holl S, Jones S, Vernachio J, Hutchins J, Bryant D, Gorovits E, Ganguly B, Hall A, Kolykhalov A, Muhammad J, Chamberlain S, Henson G. Phosphoramidate ProTides of 2'-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties. *J Med Chem.* 2010a; 53:4949–4957. [PubMed: 20527890]
- McGuigan C, Madela K, Aljarah M, Gilles A, Brancale A, Zonta N, Chamberlain S, Vernachio J, Hutchins J, Hall A, Ames B, Gorovits E, Ganguly B, Kolykhalov A, Wang J, Muhammad J, Patti JM, Henson G. Design, synthesis and evaluation of a novel double pro-drug: **INX-08189** A new clinical candidate for hepatitis C virus. *Bioorg Med Chem Lett.* 2010b; 20:4850–4854. [PubMed: 20637609]
- McGuigan, C.; Perrone, P. Chemical compounds. PCT Int Appl. WO 2008062206. 2008.
- McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterol.* 2002; 123:1061–1069.
- Medivir. Annual report. 2011a. retrieved from: [http://medivir.se/v4/images/pdf/2012/Medivir\\_annualreport.pdf](http://medivir.se/v4/images/pdf/2012/Medivir_annualreport.pdf)

- Medivir. Medivir announces start of phase 1a trial of the hepatitis C polymerase inhibitor **TMC64128**. Press release. 2011b. retrieved from: <http://www.medivir.se/v5/en/uptodate/pressrelease.cfm?releaseid=2D62DF545CEECD11&year=2011>
- Medivir. **TMC649128** enters phase 1b trial in patients chronically infected with genotype 1 hepatitis C virus. Press release. 2011c. retrieved from: <http://www.medivir.se/v5/en/uptodate/pressrelease.cfm?releaseid=1639EA2C5103B43D&year=2011>
- Medivir. Medivir announces interim results from Cohort 2 of the COSMOS study evaluating Simeprevir and Sofosbuvir in HCV patients with METAVIR scores F3–F4. Press release. 2013. retrieved from: <http://www.medivir.se/v5/en/uptodate/pressrelease.cfm?releaseid=FEBC5055C8C2C046&year=2013>
- Membrano FE, Lawitz EJ. The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors. *Clin Liver Dis*. 2011; 15:611–626. [PubMed: 21867940]
- Meppen M, Pacini B, Bazzo R, Koch U, Leone JF, Koeplinger KA, Rowley M, Altamura S, Di Marco A, Fiore F, Giuliano C, Gonzalez-Paz O, Laufer R, Pucci V, Narjes F, Gardelli C. Cyclic phosphoramidates as prodrugs of 2'-methylcytidine. *Eur J Med Chem*. 2009; 44:3765–3770. [PubMed: 19493593]
- Murakami E, Bao H, Ramesh M, McGrayer TR, Whitaker T, Micolochick Steuer HM, Schinazi RF, Stuyver LJ, Obikhod A, Otto MJ, Furman PA. Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. *Antimicrob Agents Chemother*. 2007; 51:503–509. [PubMed: 17101674]
- Murakami E, Niu C, Bao H, Micolochick Steuer HM, Whitaker T, Nachman T, Sofia MJ, Wang P, Otto MJ, Furman PA. The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. *Antimicrob Agents Chemother*. 2008; 52:458–464. [PubMed: 1799967]
- Murakami E, Tolstyk T, Bao T, Niu C, Micolochick Steuer HM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman PA. Mechanism of activation of **PSI-7851** and its diastereoisomer **PSI-7977**. *J Biol Chem*. 2010; 285:34337–34347. [PubMed: 20801890]
- Najera I. Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase. *Current Opin Virol*. 2013; 3:508–513.
- Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM, Marcellin P, Pockros P, Rodriguez-Torres M, Rossaro L, Rustgi VK, Sepe T, Sulkowski M, Thomason IR, Yoshida EM, Chan A, Hill G. Balapiravir plus peginterferon alfa-2a (4-KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. *Ann Hepatol*. 2012; 11:15–31. [PubMed: 22166557]
- Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh Hle A, Farrar J, Nguyen QT, Tran HT, Nguyen CV, Merson L, Hoang LT, Hibberd ML, Aw PP, Wilm A, Nagarajan N, Nguyen DT, Pham MP, Nguyen TT, Javanbakht H, Klumpp K, Hammond J, Petric R, Wolbers M, Nguyen CT, Simmons CP. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. *J Infect Dis*. 2013; 207:1442–1450. [PubMed: 22807519]
- Nieforth KA, Morcos PN, Chang L, Davies B, Li R, Smith PF. Study, pharmacokinetics (PK), and antiviral activity of **RG7348**, a novel Hepdirect™ liver-targeted double prodrug hepatitis C virus (HCV) nucleoside polymerase inhibitor. *Clin Pharmacol Ther*. 2012; 91:S96–S135. (poster session III (P111 131–110)).
- Nilsson M, Kalayanov G, Winqvist A, Pinho P, Sund C, Zhou XX, Wähling H, Belfrage AK, Pelcman M, Agback T, Benckestock K, Wikström K, Boothe M, Lindqvist A, Rydegård C, Jonckers TH, Vandyck K, Raboisson P, Lin TI, Lachau-Durand S, De Kock H, Smith DB, Martin JA, Klumpp K, Simmen K, Vrang L, Terelius Y, Samuelsson B, Rosenquist S, Johansson NG. Discovery of 4'-azido-2'-deoxy-2'-C-methyl cytidine and prodrugs thereof: A potent inhibitor of Hepatitis C virus replication. *Bioorg Med Chem Lett*. 2012; 22:3265–3268. [PubMed: 22472694]
- Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottlil S. Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients with Unfavorable Treatment Characteristics. *JAMA*. 2013; 310:804–811. [PubMed: 23982366]

- Pan Q, Peppelenbosch MP, Janssen HL, De Knecht RJ. Telaprevir/boceprevir era: from bench to bed and back. *World J Gastroenterol*. 2012; 18:6183–6188. [PubMed: 23180937]
- Patti J, Matson M, Boehlecke B, Barry A, Wenzel E, Pentikis H, Alam J, Henson G. A study of the safety and pharmacokinetics of single ascending oral doses of **INX-08189**, a nucleotide polymerase inhibitor, in healthy subjects. *Hepatology*. 2011; 54:S187.
- Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. *Antivir Res*. 2003; 59:1–11. [PubMed: 12834855]
- Pham TNQ, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C Virus Persistence after Spontaneous or Treatment-Induced Resolution of Hepatitis C. *J Virol*. 2004; 78:5867–5874. [PubMed: 15140984]
- Pharmasset. Pharmasset nominates **PSI-938** as a new nucleotide analog inhibitor of hepatitis C for Preclinical development. Press release. 2009. retrieved from: <http://www.prnewswire.com/news-releases/pharmasset-nominates-psi-938-as-a-new-nucleotide-analog-inhibitor-of-hepatitis-c-for-preclinical-development-62126747.html>
- Pharmasset. Pharmasset Reports Positive Preliminary Antiviral Data with **PSI-938** for the Treatment of Hepatitis. Press release. 2010. retrieved from: <http://www.virtualpressoffice.com/publicsiteContentFileAccess?fileContentId=396775&fromOtherPageToDisableHistory=Y&menuName=News&sId=&sInfo>
- Pharmasset. Pharmasset Announces Intent to Amend QUANTUM Trial. Press release. 2011a. retrieved from: <http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/3412-pharmasset-halts-testing-of-hcv-polymerase-inhibitor-psi-3938-due-to-liver-problems>
- Pharmasset. Pharmasset Halts Hepatitis C Drug in Test. *The Wall Street Journal*. 2011b. retrieved from: <http://online.wsj.com/article/SB10001424052970204553904577102383041237416.html>
- Pharmasset. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of **PSI-7977** and **PSI-938** for All HCV Genotypes. Press release. 2011c. retrieved from: <http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/3251-pharmasset-starts-trial-of-psi-7977-and-psi-3938-oral-regimens-for-all-hcv-genotypes>
- Pharmasset. **PSI-938** Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection. Press release. 2011d. retrieved from: <http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/3199-hcv-polymerase-inhibitor-psi-3938-gets-fast-track-status>
- Pierra C, Benzaria S, Amador A, Moussa A, Mathieu S, Storer R, Gosselin G. **NM283**, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. *Nucleos Nucleot Nucl*. 2005; 24:767–770.
- Pockros P, Jensen D, Tsai N, Taylor RM, Ramji A, Cooper C, Dickson R, Tice A, Stancic S, Ipe D, Thommes JA, Vierling JM. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (**RG7128**) combined with peginterferon/ribavirin in treatment-naïve HCV G1/4 patients: interim analysis from the JUMP-C trial. *J Hepatol*. 2011; 54:S538.
- Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, Dickson R, Tice A, Kulkarni R, Vierling JM, Munson ML, Chen YC, Najera I, Thommes J. JUMP-C: A randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. *Hepatology*. 2013; 58:514–523. [PubMed: 23359491]
- Pockros PJ, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW, Ghalib R, Harrison S, Nyberg L, Shiffman ML, Najera I, Chan A, Hill G. **R1626** plus peginterferon  $\alpha$ -2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. *Hepatology*. 2008; 48:285–297.
- Poijärvi-Virta P, Lönnberg H. Prodrug approaches of nucleotides and oligonucleotides. *Curr Med Chem*. 2006; 13:3441–3465. [PubMed: 17168716]
- Poynard T, Ratziu V, Benhamou Y, Opolon P, Cacoub P, Bedossa P. Natural history of HCV infection. *Best Pract Res Clin Gastroenterol*. 2000; 14:211–228.
- Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, Wilkinson J, Adair D, Rakela J, Laskus T. Persistence of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C. *Hepatol*. 2005; 41:106–114.

- Reddy PG, Bao D, Chang W, Chun BK, Du J, Nagarathnam D, Rachakonda S, Ross BS, Zhang HR, Bansal S, Espiritu CL, Keilman M, Lam AM, Niu C, Steuer HM, Furman PA, Otto MJ, Sofia MJ. 2'-Deoxy-2'- $\alpha$ -fluoro-2'- $\beta$ -C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of **PSI-352938**. *Bioorg Med Chem Lett*. 2010; 20:7376–7380. [PubMed: 21050754]
- Reddy PG, Chun BK, Zhang HR, Rachakonda S, Ross BS, Sofia MJ. Stereoselective Synthesis of **PSI-352938**: A  $\beta$ -D-2'-Deoxy-2'- $\alpha$ -fluoro-2'- $\beta$ -C-methyl-3',5'-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV. *J Org Chem*. 2011; 76:3782–3790. [PubMed: 21469736]
- Reddy R, Rodriguez-Torres M, Gane E, Robson R, Lalezari J, Everson GT, DeJesus E, McHutchison JG, Vargas HE, Beard A, Rodriguez CA, Hill GZ, Symonds W, Berrey M. Antiviral activity, pharmacokinetics, safety, and tolerability of **R7128**, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. *Hepatology*. 2007; 46:862A–863A.
- Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. *Lancet*. 1991; 337:1058–1061. [PubMed: 1673493]
- Roberts SK, Cooksley G, Dore GJ, Robson R, Shaw D, Berns H, Hill G, Klumpp K, Najera I, Washington C. Robust antiviral activity of **R1626**, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. *Hepatology*. 2008; 48:398–406. [PubMed: 18553458]
- Robson R, Berns H, Brandl M, Fettner S, Haznedar J, Hill G, Ipe D, Love J, Mannino M, O'Mara E, Tu Y, Washington C. Safety, tolerability and pharmacokinetics of **R1626**, a novel nucleoside analog targeting HCV polymerase: results from a phase 1 single dose escalation trial in healthy subjects. *Clin Pharmacol Ther*. 2007; 81:S98. (Poster PIII-41 Abstract).
- Roche. A study of HCV polymerase inhibitor prodrug in combination with PEGASYS plus COPEGUS compared with PEGASYS plus COPEGUS in patients with chronic hepatitis C genotype 1 infection. Clinical trial NCT00517439. 2008. retrieved from: <http://clinicaltrials.gov/ct2/show/NCT00517439?term=00517439&rank=00517431>
- Roche. Annual report. 2010. retrieved from: <http://www.roche.com/gb10e01.pdf>
- Roche. Annual report. 2011a. retrieved from: [http://www.roche.com/static/app/annual\\_report\\_2011/\\_data/pipeline/pipeline.html](http://www.roche.com/static/app/annual_report_2011/_data/pipeline/pipeline.html)
- Roche. Committed to innovation and profitable growth. Nine months YTD 2011 sales. 2011b. retrieved from: <http://www.roche.com/irp3q11e.pdf>
- Roche. ANNAPURNA: A Study of The Combination of **RO5466731**, **RO5190591**, Ritonavir and Copegus (Ribavirin) With or Without **RO5024048** in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment. Clinical trial NCT01628094. 2012. retrieved from: <http://clinicaltrials.gov/ct2/show/NCT01628094?term=01628094&rank=01628091>
- Rodriguez-Torres M, Lalezari J, Gane E, DeJesus E, Nelson DR, Everson GT, Jacobson IM, Reddy KR, McHutchison JG, Beard A, Walker S, Symonds W, Berrey MM. Potent antiviral response to the HCV nucleoside polymerase inhibitor **R7128** for 28 days with PEG-IFN and ribavirin: subanalysis by race/ethnicity, weight and HCV genotype. *Hepatology*. 2008; 48:1160A.
- Rodriguez-Torres M, Lawitz E, Hazan L, Barry A, Wenzel E, Alam J, Henson G, Patti J. Antiviral activity and safety of **INX-08189**, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naïve genotype-1 HCV patients. *Hepatology*. 2011; 54:535A.
- Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, DeJesus E, McHutchison JG, Cornpropst MT, Mader M, Albanis E, Jiang D, Hebner CM, Symonds WT, Berrey MM, Lalezari J. Sofosbuvir (**GS-7977**) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. *J Hepatol*. 2013; 58:663–668. [PubMed: 23183528]
- Ross BS, Ganapati Reddy P, Zhang HR, Rachakonda S, Sofia MJ. Synthesis of Diastereomerically Pure Nucleotide Phosphoramidates. *J Org Chem*. 2011; 76:8311–8319. [PubMed: 21916475]
- Ross, BS.; Sofia, MJ.; Pamulapati Reddy, G.; Rachakonda, S.; Zhang, H-R.; Chun, B-K.; Wang, P. N-[(2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-L-alanine 1-methylethyl ester and process for its production. PCT Int Appl. WO 2010135569. 2010.

- Sarma, K. Selective *O*-acylation of nucleosides. PCT Int Appl. US 2007066815. 2007.
- Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterol. 2012; 142:1340–1350.
- Schmitt R. Beitrag zur Kenntniss der Kolbe'schen Salicylsäure Synthese. J Prakt Chem. 1885; 31:397–411.
- Schröder P, Kraut K. Über Salicylverbindungen. Ann Chem Pharma. 1869; 150:1–20.
- Sheridan C. New Merck and Vertex drugs raise standard of care in hepatitis C. Nat Biotechnol. 2011; 29:553–554. [PubMed: 21747363]
- Sheridan C. Calamitous HCV trial casts shadow over nucleoside drugs. Nat Biotechnol. 2012; 30:1015–1016. [PubMed: 23138280]
- Smith, BD.; Deval, J.; Dyatkina, NB.; Beigelman, L.; Wang, G. Substituted nucleotide analogs. PCT Int Appl. WO 2010040127. 2012.
- Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R, Granycome C, Hang J, Hobbs CJ, Jiang W-R, Laxton C, Le PS, Leveque V, Ma H, Maile G, Merrett JH, Pichota A, Sarma K, Smith M, Swallow S, Symons J, Vesey D, Najera L, Cammack N. Design, Synthesis and Antiviral Properties of 4'-substituted Ribonucleosides as Inhibitors of Hepatitis C Virus Replication: The Discovery of **R1479**. Bioorg Med Chem Lett. 2007;17.
- Sofia MJ. Nucleotide prodrugs for HCV therapy. Antivir Chem Chemother. 2011; 22:23–49. [PubMed: 21860070]
- Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, H-RZ, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HMM, Niu C, Otto MJ, Furman PA. Discovery of a  $\beta$ -D-2'-Deoxy-2'-fluoro-2'- $\beta$ -C-methyluridine Nucleotide Prodrug (**PSI-7977**) for the Treatment of Hepatitis C Virus. J Med Chem. 2010a; 53:7202–7218. [PubMed: 20845908]
- Sofia, MJ.; Du, J.; Wang, P.; Nagarathnam, D. Nucleoside phosphoramidate prodrugs. PCT Int Appl. WO 2008121634. 2008.
- Sofia, MJ.; Du, J.; Wang, P.; Nagarathnam, D. Nucleoside phosphoramidates. PCT Int Appl. WO 2010075549. 2010b.
- Sommadossi, J-P.; Gosselin, G.; Pierra, C.; Perigaud, C.; Peyrottes, S. Compounds and pharmaceutical compositions for the treatment of viral infections. PCT Int Appl. WO 2008082601. 2008.
- Sommadossi, J-P.; La Colla, P. Methods and compositions for treating Flaviviruses and Pesiviruses. PCT Int Appl. WO 0192282. 2001a.
- Sommadossi, J-P.; La Colla, P. Methods and compositions for treating hepatitis C virus. PCT Int Appl. WO 01090121. 2001b.
- Sommadossi, J-P.; La Colla, P.; Strandring, D.; Bichko, V.; Qu, L. 2'-Branched nucleosides and Flaviridae mutation. PCT Int Appl. WO 2004046331. 2004a.
- Sommadossi, J-P.; La Colla, P.; Storer, R.; Gosselin, G. 2' and 3'-Nucleoside prodrugs for treating Flaviridae infections. PCT Int Appl. WO 200400300. 2004b.
- Sommadossi, J-P.; La Colla, P.; Storer, R.; Gosselin, G. Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections. PCT Int Appl. WO 2004002999. 2004c.
- Strandring, D. **IDX184** and novel nucleotides for the treatment of HCV. 20th International Round Table on Nucleosides, Nucleotides and Nucleic Acids; Montreal, Canada. 2012.
- Strandring DN, Lanford R, Li B, Panzo RJ, Seifer M, Larsson M, Good SS, Zhou XJ. Potent antiviral activity of second generation nucleoside inhibitors, **IDX102** and **IDX184**, in HCV-infected chimpanzees. J Hepatol. 2008; 48:S30.
- Strandring DN, Lanford R, Li B, Panzo RJ, Seifer M, Larsson M, Good SS, Zhou XJ. Antiviral activity of the liver-targeted nucleotide HCV polymerase inhibitor **IDX184** correlates with trough serum levels of the nucleoside metabolite in HCV-infected chimpanzees. J Hepatol. 2009; 50:S37.
- Storer, R.; Moussa, A.; Chaudhuri, N.; Waligora, F. Process for the production of 2-branched nucleosides. PCT Int Appl. WO 2004052899. 2004.
- Stuyver, LJ. Dosing regimen for Gemcitabine HCV therapy. PCT Int Appl. WO 03068164. 2003.
- Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia L, Nachman T, Grier J, Bennett MA, Xie MY, Schinazi RF, Morrey JD, Julander JL, Furman PA, Otto MJ. Inhibition of hepatitis

- C replicon RNA synthesis by  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. *Antivir Chem Chemother*. 2006; 17:79–87. [PubMed: 17042329]
- Sulkowski M, Gardiner D, Lawitz E, Hinestrosa F, Nelson D, Thuluvath P, Rodriguez-Torres M, Lok A, Schwartz H, Reddy K, Eley T, Wind-Rotolo M, Huang SP, Gao M, McPhee F, Hindes R, Symonds B, Pasquinelli C, Grasela D. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and **GS-7977** (NS5B inhibitor), +/- ribavirin, in treatment-naïve patients with chronic HCV GT1, 2, or 3. *Hepatology*. 2012a; 56:S560.
- Sulkowski, M.; Gardiner, D.; Rodriguez-Torres, M.; Reddy, K.; Hassanein, T.; Jacobson, I.; Lawitz, E.; Lok, A.; Hinestrosa, F.; Thuluvath, P.; Schwartz, H.; Nelson, D.; Eley, T.; Wind-Rotolo, M.; Huang, S-P.; Gao, M.; McPhee, F.; Sherman, D.; Hindes, R.; Symonds, W.; Pasquinelli, C.; Grasela, D. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCV genotype 1, 2, or 3. *Hepatology*; Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); Nov. 09–13 2012; Boston, MA. 2012b. p. abstract LB-02
- Sulkowski, MS.; Gardiner, DF.; Rodriguez-Torres, M.; Reddy, KR.; Hassanein, T.; Jacobson, I.; Lawitz, E.; Lok, AS.; Hinestrosa, F.; Thuluvath, PJ.; Schwartz, H.; Nelson, DR.; Everson, GT.; Eley, T.; Wind-Rotolo, M.; Huang, S-P.; Gao, M.; Hernandez, D.; McPhee, F.; Sherman, D.; Hindes, R.; Symonds, W.; Pasquinelli, C.; Grasela, DM. Sustained Virologic Response with daclatasvir plus sofosbuvir  $\pm$  ribavirin (**RBV**) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). 48th Annual Meeting of the European Association for the Study of the Liver (EASL); April 24–28, 2013; Amsterdam, The Netherlands: 2013. p. abstract 1417A14444-040 Study group retrieved from file://localhost/%20http://http://www.natap.org:2013:EASL:EASL\_1422.htm
- Surleraux, D.; Gosselin, G. Compounds and pharmaceutical compositions for the treatment of viral infections. *PCT Int Appl*. WO 2011123586. 2011.
- Surleraux, D.; Gosselin, G. Compounds and pharmaceutical compositions for the treatment of viral infections. *PCT Int Appl*. WO 2012154321. 2012.
- Tibotec, B. A Trial in Genotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of **TMC649128**, Alone and Combined With Pegylated Interferon + Ribavirin. Clinical trial NCT01391117. 2011a. <http://clinicaltrials.gov/ct2/show/NCT01391117?term=TMC01649128&rank=01391111>
- Tibotec, P. First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses of **TMC649128** in Healthy Volunteers. Clinical trial NCT01288677. 2011b. retrieved from: <http://clinicaltrials.gov/ct2/show/NCT01288677?term=TMC01649128&rank=01288672>
- Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? *Hepatology*. 2010; 52:1497–1505. [PubMed: 20635398]
- Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-Associated hepatitis C. *New Engl J Med*. 1995; 332:1463–1466. [PubMed: 7739682]
- Tong X, Pogam SL, Li L, Haines K, Piso K, Baronas V, Yan J-M, So S-S, Klumpp K, Nájera I. In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir. 2013 Epub Oct 23. 10.1093/infdis/jit1562
- Toniutto P, Fabris C, Bitetto D, Fumolo E, Fornasiere E, Pirisi M. **R-1626**, a specific oral NS5B Polymerase Inhibitor of Hepatitis C Virus. *IDrugs*. 2008; 11:738–749. [PubMed: 18828074]
- Traut TW. Physiological concentrations of purines and pyrimidines. *Mol Cell Biochem*. 1994; 140:1–22. [PubMed: 7877593]
- Verheyden JPH, Moffatt JG. 4'-Substituted nucleosides. I Synthesis of 4'-methoxyuridine and related compounds. *J Am Chem Soc*. 1975; 97:4386–4395. [PubMed: 1141601]
- Vernachio J, Bleiman B, Byrant KD, Chamberlain S, Hunley D, Hutchins J, Ames B, Gorovits E, Ganguly B, Hall A, Kolykhalov A, Liu Y, Muhammad J, Raja N, Walters R, Wang J, Williams K, Patti JM, Henson G, Madala K, Aljarah M, Gilles A, McGuigan C. **INX-08189**, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis

C virus replication with excellent pharmacokinetic and pharmacodynamic properties. *Antimicrob Agents Chemother.* 2011; 55:1843–1851. [PubMed: 21357300]

Vertex. Vertex and Alios BioPharma Announce Exclusive Worldwide Licensing Agreement for Two Nucleotide Drug Candidates, Broadening Vertex's Efforts to Develop New Combinations of Medicines for Hepatitis C. Press release. 2011. retrieved from: <http://investors.vrtx.com/releasedetail.cfm?ReleaseID=584023>

Vertex. Vertex Announces Collaboration with Janssen To Initiate Phase 2 All-Oral Study of **VX-135** and Simeprevir (**TMC435**) for the Treatment of Hepatitis C. Press release. 2012a. retrieved from: <http://investors.vrtx.com/releasedetail.cfm?ReleaseID=717772>

Vertex. Vertex Announces New Data on **ALS-2200** in People With Hepatitis C, Supporting Advancement into Phase 2 All-Oral Studies in 2012; Ends Development of **ALS-2158**. Press release. 2012b. retrieved from: <http://investors.vrtx.com/releasedetail.cfm?ReleaseID=709250>

Vertex. Vertex enters agreement with Bristol-Meyers Squibb for Phase 2 all-oral studies of **VX-135** in combination with daclatasvir for the treatment of Hepatitis C. Press release. 2012c. retrieved from: <http://investors.vrtx.com/releasedetail.cfm?ReleaseID=754494>

Vertex. Vertex Enters Agreement with GlaxoSmithKline for Phase 2 All-Oral Study of **VX-135** and **GSK2336805** for the Treatment of Hepatitis C. Press release. 2012d. retrieved from: <http://investors.vrtx.com/releasedetail.cfm?ReleaseID=717777>

Vertex. Vertex Provides Update on Ongoing All-Oral Studies of **VX-135** in Hepatitis C. Press release. 2013. retrieved from: <http://investors.vrtx.com/releasedetail.cfm?ReleaseID=780456>

Von Gilm H. Acetyl derivative der Phloretin und Salicylsäure. *Ann Chem Pharma.* 1859; 112:180–185.

Waheed Y, Bhatti A, Ashraf M. RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs. *Infect Genet Evol.* 14:247–257. 013. [PubMed: 23291407]

Wang P, Chun BK, Rachakonda S, Du J, Khan N, Shi J, Stec W, Cleary D, Ross BS, Sofia MJ. An Efficient and Diastereoselective Synthesis of **PSI-6130**: A Clinically Efficacious Inhibitor of HCV NS5B Polymerase. *J Org Chem.* 2009; 74:6819–6824. [PubMed: 19642660]

Wedemeyer H, Jensen D, Herring RJ, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J, Ipe D, Lou Munson M, Chen YC, Najera I, Thommes J. PROPEL: A randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin therapy in treatment-naïve HCV Genotype 1/4 patients. *Hepatology.* 2013; 58:524–537. [PubMed: 23348636]

WHO. Hepatitis C. Fact Sheet #164. 2012. retrieved from: <http://www.who.int/mediacentre/factsheet/fs164/en/>

Wong T, Lee SS. Hepatitis C: a review for primary care physicians. *Can Med Assoc J.* 2006; 174:649–659. [PubMed: 16505462]

Zhou XJ, Pietropaolo K, Chen J, Khan S, Sullivan-Bolyai J, Mayers D. Safety and Pharmacokinetics of **IDX184**, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. *Antimicrob Agents Chemother.* 2011; 55:76–81. [PubMed: 21060109]

Zhou XJ, Pietropaolo K, Sullivan-Bolyai J, Kuca B, Liu W, Xu L, Belanger B, Khan S, Mayers D. **IDX184**, a liver-targeted nucleotide HCV polymerase inhibitor: results of a first-in-man safety and pharmacokinetic study. *J Hepatol.* 2009; 50:S351.


Nucleoside analogs target the hepatitis C (HCV) NS5B RNA-dependent RNA polymerase.

At least twelve nucleoside analogs have reached clinical study for HCV infection.


Nucleoside analogs have activity against the various HCV genotypes.

Nucleoside analogs have a high barrier to resistant virus compared to other classes of inhibitors.

Nucleoside analogs that have reached human clinical trials are the focus of this review.




**Fig. 1.**  
Structures for ribavirin (**RBV**), boceprevir (Victrelis) and telaprevir (Incivek).





**Fig. 2.**


Nucleosides transform via three successive cellular kinases to the biologically active nucleoside analog triphosphates. Natural ribo- and 2'-deoxyribonucleoside bases.




**Fig. 3.**  
Synthesis of acetylsalicylic acid from salicylic acid.

**NM107****NM283**  
(valopicitabine)


**Fig. 4.**  
Chemical structures of NM107 and NM283.




**Fig. 5.**  
4'-Azidocytidine analogs used in the human clinical treatment of HCV.




**Fig. 6.**  
Metabolism and metabolites of **RG7348**: (a) esterases; (b) CYP3A4; (c) kinases.



**Fig. 7.**  
Metabolism of **PSI-6130** leads to both the active triphosphate and the inactive nucleoside **PSI-6206**.




**setrobuvir (ANA598)**




**danoprevir (RG7227)**


**Fig. 8.**  
Structures of setrobuvir (ANA598, non-nucleoside polymerase inhibitor) and danoprevir (RG7227, protease inhibitor).




**Fig. 9.**  
Chemical structure of HCV protease inhibitor **IDX320**.




**Fig. 10.**  
Structure of 2'-F-2'-C-methyluridine, **PSI-6206**, and its triphosphate **PSI-6206-TP**.




**Fig. 11.**  
Structures, anti-HCV replication activity and cytotoxicity of phosphoramidate prodrug **PSI-7851** and its diastereoisomers **PSI-7976** and **PSI-7977**.




**Fig. 12.**  
Structures of daclatasvir, ledipasvir and simeprevir.



|                                                         |                                                                           |
|---------------------------------------------------------|---------------------------------------------------------------------------|
| <b>R-1479</b> ( $R^1 = \text{OH}$ , $R^2 = \text{H}$ )  | $\text{EC}_{50} = 1.3 \mu\text{M}$ ; $\text{CC}_{50} > 100 \mu\text{M}$   |
| <b>RO-0622</b> ( $R^1 = \text{H}$ , $R^2 = \text{F}$ )  | $\text{EC}_{50} = 0.027 \mu\text{M}$ ; $\text{CC}_{50} > 100 \mu\text{M}$ |
| <b>RO-9187</b> ( $R^1 = \text{H}$ , $R^2 = \text{OH}$ ) | $\text{EC}_{50} = 0.17 \mu\text{M}$ ; $\text{CC}_{50} > 100 \mu\text{M}$  |
| <b>33</b> ( $R^1 = \text{H}$ , $R^2 = \text{Me}$ )      | $\text{EC}_{50} = 1.2 \mu\text{M}$ ; $\text{CC}_{50} > 98 \mu\text{M}$    |
| <b>34</b> ( $R^1 = \text{F}$ , $R^2 = \text{H}$ )       | $\text{EC}_{50} = 4.0 \mu\text{M}$ ; $\text{CC}_{50} > 100 \mu\text{M}$   |



**Fig. 13.**  
 Structure of prodrug **TMC649128** and related nucleosides.



**Fig. 14.**  
Structure of GSK2336805.







Fig. 15.  
Structure of BMS-986094.

**Scheme 1.**


Synthesis of valopicitabine (NM283). Reagents and conditions: (a) i. CaO, water; ii. CO<sub>2</sub>, oxalic acid, 18%; (b) BzCl, TEA, DMAP, DME, 83%; (c) Red-Al/EtOH, toluene, 99%; (d) BzCl, TEA, DMAP, DME, 52%; (e) bis(trimethylsilyl)acetamide, cytosine, SnCl<sub>4</sub>, CAN; (f) MeONa, MeOH, r.t., 90% over two steps; (g) *N*-Boc-L-valine, CDI, DMAP, TEA, DMF/THF, 91%; (h) HCl, EtOH, 97%.

**Scheme 2.**


Synthesis of **R1479** and its prodrug balapiravir (**R1626**). Reagents and conditions: (a)  $I_2$ ,  $PPh_3$ , imidazole, THF, 83%; (b) NaOMe, MeOH, 75%; (c)  $BnN(Et)_3Cl$ ,  $NaN_3$ , 4-NMM,  $I_2$ ,  $CH_3CN$ ; (d)  $BzCl$ , Pyr., 74% over two-steps; (e)  $K_2HPO_4$ , *m*-CPBA,  $CH_2Cl_2$ , 71%; (f) 1,2,4-triazole,  $POCl_3$ ,  $Et_3N$ , MeCN, 88%; (g)  $NH_4OH$ , MeOH,  $H_2SO_4$ -isopropanol, 95%; (h) isobutyric anhydride, KOH, DMAP, THF, 80%.

**Scheme 3.**


Synthesis of **PSI-6130**. Reagents and conditions: (a)  $\text{Ph}_3\text{PC}(\text{Me})\text{CO}_2\text{Et}$ , DCM,  $-40^\circ\text{C}$ ; (b)  $\text{KMnO}_4$ , acetone,  $0^\circ\text{C}$ , 53% over two steps; (c) i.  $\text{SOCl}_2$ , TEA, DCM,  $0^\circ\text{C}$ ; ii. aq.  $\text{NaOCl}$ , TEMPO,  $\text{NaHCO}_3$ ,  $\text{CH}_3\text{CN}$ ,  $0^\circ\text{C}$ ; (d) i. TEAF, dioxane,  $100^\circ\text{C}$ ; ii.  $(\text{MeO})_2\text{C}(\text{Me})_2$ , conc.  $\text{HCl}$ , dioxane, r.t.; (e)  $\text{EtOH}$ , conc.  $\text{HCl}$ , r.t.; (f)  $\text{BzCl}$ , pyridine, r.t., 47% from (**14**); (g) i.  $\text{Li}(\text{O}-i\text{Bu})_3\text{AlH}$ , THF,  $-20^\circ\text{C}$ ; ii.  $\text{Ac}_2\text{O}$ , DMAP,  $-20^\circ\text{C}$ ; (h) i. silylated  $N^4$ -benzoylcytosine,  $\text{SnCl}_4$ ,  $\text{PhCl}$ ,  $65^\circ\text{C}$ ; ii.  $\text{NH}_3$ ,  $\text{MeOH}$ , r.t., 29% from (**18**).

**Scheme 4.**

Synthesis of **RG7128**. Reagents and conditions: (a) DMAP, THF/H<sub>2</sub>O, TEA, isobutyryl chloride, pH 6.4, 0 °C.


**Scheme 5.**

Synthesis of **IDX184**. Reagents and conditions: (a) TrCl, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, reflux, overnight; (b) NaOH, dioxane, reflux, 16 h, 92% over two steps; (c) i. CDI, toluene/DMF (2/1, v/v), r.t., 30 min; ii. 2-mercaptoethanol, toluene/DMF (2/1, v/v), -10 °C, 3 h; (d) i. H<sub>3</sub>PO<sub>3</sub>, PivCl, pyridine, 0 °C to r.t., 3 h; ii. TEAB, 90% over two steps; (e) (**23**), PivCl, pyridine, -15 °C, 2 h, 32%; (f) Benzylamine, CCl<sub>4</sub>, r.t., 1 h, quantitative yield; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 30 min, 39%.


**Scheme 6.**

Synthesis of **PSI-7976** and **PSI-7977** (sofosbuvir, **GS-7977**) via column purification.


Reaction conditions: (a) 70% aqueous acetic acid, 100 °C; (b) 25% methanolic ammonia, 0–15 °C, 78% overall yield; (c) (**28a**) (*R<sub>p</sub>*:*S<sub>p</sub>* = 1:1) (6.5 equiv), NMI (8 equiv), CH<sub>2</sub>Cl<sub>2</sub>, r.t., overnight, 6%, 1:1 mix of **PSI-7976** and **PSI-7977**; (d) (**28b**) (*R<sub>p</sub>*:*S<sub>p</sub>* ≈ 1:1) (2 equiv), *t*-BuMgCl (2.1 equiv), THF, r.t., 48 h, 47%, 3:1 mix **PSI-7977**:**PSI-7976**.

**Scheme 7.**


Synthesis of single isomer **PSI-7977** (sofosbuvir, **GS-7977**). Reaction conditions: (a) THF,  $t$ -BuMgCl (2.1 equiv) added over 30 min at r.t., stirred 30 min then **(28c)**, r.t., 60 h, 40 %; (b) THF,  $t$ -BuMgCl (2.1 equiv) added over 30 min at  $-5\text{ }^{\circ}\text{C}$ , stirred 30 min, warmed up to  $20\text{ }^{\circ}\text{C}$  and stirred for 30 min and then cooled to  $5\text{ }^{\circ}\text{C}$  then **(28d)** (1.2 equiv) was added over 30 min, stirred for 18 h at  $5\text{ }^{\circ}\text{C}$ , 68%.

**Scheme 8.**


Synthesis of **PSI-938** intermediate lactone **29**. Reagents and conditions: (a) *p*-Cl-BzCl, pyr., r.t., 70%.

**Scheme 9.**


Synthesis of **PSI-938**. Reagents and conditions: (a)  $\text{LiAl}(t\text{-BuO})_3\text{H}$ , THF,  $-20^\circ\text{C}$ , 61%; (b)  $\text{CBr}_4$ ,  $\text{PPh}_3$ ,  $\text{CH}_2\text{Cl}_2$ ,  $-20^\circ\text{C}$ , 1 h, 79%; (c) 2-amino-6-chloropurine,  $t\text{-BuOK}$ ,  $t\text{-BuOH}$ ,  $\text{CH}_3\text{CN}$ ,  $50^\circ\text{C}$ , 16 h, 65%; (d)  $\text{NaOEt}$ ,  $\text{EtOH}$ , reflux, 1 h, 92%; (e) isopropylidichlorophosphate,  $\text{NMI}$ ,  $\text{Et}_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ , 52%.

**Scheme 10.**

Synthesis of 4'-azido-2'-deoxy-2'-methyl cytidine (**TMC649128**). Reagents and conditions: (a) bis(trimethylsilyl)uracil,  $\text{SnCl}_4$ ,  $\text{CH}_3\text{CN}$ , r.t., 20 h, 96%; (b)  $\text{NH}_3$ ,  $\text{CH}_3\text{OH}$ , 0–4 °C, 2 days, >99%; (c)  $\text{TIPDSCl}_2$ , imidazole, DMF, r.t., 2 h, 65%; (d)  $\text{ClCOCO}_2\text{Me}$ , DMAP,  $\text{CH}_3\text{CN}$ , r.t., 1 h; (e)  $n\text{-Bu}_3\text{SnH}$ , AIBN, toluene, reflux, 2 h, 97% ( $\beta/\alpha$  93:7, de 86%) over two steps; (f) TBAF/THF, r.t., 1 h, >99% ( $\beta/\alpha$  93:7); (g)  $\text{I}_2$ ,  $\text{PPh}_3$ , imidazole, THF, 76%; (h)  $\text{NaOMe}$ ,  $\text{MeOH}$ , 75%; (i) i.  $\text{I}_2$ , NMO,  $\text{Bn}(\text{Et})_3\text{NN}_3$ ; ii.  $\text{BzCl}$ , NMP, DMAP, THF, 81% over 2 steps; (j)  $m\text{-CPBA}$ ,  $(\text{NH}_4)_2\text{SO}_4$ , DCM, 68%; (k) i. pyridine, 2-chlorophenyldichlorophosphate, 1-*H*-tetrazole; ii. dioxane,  $\text{NH}_3$ ; iii.  $\text{NH}_3$ ,  $\text{MeOH}$ , 61% over 3 steps; (l)  $i\text{-PrCOCl}$ , TEA, DCM, r.t., >99%.

**Scheme 11.**

Synthesis of **GS-6620**. Reagents and conditions: (a) (**44**), 1,1,4,4-tetramethyl-1,4-dichlorodisilylene (1.0 equiv) and *n*-BuLi (3.3 equiv), THF,  $-78^{\circ}\text{C}$  followed by addition of (**43**), 1 h, 65–80%; (b) TMSCN (6 equiv), TMSOTf (4 equiv),  $\text{CH}_2\text{Cl}_2$ ,  $-15$  to  $0^{\circ}\text{C}$ , 2 h, 85–95%; (c)  $\text{BCl}_3$  (3 equiv),  $\text{CH}_2\text{Cl}_2$ ,  $0^{\circ}\text{C}$ , 1 h, 90%; (d) *N*-methylimidazole, trimethylphosphate and THF,  $0^{\circ}\text{C}$  to r.t., 2 h, overall yield 59%; (e) i. *N,N*-dimethylformamide dimethyl acetal,  $\text{CH}_3\text{CN}$ , r.t., 1 h; ii. isobutyric acid, DCC,  $\text{CH}_3\text{CN}$ , r.t., 48 h; iii. water-TFA,  $0^{\circ}\text{C}$  to r.t., 64 h, overall yield 73%.



**Scheme 12.**

Synthesis of **BMS-986094**. Reagents and conditions: (a) 2-amino-6-chloropurine, DBU, MeCN, TMSOTf, 65 °C, 4 h, 79%; (b) NaOMe, MeOH, r.t., 24 h, 76%; (c) POCl<sub>3</sub>, Et<sub>3</sub>N, Et<sub>2</sub>O, -78 °C, 1 h then r.t., overnight, 95%; (d) *t*BuCH<sub>2</sub>-L-valine ester, Et<sub>3</sub>N, DCM, -78 °C, 1 h then r.t., 2 h; (e) NMI, THF, r.t., overnight, 18%.

**Table 1**

Participants with HCV infection and results of the ELECTRON study.

| Cohort # | # of Patients   | Genotype  | sofosbuvir (weeks) | RBV (weeks)       | IFN (weeks) | SVR (%)                 |
|----------|-----------------|-----------|--------------------|-------------------|-------------|-------------------------|
| 1        | 10 <sup>a</sup> | GT2 and 3 | 400 mg QD (12)     | 1,000 mg BID (12) | (4)         | SVR24 (100)             |
| 2        | 10 <sup>a</sup> | GT2 and 3 | 400 mg (12)        | 1,000 mg BID (12) | (8)         | SVR24 (100)             |
| 3        | 10 <sup>a</sup> | GT2 and 3 | 400 mg (12)        | 1,000 mg BID (12) | (12)        | SVR24 (100)             |
| 4        | 10 <sup>a</sup> | GT2 and 3 | 400 mg (12)        | 1,000 mg BID (12) | none        | SVR24 (100)             |
| 5        | 10 <sup>a</sup> | GT2 and 3 | 400 mg (12)        | none              | none        | SVR24 (60)              |
| 6        | 10 <sup>a</sup> | GT2 and 3 | 400 mg (8)         | 1,000 mg BID (8)  | (8)         | SVR24 (100)             |
| 7        | 25 <sup>a</sup> | GT2 and 3 | 400 mg (8)         | 1,000 mg BID (8)  | none        | SVR24 (100)             |
| 8        | 10 <sup>a</sup> | GT2 and 3 | 400 mg (8)         | 800 mg BID (8)    | none        | SVR24 (60)              |
| 9        | 25 <sup>b</sup> | GT2 and 3 | 400 mg (8)         | 1,000 mg BID (8)  | none        | RVR (100)<br>SVR12 (68) |
| 10       | 10 <sup>c</sup> | GT1       | 400 mg (12)        | 1,000 mg BID (12) | none        | SVR12 (10)              |
| 11       | 25 <sup>a</sup> | GT1       | 400 mg (12)        | 1,000 mg BID (12) | none        | SVR12 (84)              |

<sup>a</sup>Treatment-naïve patients;

<sup>b</sup>Treatment-experienced patients;

<sup>c</sup>Null-responders

## SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800.176.089-2

-/-



Industria y Comercio

SUPERINTENDENCIA

## RECIBO DE CAJA

No. 15 - 007212

Bogotá D.C., Enero 20 de 2015 - 16:43:10

RECIBIDO DE : LLOREDA &amp; CIA. S.A.

NI 830.022.145

RE

## \*\*\* Soporte del Pago \*\*\*

| TIPO PAGO    | BANCO     | CUENTA | No. PAGO   | FECHA PAGO | VR PAGO       |
|--------------|-----------|--------|------------|------------|---------------|
| RECIBO DE CA | 999999999 | 5875   | 20/01/2015 |            | 24.945.000.00 |
| RECIBO DE CA | 999999999 | 7174   | 20/01/2015 |            | 1.054.000.00  |

## \*\*\* Conceptos Pagados \*\*\*

| CANT. | RENTISTICO                                                                                                   | CONCEPTO | Vr.UNDITARIO | Vr.CONCEPTO  |
|-------|--------------------------------------------------------------------------------------------------------------|----------|--------------|--------------|
| 1     | 50005-01-03 CAMBIO DE MODALIDAD Y MODIFICACIONES EN LA CREACION CORRECCION A SOLICITUD EN TRAMITE / MODIFICA |          | 132.000.00   | 132.000.00   |
|       |                                                                                                              |          |              | \$132.000.00 |

SON: \*\*CIENTO TREINTA Y DOS MIL PESOS MONEDA CORRIENTE\*\*\*

Responsable: \_\_\_\_\_

Recibo de Caja Aplicado al Expediente No. \_\_\_\_\_

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 13-089868-00015-0000

Fecha: 2015-03-06 16:42:51 Dep. 2020 DIR.NUEVAS  
 Tra. 11 PATENTEIYII Eve: 379 FASENACIONAL  
 Act. 412 REPOSPRESRECU Folios: 65

Sede Centro: Carrera 13 No. 27 - 00 Pisos 3,4,5 y 10 Bogotá, D.C.- Colombia

Web: www.sic.gov.co e-mai: info@sic.gov.co Conmutador: (571) 5870000 Fax: (571) 5870284 Línea: 018000-910165 Call Center: (571) 6513240

Enero 20 de 2015 - 16:43:37